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Abstract 
Spinal cord injury (SCI) is a debilitating neurodegenerative disease that affects many 
people worldwide. Those that are unfortunate to experience SCI also experience a 
reduced quality of life due to partial or complete paralysis. Whilst there is no cure to 
date much of the SCI research in animal models is centred on axon regeneration and 
preservation in an aim to cure paralysis. Whilst many animal models are used to 
imitate SCI, mice and rats are widely studied and experienced models. The vascular 
disruption, blood vessel loss and cavitation that occur at SCI epicentres in humans 
are known to be different in mice and rats. This study investigates acute SCI 
responses and documents angiogenic and inflammatory factors and matrix 
deposition in both species. Although cavitation was absent in mice, the lesion site in 
rats was 21- and 27-fold larger at 8 and 15 days post lesion (dpl), respectively, 
compared to intact controls. Absence of cavitation in mice correlated with increased 
levels of immunoreactive pro-angiogenic/wound healing factors, e.g. laminin, matrix 
metalloproteinase-1 (MMP-1) and vascular endothelial growth factor-A (VEGF-A) 
within the wound, which were 6.0-, 2.9-, and 2.8-fold, respectively, higher in mice 
compared to rats at 8 dpl. Increased axonal sparing was observed after dorsal 
column (DC) injury, detected by higher levels of PKC-γ and NF200 immunoreactivity 
in the DC of mice compared to rats at both T7 and T9 spinal segments. Despite 
similar post SCI deficits in plantar heat tests at 2 hours after injury (1.4- and 1.6-fold 
lower than control mice and rats, respectively), by 7 days the magnitude of these 
responses were comparable to sham-treated controls in both species. Microarray 
analysis revealed angiogenic/wound healing-related genes such as, protein kinase C 
eta (PRKCH), retinoic acid receptor beta (RARβ) and metallothionein 1H (MT1H) to 
be differentially regulated in mice and rats after sub-acute SCI. Furthermore, inducing 
inflammation directly after injury using zymosan in our model demonstrated distinct 
inflammatory-induced angiogenic responses between mice and rats at 8 dpl that 
further contribute to tissue damage and micro-cavities in the CNS microenvironment 
of mice and rats. In conclusion the robust angiogenic/wound healing response in the 
mouse attenuates post-injury wound cavitation, and may protect against secondary 
axon damage, creating an environment more conducive to axon 
sprouting/regeneration. These results suggest the potential therapeutic utility of 
manipulating the angiogenic and inflammatory response after human SCI.   
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Sections of the introduction are published in the following reviews: 
Kundi S., Bicknell R., Ahmed Z. (2013). The role of angiogenic and wound-healing 
factors after spinal cord injury in mammals. Neuroscience Research. 76, 1-9. 
Kundi S., Bicknell R., Ahmed Z. (2013). Spinal cord injury: Current mammalian 
models. American Journal of Neuroscience. 4 (1), 1-12. 
 
1.1 Overview of SCI 
To date spinal cord injury (SCI) is defined as ‘damage or trauma to the spinal 
cord that results in a loss or impaired function causing reduced mobility or feeling’ 
(Apparelyzed.com). SCI can be sub-divided into two main categories; complete and 
incomplete injury (Figure 1.1). According to the ASIA neurological classification 
complete SCI refers to ‘no preservation of motor and/or sensory function that exists 
more than three segments below the level of injury’, whereas incomplete SCI refers 
to ‘some preservation of motor and/or sensory function existing more than three 
segments below the level of the injury’ (American Association of Spinal Cord Injury, 
2004). 
Although advances have been made through research, there are currently no 
fully restorative therapy for SCI and therefore, safety measures especially in the 
sports industry have been put in place to reduce the risk of developing new cases 
(Thuret et al., 2006). SCI can lead to devastating long term effects and 
Methylprednisolone; the only treatment for acute human SCI, helps to reduce 
inflammation and pain for the individual (Akhtar et al., 2008, Turner et al., 2001, 
Balazy, 1992). The life expectancy of an individual diagnosed with SCI can be 
significantly reduced, impacting on their quality of life which results in income loss if 
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the severity of the condition worsens (Hagg and Oudega, 2006, Krassioukov et al., 
2003, Rintala et al., 1998, Cairns et al., 1996, Segatore, 1994). This further impact’s 
on the economic burden along with the high costs associated with primary care of the 
individual (Talac et al., 2004, Nakae et al., 2011).  
After SCI, pathological changes at the lesion site ultimately play a part in 
nerve conduction loss and prolonged demyelination. These changes include 
increased inflammation, disruption of blood-spinal cord barrier (BSCB)  and extensive 
haemorrhage, along with an increase in necrosis, apoptosis, cavitation and ischemia 
(James et al., 2011, Byrnes et al., 2010, Benton et al., 2009, Benton et al., 2008, 
Carmeliet, 2005, Whetstone et al., 2003, Sroga et al., 2003, Segal et al., 1997). An 
upregulation of all these factors results in detrimental effects on axon regeneration 
after injury.  
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Figure 1.1 A diagrammatic illustration demonstrating complete vs. incomplete SCI. 
Complete injury transects the whole of the spinal cord resulting in complete loss of 
sensory and/or motor function (A). Whilst incomplete injury only transects part of the 
spinal cord resulting in reduced sensory and/or motor function. The orientation of the 
spinal cord (B). 
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1.2 Prevalence and demographics of SCI 
The prevalence and incidence of SCI is increasing over recent years as a 
result of car accidents, sports injuries and trips and falls, particularly in developing 
countries due to the large amounts of manual labour (Singh et al., 2003). In the US, it 
is estimated that 273,000 people are living with SCI and 12,000 new cases occur 
annually with road accidents being the major cause accounting for 46% (Bernhard et 
al., 2005, Burke et al., 2001, NSCISC, 2013, Sekhon and Fehlings, 2001). 80% of 
spinal cord injured patients are also reported to be male which could be a 
consequence of sport related injures (Beers and Porter, 2006, Bernhard et al., 2005, 
Jackson et al., 2004, NSCISC, 2013, Sekhon and Fehlings, 2001, Strauss et al., 
2006). Most new cases occur in the younger generation with an estimated 50%-70% 
of those aged between 15-35 years (Bernhard et al., 2005). The estimated racial and 
ethnic distribution of SCI patients reported is 77% Caucasian, 25% African American, 
8% Hispanic and 2% other (NSCISC, 2013). However, in UK and Ireland there are 
approximately 1,000 new cases each year with road accidents being the major 
contributor (Spinal Research, 2011).  
SCI affects more than 2.5 million people worldwide and 130,000 new cases 
are reported each year (International Campaign for Cures of Spinal Cord Injury 
Paralysis). Recent reports have shown that the global incidence rate in 2007 was 
179,312 cases per annum/ 23 cases per million extracted from regional data (Lee et 
al., 2014). Whilst a systemic review reported that global incidence varies between 8-
246 cases per million and the global prevalence is 236-1,298 cases per million 
(Furlan et al., 2013). These results show the huge variation in incidence and 
prevalence and one of the key factors that could affect the reported cases of SCI is 
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the unreported cases. This in particular is seen in developing countries where lifting 
large heavy loads results in injures to the back (Singh et al., 2003). 
 
1.3 Complex systems in the human body 
The human body is a complex organism functioning under numerous intricate 
systems enabling us to perform simple gestures such as thinking, moving and 
talking. Amongst some of the major systems like the cardiovascular and respiratory 
systems, the nervous system acts as a central control system for the entire body 
regulating voluntary and involuntary actions. Information received from a stimulus, 
such as; pain, taste or smell, is processed to bring about a response through other 
organ systems. The nervous system is further subdivided into two categories that 
include the central nervous system (CNS) and peripheral nervous system (PNS). The 
current research under taken concentrates on the CNS and in particular the spinal 
cord and the effects on the microvasculature after injury in an aim to translate 
research efforts for clinical outcomes.  
 
1.4 Spinal cord anatomy 
The spinal cord is a major component of the CNS, playing an essential role in 
relaying information between the brain and the body. The spinal cord is surrounded 
by cerebral spinal fluid (CSF), encased within a vertebral column and, like the brain, 
is encapsulated by three CNS membranes known as the meninges; pia mater, 
arachnoid and dura mater. The dura mater is the tough outer sheath and directly 
beneath it is the arachnoid and then the pia mater is the innermost layer that adheres 
to the surface of the spinal cord (Nogradi and Vrbova, 2000). The human spinal cord 
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is made up of 31 segments that are subdivided into 5 groups; cervical, thoracic, 
lumbar, sacral and coccygeal. There are 8 cervical (C) segments, 12 thoracic (T), 5 
lumbar (L), 5 sacral (S) and 1 coccygeal (Co). The spinal cord consists of three main 
components; white matter (WM), grey matter (GM) and a small central canal filled 
with CSF that runs along the entire length (Figure 1.2). However, it is important to 
note that the ratio between the WM and GM varies depending on the level of the 
spinal cord. The WM that surrounds the GM mainly contains myelinated and 
unmyelinated nerve fibres, and is divided into three sectional areas known as the 
dorsal (posterior), lateral and ventral (anterior) columns, that contain both ascending 
and descending axon fibre tracts (Figure 1.2). Whilst, the GM, characteristically 
shaped like a ‘butterfly’, contains mainly cell bodies of neurones and glia.  
There are entry and exit sites at each level of the spinal cord that harbour the 
spinal nerves; sensory and motor nerve roots, which are named in accordance to the 
site of their emergence. C1-8 spinal nerves contribute largely to motor control in the 
head, neck and upper extremities. Whilst T9-T20 provides control for the abdominal 
musculature and the lumbar and sacral segments of the spinal cord provide control to 
the lower extremities. The ascending tracts relay sensory information via the dorsal 
root ganglion (DRG) from the sensory receptors to the brain, whilst the descending 
tract carries information via the ventral root from the brain to the target organ, muscle 
or cell.  
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Figure 1.2 A diagrammatic illustration of the components of the spinal cord (Adapted 
from Mautes et al., 2000). The white matter (WM) largely surrounds the grey matter 
(GM) with a small central canal containing the cerebral spinal fluid (CSF). The spinal 
cord is divided into three main areas; dorsal, lateral and ventral, in which the 
anatomical structures are named after to understand the orientation (DRG = dorsal 
root ganglion). 
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1.5 Vascular supply to the uninjured spinal cord 
The blood supply to the spinal cord arises from extrinsic and intrinsic arterial 
supply, and in the thoracic region the extrinsic blood supply arises from the 
intercostal artery that enters via the intervertebral foramen. The spinal artery then 
divides into three branches; the anterior and posterior spinal canal arteries and the 
radicular arteries (Crock and Yoshizawa, 1977) (Figure 1.3). The radicular artery 
further divides into the anterior radicular artery and the posterior radicular artery that 
penetrates the dura mater and joins three major arteries on the surface of the spinal 
cord; right and left posterolateral longitudinal spinal arteries and the anterior median 
longitudinal spinal artery (Dommisse, 1975). Among these arteries is a branching 
network of small arteries called the arterial vasocorona. The vasocorona and central 
arteries, originating from the anterior median longitudinal spinal artery, make up the 
intrinsic arterial blood supply to the spinal cord (Figure 1.4). The vasocorona 
connects the anterior and posterior spinal arteries on the surface of the spinal cord 
allowing an uninterrupted blood supply to the entire length through the pia mater. 
Both systems are characterised by different blood flow directions in an aim to supply 
the whole length of the spinal cord. But regions arise that may not receive a direct 
blood supply referred to as the ‘watershed zone’ that are dependent on the 
overlapping vascular fields and thus may be prone to vulnerability (Mautes et al., 
2000). In the thoracic region the blood is largely supplied by the anterior radicular 
artery and in a CNS injury model occlusion to the artery results in ischemia (Zivin and 
DeGirolami, 1980). 
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Figure 1.3 A diagrammatic illustration of the extrinsic blood supply to the spinal cord 
to the thoracic region (Adapted from Mautes et al., 2000). The incoming intercostal 
artery divides into three branches: the radicular artery and the anterior and posterior 
spinal canal arteries, which aid in the extrinsic blood supply. The radicular artery 
travels along the nerve root to further divide into the anterior and posterior radicular 
arteries. 
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Figure 1.4 A diagrammatic illustration of the intrinsic blood supply to the spinal cord 
(Adapted from Mautes et al., 2000). The central artery and the vasocorona are the 
main intrinsic systems that supply the blood to the spinal cord. Note the different 
blood flow directions within the cord itself.  
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1.5.1 Vascular supply after SCI 
After SCI it is known that the primary injury results in the deleterious 
secondary consequences, such as haemorrhage, as a result to injured blood vessels 
in the spinal cord coinciding with cavity development (Noble and Wrathall, 1989a, 
Noble and Wrathall, 1989b). Blood can be toxic to the CNS due to the disruption of 
blood vessels form the primary injury playing a role in the secondary pathogenesis of 
SCI (Mautes et al., 2000). In the spinal cord the blood flow is not unidirectional and 
therefore can reverse in some of the vessels known as ‘partial blood flow theory’, 
where ascending and descending blood flow currents exist in the radicular arteries 
resulting in the multidirectional flow (Adamkiewicz, 1882, Thron, 1988). This 
multidirectional flow may serve as protection to the spinal cord after injury when local 
blood vessels are damaged and incapable of supporting the surrounding tissue 
(Mautes et al., 2000). 
 After SCI the highly vascularised central GM undergoes immediate 
vasospasm of the superficial vessels and haemorrhage (Ducker and Assenmacher, 
1969). These superficial vessels are subject to shear stress and stretching and thus 
impairing microcirculation and perfusion that results in reduced spinal cord blood 
supply and the impairment of autoregulatory systems (Young et al., 1981, Senter and 
Venes, 1978, Dohrmann et al., 1972). The extent of haemorrhage is directly 
proportional to the severity of the injury (Noble and Wrathall, 1989a, Noble and 
Wrathall, 1989b, Noble and Wrathall, 1985). This haemorrhage is dominant at the 
site of injury in both the WM and GM, extending to distant sites in the rostral and 
caudal segments of the cord away from the injury epicentre. Haemorrhage can 
further exacerbate the damage in the CNS contributing to cavity development and 
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cell damage (Bullock and Fujisawa, 1992, Noble and Wrathall, 1989a, Noble and 
Wrathall, 1989b). 
 
1.5.2 Cellular responses to SCI 
One phenomenon that has received attention after SCI is cavitation (Figure 
1.5). Cavities are fluid-filled cysts that form around the injury site after SCI and occur 
as a result of lysosomal spinal cord autotomy (Kao et al., 1977). Experimentally, 
spinal cord cavitation occurs after intraspinal injection of quiscolic acid; a known  
excitatory amino acid (EAA) agonist that causes cell death (Bhatoe, 2009). 
Inflammation is also a key regulator in activating a cascade of events that leads to 
secondary damage, progressive cavitation and glial scarring in the CNS (Singh et al., 
2012, Fitch et al., 1999). Cavitation can also occur in regions of chronic ischemia of 
vascular origin (Sherk et al., 1984).  
SCI is a two-step process marked by distinct changes during the primary and 
secondary injury phases. ‘Primary injury refers to damage sustained by the neural 
elements at the time of trauma through shear forces to axons or blood vessels and 
results in irreversible injury (Cadotte and Fehlings, 2011). The secondary injury 
phase refers to the body’s response to the primary injury and involves a host of 
cellular processes that occur immediately after injury and persists for months to 
years’ (Cadotte and Fehlings, 2011). The primary injury produces the cyst, which is a 
characteristic cumulative effect that brings about the secondary injury causing the 
progression of the initial lesion. Initiation of the secondary injury is brought about 
when the injured site becomes infiltrated with immune cells, such as, monocytes and 
macrophages. This occurs within the first few hours after the initial injury and over the 
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next few days or weeks the lesion site becomes enlarged causing the formation of a 
glial scar lining the cavity (Fitch et al., 1999) (Figure 1.5 and 1.6). The cyst contains 
extracellular connective tissue matrix (ECM) proteins such as collagen type 1, 2 and 
3, laminin, fibronectin and chondroitin sulphate proteoglycans (CSPGs) that become 
fluid-filled (Sroga et al., 2003). These cysts are located in and around the lesion 
epicentre, preventing re-growth of damaged axons. Demyelination is the loss of 
oligodendrocytes, the myelin forming cells of the CNS (Guest et al., 2005). Prolonged 
demyelination of the spared axons can lead to degeneration resulting in the loss of 
nerve conduction in the spinal cord. In an attempt to remyelinate axons, cells that 
produce oligodendrocytes (oligodendrocyte progenitor cells (OPC)) which are located 
in the spinal cord migrate towards the site of demyelination.  
After SCI, astrocytes become reactive, up-regulating the expression of glial 
fibrillary acidic protein (GFAP) which increases the flow of ions and neurotransmitters 
from neurons to the extracellular fluid (Faulkner et al., 2004). The astrocytes divide 
and fill the vacant spaces with glial scar tissue, where the axons of pre-injury neurons 
are occupied; this is where regenerating axons would be located prior to the injury, 
thus resulting in regenerative failure (Thuret et al., 2006). Glial scarring is the bodies’ 
mechanism to protect and begin the healing process in the CNS.  
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Figure 1.5 A diagrammatic representation of the formation of fluid-filled cysts after 
SCI. (Adapted from Springer Images). The primary injury is the initial lesion sustained 
to the cord causing an influx of immune cells and macrophages into the lesion site. It 
is the constant influx of these invading immune cells that leads to the formation of 
fluid-filled cysts or cavities, which bring about the secondary injury, causing the up-
regulation of reactive astrocytes that divide and fill the vacant spaces with glial scar 
tissue lining the cavity. The glial scar then acts as an inhibitory factor leading to 
myelin degradation, and nerve conduction loss. 
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Figure 1.6 Longitudinal section from a T8 dorsal column crush injured rat 
demonstrating laminin immunostaining at 8 days post lesion (dpl) (counterstained 
with Haematoxylin) and the extent of the cavitation at the lesion site. A large cavity is 
observed at the epicentre of the lesion (*) while smaller cavities are observed in 
adjacent areas (+). These cavities lead to destruction of axon and eventual loss of 
function. Scale bar = 100µm.  
 
Although the glial scar has a beneficial effect such as stimulating neovascularisation 
of blood capillaries to increase the support of the nervous tissue, it can also have a 
detrimental effect on the CNS such as preventing neuronal re-growth by acting like a 
physical barrier. Following demyelination there is also an increase in apoptosis, 
necrosis and secretion of inhibitory molecules such as ephrins, semaphorins, 
oligodendrocyte-derived myelin glycoprotein (OMgp), Nogo and myelin associate 
glycoprotein (MAG) that inhibit axon regeneration (Vourc'h and Andres, 2004, Hamill 
et al., 2005). Therefore, suppressing or arresting the development of secondary 
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damage will provide a more conducive environment for the growth of regenerating 
axons through the SCI sites (Kundi et al., 2013).                     
After SCI, the lesioned area contains cavities that are subdivided into two 
categories; Type I and II cavities. These are classified on the basis of their cellular 
and ECM content and lining (Lagord et al., 2002). Type I cavities contain ECM 
proteins including laminin and collagen and are in continuity with the subarachnoid 
space, whereas Type II cavities contain mainly inflammatory cells with no ECM 
proteins and no continuity with the subarachnoid space (Fitch et al., 1999). Typically 
mice develop small Type I cavities after SCI whereas in the rat, Type II cavities 
predominate. 
The condition present in humans that results in cavitation after SCI is known 
as post-traumatic Syringomyelia, affecting approximately 40,000 people in the UK 
(The Back-up Trust.org.uk). This condition can cause progressive pain, headaches 
and loss of upper extremity function, which can be life-threatening and potentially 
disastrous complication of SCI if the syrinx extends rostrally into the brain stem and 
interferes with the nerve impulses (Edgar and Quail, 1994, Biyani and el Masry, 
1994). Symptoms do not develop at a specific time but can manifest soon after injury 
or later in life. Due to the availability of MRI for diagnosis and follow-up, 
Syringomyelia is increasingly being recognised as an important cause of delayed 
neurological deterioration after SCI. Management of the condition involves drainage 
of the syrinx with a thecal shunt and correction of deformity allowing relief from the 
sensory symptoms (Lam et al., 2008).  
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1.5.3 Angiogenesis and cavitation 
Angiogenesis is a multistep process requiring the interaction of the ECM and 
its component cells that is primarily triggered by tissue hypoxia after injury (Chung et 
al., 2010). After an angiogenic stimulus, endothelial cells adopt a proteolytic 
phenotype losing their contact with the vascular basement membrane and causing 
the basement membrane to be degraded by matrix metalloproteinases (MMPs) 
(Hughes, 2008, Haas, 2005). The pro-angiogenic factor, vascular endothelial growth 
factor (VEGF)-A, stimulates the outgrowth of endothelial tip-cells and proliferation of 
stalk cells allowing new vessels to sprout at the basement membrane along with 
pericyte detachment (Gerhardt et al., 2003, Ruhrberg et al., 2002). When endothelial 
cells and the basement membrane re-establish contact, tissue inhibitors of 
metalloproteinases (TIMP)-2 switch off the proteolytic phenotype of endothelial cells  
allowing cell migration and proliferation to occur in response to activated pro-
angiogenic proteins such as VEGF, basic fibroblast growth factor (FGF2) and MMPs 
(Saunders et al., 2006). As vessels mature, endothelial cells align, aided by platelet-
derived growth factor (PDGF), MMPs, and angiopoietins recruiting pericytes. 
Pericyte/endothelial cell/vascular smooth muscle cell association is essential for the 
maturation of endothelial tubes into blood vessels (Chung et al., 2010). 
In humans, inhibited angiogenesis occurs after suppressing VEGF and its 
receptor: VEGF-R whilst VEGF-R alone has shown to induce cavitation in lung and 
non-small-cell lung tumours (Johnson et al., 2004, Marom et al., 2008, Crabb et al., 
2009). Cavitation in the rat SCI lesion site is associated with vascular regression and 
endothelial cell loss at the lesion epicentre that causes ischemia, haemorrhage and 
blood spinal cord barrier (BSCB) disruption (Loy et al., 2002, Casella et al., 2006). 
19	  |	  P a g e 	  
	  
Such vascular dysfunction after SCI is an important contributor to the ensuing 
neurological deficits (Fassbender et al., 2011). 
 
1.6 Current mammalian models of SCI  
Animal models have been developed with the aim of recreating features of either 
complete or incomplete SCI allowing understanding of the anatomical and biological 
consequences of SCI to be investigated. Animal models have several obvious 
advantages over their human counterpart: for example, the specified tissue needed 
can be used and processed for histological purposes to investigate co-localisation of 
proteins of interest, mRNA analysis (microarray) to give expression levels of genes, 
and protein analysis (western blotting) to give levels of protein. Rat models are most 
widely used to study SCI since they are inexpensive, have few surgical infections, 
are easy to care for and can be studied in large numbers but increasingly mouse 
models have also been implemented in SCI research (Talac et al., 2004). Larger 
mammals such as dogs and cats are also used but less established models in SCI 
research, requiring expensive after care and housing as well as stringent ethical 
considerations (Kundi et al., 2013). 
Currently there are range of models that are used by researchers (Table 1.1) 
that include contusion, compression and transection-based models amongst others. 
The limitation of these different animal models is that they can never truly express 
the clinical characteristics of the human condition (Davoody et al., 2011), but the real 
question is ‘have animal models contributed to actual therapies?’. The only actual 
therapy for the treatment of acute SCI in humans is Methylprednisolone (MP), and 
even though it has shown a significant benefit in animal models the benefits on 
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human SCI remain unproven and is not considered a regulatory treatment for SCI 
(Akhtar et al., 2008, Hugenholtz, 2003, Hurlbert, 2000, Blight, 2000, Hall, 1992, Hall 
and Braughler, 1982). This review aims to establish the current animal models that 
are used to study SCI and the advantages and disadvantages of the techniques and 
therefore the potential outcomes in relation to the human condition. 
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Model Description Advantages/Disadvantages  
Contusion • Induced with an impactor i.e. weight-
drop from a specified height (Allen, 
1911), thoracic contusion is most 
commonly used (Jakeman et al., 2000, 
Behrmann et al., 1993) 
• Impact from contusion can be 
difficult to assess pain 
behaviour due to variation of 
distance 
• Dogs, rats 
and mice 
Clip 
Compression 
• Induced with clips calibrated to exert a 
force of 50/35g- 50g=severe response 
and 35g=moderate response 
• The clip is closed over the entire cord 
for 1 minute (Bruce et al., 2002) 
• Allows for precise control of 
injury 
• Does not resemble injury seen 
in humans 
• Rats only 
Balloon 
Compression 
• Uses different volumes of balloon 
inflation and different durations of 
expression to create contusion (Lim et 
al., 2007) 
• Controlled environment 
• Non-invasive method of 
creating SCI 
• Dogs and 
monkeys 
Computer 
Controlled 
Contusion 
• Uses an animal trap that delivers a set 
weight to the exposed spinal cord; the 
computer monitors the impact (Stokes 
and Jakeman, 2002) 
• Reproducible, controlled 
environment 
• But equipment is expensive 
• Mice only 
Spinal Cord 
Displacement 
• Attempts to regulate trauma impact by 
controlling displacement length of the 
• Controlled displacement and 
monitoring of biochemical 
• Mice and 
rats 
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spinal cord (Nakae et al., 2011) parameters at the time of 
impact helps reduce outcome 
variability- controlled 
environment 
Transection • Complete spinal transection, performed 
using spring scissors (Nakae et al., 
2011, Kang et al., 2011) 
• Widely used to asses 
regeneration (Talac et al., 2004) 
but it’s clinically irrelevant (Poon 
et al., 2007) 
• Rats only 
Photochemical • The use of a dye induces the 
photochemical reaction by activating an 
argon laser to produce single oxygen 
molecules on the endothelial surface of 
spinal cord vessels (Watson et al., 
1986) 
• Reliable and reproducible 
• Does not induce mechanical 
trauma to the cord  
• Extent of injury is difficult to 
control 
• Rat and 
mouse 
Excitotoxic • Intraspinal/intrathecally injection of 
excitotoxins e.g. quiscolic acid (Bhatoe, 
2009) 
• Long-lasting spontaneous pain, 
thermal hyperalgesia and 
mechanical allodynia (Fairbanks 
et al., 2000, Yezierski et al., 
1998) 
• Has ability to correlate specific 
areas of tissue damage  
• Rats only 
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Spinothalamic 
Tract Lesions 
• Lesions core pain pathway; 
spinothalamic tract area using tungsten 
microelectrode (Nakae et al., 2011, 
Zeilig et al., 2011) 
• Resembles allodynia and 
hyperalgesia  
• Provides useful and novel 
insights into the underlying 
biological mechanisms of SCI 
• Rats only 
Canal Stenosis • Is entrapment of the cauda equine 
and/or lumber nerve roots by 
hypertrophy of osseous and soft tissue 
structures surrounding the lumber 
spinal cord that reduces blood flow 
(Sekido et al., 2012) 
• This model helps clarify 
pathophysiology of chronic, light 
pressure to the spinal cord 
(Sekiguchi et al., 2004) 
• Rats only 
 
Table 1.1 Summary of the current SCI animal models that are used in research to mimic the clinical human SCI. These animal 
models are used to assess pain, behaviour, histology and genetic alterations following SCI, but more importantly to assess 
neural and molecular outcomes. These models are more frequently developed on rat and mice and less frequently on larger 
animals such as cats and dogs. 
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1.6.1 Contusion Models 
The vast majority of human SCI are caused as a result of motor vehicle 
accidents, falls and sporting injuries involving a sudden compression of the spinal 
cord. This results in vertebral damage that allows the bone or vertebral disc to 
encroach on the spinal canal space. Other instances include laceration of the spinal 
cord, bullet wounds and slow compression injuries that can result from tumour 
growth. The contusion model is the most widely used animal model that relies on an 
impactor device, such as weight-drop from a specified height. The impact of the 
weight can vary depending on the distance moved by the weight. The first tightly 
controlled contusion model of SCI was described by Allen (1911), in which a 
specified weight could be dropped from a defined height, delivering a defined amount 
of energy to the exposed spinal cord in canine. This caused injury to the spinal cord 
as a result of compression and displacement and was used to study the effects of 
myelotomy on the outcome of SCI (Allen, 1911). Later, a modification to this model 
was introduced in the form of the New York University Impactor developed in rats 
(Gruner, 1992). More recently the Ohio State University Spinal Cord Research 
Centre has produced a weight-drop device controlled by a computer to closely 
control a particular level of spinal cord compression in mice and rats (Stokes et al., 
1992, Behrmann et al., 1993, Jakeman et al., 2000). A variety of slow rapid 
compression models have been used but it is the extent of the cord displacement 
that determines the severity of the injury. However, the clinical relevance of such 
contusion models has not been established. 
 Nonetheless, the contusion model has been used in a variety of studies that 
include: (1), the use of CM101, a polysaccharide derived from group B streptococcus 
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which inhibited inflammatory angiogenesis, protecting axons from Wallerian 
degeneration and improving functional outcome in mice (Wamil et al., 1998, Nanney 
et al., 2001) (2), suppression of CD47, an inhibitor of angiogenesis improved 
functional outcomes in knockout mice (Myers et al., 2011a, Myers et al., 2011b) (3), 
the use of human CNS stem cells grown as neurospheres that were isolated from 
brain tissue and were implanted after a moderate contusion injury improving 
locomotor recovery in mice (Hooshmand et al., 2009); and (4), transplantation of 
bone marrow mesenchymal stem cells (BMSCs) also increased motor function in rats 
by upregulation of VEGF expression and induced angiogenesis (Yu et al., 2011). 
However, this initial model has been modified to use other devices that bring 
about compression to injure the cord; such as clip compression, balloon 
compression, computer controlled contusion and spinal cord displacement. These 
are all examples that bring about incomplete SCI. 
 
1.6.1.1 Clip Compression 
The clip compression model in some ways resembles the contusion model as the 
injury is caused by pressure to the cord. The injury is induced using clips calibrated 
to exert a specific force. A force of 50g is normally used to produce an outcome that 
would have a severe response and a force of 35g is used to produce an outcome 
that would have a moderate response. The clip is then closed over the cord for 1 
minute allowing precise control over the pressure exerted and the time that the 
pressure is used for, but this model does not truly mimic the injury seen in humans 
(Bruce et al., 2002). Despite this the model is reproducible in rats at the thoracic level 
(Poon et al., 2007). 
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The clip compression model has also been applied to the cervical region of the 
cord in rats to evaluate the efficacy of antagonising the Fas receptor using a soluble 
Fas receptor post-injury (Fehlings and Robins-Steele, 2012). This study showed 
behavioural recovery along with enhanced cell survival, tissue sparing and integrity of 
descending fibre tracts when soluble Fas was administrated via an intrathecal 
catheter either 8 or 24 hours post-injury. Clip compression has also been applied to 
the cord at the thoracic level in rats to test if neutralization of nerve growth factor 
(NGF) with a fusion protein to Trk-A blocked the development of autonomic 
dysreflexia, a life-threatening condition caused by aberrant primary afferent sprouting 
in the dorsal horn that is NGF-dependent (Marsh et al., 2002). The model has also 
been used to carry out kinematic studies to assess locomotor recovery following 
spinal cord clip compression in adult rats, suggesting that kinematic parameters (e.g. 
daily training on a treadmill over a six week period) should be taken into account 
when looking at new strategies to improve locomotor function after SCI (Alluin et al., 
2011). 
 
1.6.1.2 Balloon Compression 
The Balloon Compression model was first described by Tarlov in 1953 and has been 
modified since then. The method uses different volumes and durations of balloon 
inflation to induce injuries at varying severities, allowing for a controlled environment 
(Lim et al., 2007). In an initial description of the balloon compression model, an 
embelectomy catheter was inserted into the epidural space through a 
hemilaminectomy hole at the vertebral arches and balloons were then inflated with 
varying amounts of contrast agents, causing direct compression to the spinal cord 
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(Lim et al., 2007). This method was further adapted and improved such that 
hemilaminectomy was not required, but that balloons were inserted through the 
lumbosacral space into the epidural space, where balloons were then inflated (Lee et 
al., 2008). A variety of different species from canine to monkeys have been assessed 
through this model to gain a controlled compression model of SCI (Guizar-Sahagun 
et al., 2011). 
 
1.6.1.3 Computer controlled contusion 
A computer controlled contusion model consists of an animal trap that reproducibly 
delivers a defined weight to the exposed spinal cord, with a computer monitoring the 
dynamics of the impact (Stokes et al., 1992, Stokes and Jakeman, 2002). The device 
allows the researcher to take control of the degree of the injury produced and 
demonstrates that a well-controlled contusion injury can be observed in mice 
(Jakeman et al., 2000). This is because it reduces the variability of the experiment 
and allows monitoring of biochemical parameters as well as assessments of 
behavioural and histological outcomes following contusion injury (Ma et al., 2001).  
 
1.6.1.4 Spinal cord displacement 
Spinal cord displacement allows the cord to be exposed to a single rapid and 
calibrated displacement at the site of a laminectomy. The injury is initiated at the tip 
of a vertical shaft driven by an electromagnetic shaker. Transducers are arranged in 
series with the shaft recording the patterns of displacement and force during the 
impact in mice (Jakeman et al., 2000). The results demonstrate that the 
electromagnetic device can be used to produce a well-controlled contusion injury. 
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The model attempts to regulate trauma impact by controlling displacement length of 
the spinal cord and therefore helps to reduce outcome variability (Nakae et al., 2011). 
Sensory testing after SCI in rats has been carried out, and it is thought that 
SCI injury impairs sensory systems causing allodynia, showing that early detection of 
this provoked pain pathway can identify mechanisms that are responsible for its 
development (Detloff et al., 2010). Hypothermia improves mobility in rodents and 
experiments have reported the preservation of neurons immediately after injury and a 
faster rate of recovery occurs after cervical displacement when hyperthermia is 
implemented (Lo et al., 2009).  
 
1.6.2 Transection Models 
The transection model is referred to as a complete spinal transection which is 
performed using spring scissors following laminectomy, producing a laceration to the 
cord. This model may reflect complete SCI in patients  but this type of injury is rarely 
seen in the clinic (Nakae et al., 2011, Poon et al., 2007, Talac et al., 2004). However, 
partial transection (hemisection) is also modelled and has become popular for 
studies in the mechanisms of pain. Transection models are also increasingly used to 
model the effects of scaffolds and biomaterials on axon regeneration after injury. For 
example, a polymer scaffold with rat bone marrow stem cells has been used to 
promote plasticity and limited regeneration in spinal cords after injury (Kang et al., 
2011). Combinatorial therapies have also been used where neurotrophic factors have 
been combined with biomaterials after complete transection of the spinal cord in rats 
(Fan et al., 2011). Enhancing axonal regrowth appears to be a promising therapeutic 
approach to repair the injured spinal cord. To allow for regeneration, sterile gel foams 
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have been placed between the two ends of transected cords with variable degree of 
success (Nakae et al., 2011). Particularly, after complete transection sterile gel 
foams were implanted with neurotrophic factors administered exogenously via a 
minipump. Results demonstrated that host axons are able to grow into the transplant. 
Furthermore, there was an increase in motor function recovery and regeneration from 
supraspinal pathways (Coumans et al., 2001). 
Neurotrophic factors have also been used in studies by García-Alías et al 
(2011) after a lateral hemisection to the spinal cord, combining NT-3 with 
Chondroitinase ABC treatment as it restores plasticity in the adult CNS. They found 
that these animals displayed inter-limb coordination and improved body stability. 
Furthermore, neural stem/progenitor cells (NSPCs) have been used to deliver soluble 
Nogo66  receptor protein (blocks the inhibitory effects of myelin-based inhibitors) and 
growth factors to rat spinal cord following complete transection (Guo et al., 2012). 
Results show an increase in survival of transplanted NSPCs while soluble Nogo66 
enhanced axonal regeneration, although no effect on functional recovery was 
observed, since a small number of descending corticospinal tract axons grew into the 
central portions of the bridges. Nogo-66 has been discussed previously by Wei et al 
(2010) following hemisection in rats to show the effects of using hyaluronic acid 
hydrogels modified with Nogo66 receptor antibodies in supporting angiogenesis and 
inhibiting the glial scar at the lesion site (Wei et al., 2010). Despite the fact that 
transection is rarely seen in the clinic patients with this type of injury would be 
considered for clinical trial. But this is very much dependant on the type of trial 
instigated. However, these models have served useful purposes in allowing the use 
of biomaterials, stem cells and neural progenitor cells to show that some of these 
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therapies, when used in combination can restore some degree of function through 
mainly plasticity-related changes to the spinal circuits.  
 
1.6.3 Photochemical Models 
This method was first developed by Watson et al (1986), which showed a 
photochemical-based rat model of SCI, and is now widely used to study neurotrauma 
(Gaviria et al., 2002, Watson et al., 1986). To bring about the injury, a dye is used to 
induce the photochemical reaction by activating an argon laser to produce single 
oxygen molecules on the endothelial surface of spinal cord vessels. This causes 
intense platelet responses, vessel occlusion and damage to parenchymal tissues 
(Hao et al., 1991). The model is reliable and reproducible and does not require 
mechanical trauma and therefore there is no need for a laminectomy since the injury 
is caused purely by ischemia. Once the injury has been induced, behavioural studies 
can be performed. 
The model reproduces the phenomenon of secondary lesions such as; 
cavitation that is seen after SCI. Using this model, motor recovery after 
photochemical SCI, induced before or after intrathecal injection of bupivacaine (an 
anaesthetic drug belonging to an amino amide group that blocks sodium channels 
and therefore prevents the influx of sodium and thus depolarisation) resulted in 
improved motor recovery in rats (Lopez et al., 2004). The model has also been 
successfully adapted in the mouse showing that it is reproducible and reliable (Piao 
et al., 2009, Gaviria et al., 2002). Different exposures to a cold light source correlated 
with the extent and severity of the injury, while histopathological analysis showed 
cavity formation in the ischemic environment. How these models relate to the human 
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condition needs further investigation but these studies can model some of the 
features of the secondary injury phase and thus may be beneficial. 
 
1.6.4 Excitotoxic Models 
An excitotoxic model is induced via intraspinal/intrathecal injection of 
excitotoxins such as, quiscolic acid. The use of excitotoxins produces long-lasting 
spontaneous pain, thermal hyperalgesia and mechanical allodynia but also produce 
cavity formation, neuronal loss and astrocytic scaring (glial scar tissue which 
correlates with the general environment observed after SCI). The advantage of this 
model is that it has the ability to correlate specific areas of tissue damage with 
behavioural changes (Nakae et al., 2011). Animals that are exposed to SCI using this 
method do exhibit pain that is much greater than any other model due to the 
excitotoxic injury inducing spontaneous and/or evoked pain behaviours that are 
associated with chronic neuropathic pain (Yezierski et al., 1998). Yezierski et al 
injected AMPA-metabatrophic receptor agonist quiscolic acid to stimulate injury, 
resembling ischemic events and cavitation observed after SCI, characteristic of the 
clinical condition known as post-traumatic Syringomyelia. Intraspinal injection of 
quiscolic acid has also been used to induce excitotoxic SCI in rats demonstrating 
pathological changes that correlate with clinical SCI; such as, neuronal loss, 
haemorrhage and cavitation (Bhatoe, 2009, Berens et al., 2005, Schwartz et al., 
1999). Although the excitotoxic model is a non-traumatic model it displays the 
characteristic pathological differences that would be seen after clip compression and 
contusion models that are more commonly used. Therefore, the model is useful in 
investigating excitotoxic-mediated changes after SCI. 
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1.6.5 Spinothalamic Tract Model 
This model restricts injury to the spinothalamic tract, which is the main pain 
pathway in animals, using tungsten microelectrodes (Nakae et al., 2011). The model 
provides useful and novel insights into the underlying biological mechanisms of SCI, 
resembling some features of SCI in humans including hyperalgesia and allodynia in 
rodent models (Wang and Thompson, 2008). The model is particularly useful in 
studying pain behaviour, as it works with the central pain pathway, although it has 
been claimed that the loss of spinothalamic functions in patients with neuropathic 
pain does not appear to be a predictor for central pain in SCI, but is a contributor 
(Finnerup et al., 2007).  
Zeilig (2011) showed that the hyperexcitabilty of neurones may be due to 
damage to the spinothalamic tract where the central pain pathway causes a build-up 
in response (Zeilig et al., 2011). Spinothalamic tract neurones show an increased 
expression of metabotropic glutamate receptor subtype 1, which parallels the 
development of hyperalgesia and allodynia, both of which contribute to central pain 
after injury (Mills and Hulsebosch, 2002). 
 
1.6.6 Canal Stenosis 
Canal stenosis is described as the entrapment and narrowing of the cauda 
equine and/or lumbar nerve roots by hypertrophy of osseous and soft tissue 
structures surrounding the lumbar spinal cord, causing ischemia at the site of injury 
(Nakae et al., 2011). The model therefore causes demyelination and subsequent 
axonal degeneration. Canal stenosis helps to clarify pathophysiology of chronic, light 
pressure on the spinal cord (Ito et al., 2007, Sekiguchi et al., 2004). Only recently an 
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animal model has been developed know as, rat lumbar spinal canal stenosis (LCS) 
model  which can be used to study mainly bladder function after injury (Sekido et al., 
2012). Trauma contributes to the primary injury sustained but age can play a major 
factor in narrowing of the spinal canal (Akuthota et al., 2003). Injury to the nerve does 
not always occur in this model but factors such as degeneration of neurones, 
ischemia and inflammation around the site of injury play major contributions to the 
injury of the nerve. It remains to be seen how useful this model will be in 
understanding some of the pathological changes that occur after SCI. 
 
1.6.7 Limitations of SCI models 
As previously discussed, each model presents various limitations with the 
major holdback being that animal models never truly capitulates the injury seen in 
humans for a variety of reasons. For example, it may be difficult to assess pain using 
a contusion model, as sometimes pain behaviour is not always apparent if the weight 
is released on the specified area from a short distance. The contusion model is also 
performed mainly in the thoracic region, as cervical contusion can be life-threatening  
due to respiratory and cardiovascular functions being compromised at the level of 
injury (Nakae et al., 2011, Yisheng et al., 2007). For example, upper cervical SCI can 
disrupt the transmission of respiratory signals from the brain stem to the phrenic 
motor neurones (transmit signals to the diaphragm) therefore causing paralysis 
(Zimmer et al., 2007).  Using computer controlled contusion as a method to obtaining 
reproducible and reliable SCI is an expensive method due to the sophisticated 
equipment that is required. The method also produces lesions that are difficult to 
distinguish between spared and regenerating axons, especially if the focus of the 
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study is axon regeneration (Talac et al., 2004). Although complete transection 
models are widely used to asses regeneration with the help of biomaterials and 
scaffolds, it does produce a large scar at the epicentre and therefore represents a 
severe model and so animals require intensive post-operative care (Talac et al., 
2004, De Winter et al., 2002). However, transection models are difficult to 
standardise if several segments of the cord are removed (Blight, 2000). In addition 
this model is rarely seen in humans and therefore has no clinical relevance except to 
evaluate implantation devices and axon regeneration (Talac et al., 2004). 
Hemisection models however, do not completely cut the corticospinal tract due to the 
injury being incomplete. It is also difficult to control the extent of injury if SCI is 
induced through the photochemical method since large areas may be affected by the 
ischemic environment created as a result of this model. 
The anatomical location of injury between experimental animal models and 
clinical human SCI differ greatly. As discussed above, experimental SCI is potentially 
dangerous at the cervical level as it may lead to life threatening complications to the 
animal. SCI at the thoracic level is more commonly used in experimental models, 
however humans commonly present with SCI at the cervical region  and therefore the 
site of injury can greatly affect the pathology and the severity of the injury presented 
in a clinical setting (Akhtar et al., 2008). 
Two other factors play a crucial role in experimental SCI not mimicking the 
clinical injury presented by humans; laminectomy and anaesthesia. If laminectomy is 
performed on a patient, it not only increases the local trauma but can cause spinal 
instability. This can also occur in animal models of SCI as surrounding muscle, bone 
and ligaments are removed during induction of injury. Removal of specific 
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components at the region of injury can have a major impact and alter the 
physiological responses to injury. In some ways, laminectomy free methods such as, 
balloon compression models may mimic the human condition more accurately.  
Anaesthesia on the other hand, affects the CNS pathology and recovery 
following injury, either directly or indirectly (Akhtar et al., 2008). It can affect blood 
pressure, respiratory rate and metabolism as each individual can react differently 
under different concentrations of the same anaesthetic. As stated above motor 
recovery following photochemical SCI being induced before or after intrathecal 
injection of bupivacaine shows that anaesthesia can affect recovery and functional 
outcomes after SCI (Lopez et al., 2004). 
Functional outcomes and behavioural assessments between clinical models 
and experimental models of SCI also vary. It is very easy for human’s to 
communicate pain and symptoms that the injury presents but very difficult to do so 
with animal models. Therefore, specific tests and analysis methods are carried out 
post-injury to correlate the injury with their behavioural patterns and specific 
biomarkers. The behavioural patterns often correlate with the severity of the injury 
produced and is a measurement that is quite reasonable to carry out in a clinical 
environment but for animal models it is quite limited and indirect (Blight, 2000). The 
main way that functional outcomes are assessed in animals is by using the BBB 
score, which is a locomotor activity evaluation, originally developed at the Ohio State 
University (Basso et al., 1995, Basso et al., 1996). The BBB score evaluates the 
movements of the hind limb of an animal after injury to express recovery. Although 
this analysis is reliable and reproducible, researchers have tested it through the 
severity of the condition, where the BBB score is reproducible in animals with mild 
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severity but as the condition becomes more serve, reproducibility is reduced (Filho 
and Molina, 2007). While the BBB score only assess hind limb function, it does not 
take into account pain, bladder and bowel function which are other symptoms that 
require coordinated spinal cord activity (Akhtar et al., 2008). Other ways of evaluating 
locomotor recovery are also commonly used, such as grid-walking, which tests the 
animal’s ability to deal with challenging limb control problems (Blight, 2000). In 
patients, sensory assessment can be performed by testing whether they can 
distinguish between a sharp or dull edge of a pin but this cannot accurately be 
reproduced in animals and researchers solely attempt to assess sensory function 
based on the loss of motor functions (Akhtar et al., 2008). 
 However, it is important to note that whilst spinal cord cavitation is 
extensively documented in the rat, there is evidence that demonstrates that other 
mammals including rabbits, cats and hamsters do exhibit this detrimental pathology 
after SCI (Vink et., 1989; Anghelescu et al., 1995; Shimada et al., 1995; Shamir et 
al., 1997; Inman et al., 2003). 
  
1.7 Hypothesis 
Previous research has demonstrated that mice and rats display differential 
inflammatory, cavity and scarring responses to SCI and it has been further suggested 
that mice may have a robust wound healing response that demonstrates the cavity 
free lesioned area after injury. This led to the hypothesis that after SCI there is an 
increase in angiogenic/wound healing-related factors that aid in the adequate 
balance of vascularisation, wound healing and scar deposition in mice that ultimately 
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prevents cavitation, spares axons and results in better functional recovery compared 
to rats.  
 
1.8 Overall research aims 
• Determine cavity lesion responses over time after T8 dorsal column (DC) 
between mice and rats. 
• Analyse the localisation and expression levels of angiogenic/wound healing-
related proteins in mice and rat spinal cord sections after SCI using 
immunohistochemistry and western blot and subsequent densitometry. 
• To determine functional recovery in correlation with cavity and angiogenic 
responses between the two species after SCI using Infar-Red (IR) plantar heat 
test and Von Frey hair filament test. 
• To analyse known genome wide angiogenic/wound healing-related genes 
between mice and rats after SCI by microarray analysis.  
• To assess the inflammatory responses between the two species in correlation 
to cavity and angiogenic responses observed after SCI. 
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39	  |	  P a g e 	  
	  
2.1 Animal surgery 
All surgical procedures were licensed by the UK Home Office and approved by the 
University of Birmingham Ethical Review Committee. Female Sprague Dawley rats 
and C57BL6 mice (Charles River, Margate, UK) were the strains used, weighing 
between 180-250g and 20-25g, respectively, in all experiments. T8 dorsal column 
(DC) crush was performed according to the established methods described by us 
previously (Ahmed et al., 2010; Lagord et al., 2002). Animals were anaesthetised 
using 5% isoflurane with 1.8l/mg of oxygen, and given a subcutaneous injection of 
the analgesic Temgesic (Buprenorphine); 0.2ml and 0.05ml, respectively, prior to 
surgery. After a partial laminectomy and identifying the midline of the spinal cord, DC 
were crushed bilaterally at the level of T8 (Figure 2.1 A and B) using a calibrated 
watchmaker’s forceps inserted through the DC meninges to a depth and width of 
0.5mm x 0.5mm in mice and a depth and width of 1mm x 1mm in rats. These 
dimensions were determined using a spinal cord atlas of T8 in both mice and rats 
from the Christopher and Dana Reeve Foundation Text and Atlas (Figure 2.2 A and 
B). Animals were allowed to recover and tissues (defined areas – see relevant 
section) were harvested at specific time points for various tissue processing and 
analyses (outlined below).  
 
40	  |	  P a g e 	  
	  
 
Figure 2.1 Diagrammatic illustration of the spinal cord demonstrating bilateral 
thoracic 8 (T8) dorsal column (DC) crush lesion (A). A cross section of the spinal cord 
highlighting the area of disruption through the corticospinal tract, the grey matter 
(GM) and the white matter (WM) (B).  
Dorsal root (DR) 
Dorsal median fissure (DMF) T8 Lesion  
T8  
Corticospinal tract Central canal 
DR 
GM WM 
DMF 
Lesioned area 
A. 
B. 
Anterior 
surface  
Posterior 
surface  
41	  |	  P a g e 	  
	  
 
Figure 2.2 To achieve disruption of only the dorsal funiculi (DF) for an acute SCI 
response after a bilateral DC crush in both mouse and rat, the cross-sectional spinal 
atlas of region T8 from each species was used to measure the exact width and depth 
of the DF. In this instance watchmakers forceps were calibrated to a width and depth 
of 0.5 mm x 0.5 mm and 1 mm x 1 mm, respectively, for mouse (A) and rat (B). 
(Adapted from “The Spinal Cord: A Christopher and Dana Reeve Foundation Text 
and Atlas”). 
B 
A 
0.5mm 
Width and depth measured of the dorsal funiculi = 2.6cm = 0.5mm based on the scale bar. 
1mm 
Width and depth measured of the dorsal funiculi = 3.1cm = 1mm based on the scale bar. 
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2.2 Tissue preparation 
 2.2.1 Histology and immunohistochemistry  
Animals were killed by exposure to rising concentrations of CO2 and intracardially 
perfused with 4% paraformaldehyde (PFA; TAAB Laboratories, Berkshire, UK) 
buffered at pH 7.4 in phosphate buffed saline (PBS, pH 7.3 ± 0.2). The lesion site at 
T8 was identified and 1 cm portion of the spinal cord (0.5 mm either side of the lesion 
epicentre in both mice and rats (Figure 2.3)) dissected out, post fixed in PFA for 2 
hours	  at 4⁰C followed by cryo-protection by overnight incubations in 10%, 20% and 
30% sucrose solutions in PBS. Spinal cord segments were embedded in OCT and 
stored at -20⁰C until required. Sections were cut at 15µm thick using a Bright cryostat 
(Bright Instrument, Cambridgeshire, UK) through the parasagittal plane of the cord, 
adhered onto Superfrost Plus Slides (Fisher Scientific, Loughborough, UK) and 
stored at -20⁰C until required. 
 
2.2.2 Western blot and microarray 
Animals were killed at 8 dpl by intraperitoneal injection of Euthatal; 0.5ml for rats and 
0.2ml for mice to minimise protein and RNA degradation. The T8 lesion sites were 
isolated (lesion site + 3 mm of cord either side of the lesion epicentre for rats and 2 
mm either side of the lesion epicentre for mice (Figure 2.3)) and immediately snap 
frozen in liquid nitrogen until required.  
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Figure 2.3 After mice and rats underwent an acute T8 bilateral DC crush, tissues 
were collected at various time points, depending on the type of analysis different 
amounts of the T8 region was collected. In this instance 5 mm on either side of the 
lesion epicentre (total 1 cm portion) was collected for histological and 
immunohistochemical purposes (A). Whilst, for western blot analysis and microarray 
analysis either 2 mm (mice) or 3 mm (rats) on either side of the lesion epicentre was 
collected to ensure only those genes involved in the injury response were being 
analysed (B).  
A. Histology and immunohistochemistry 
Lesion epicenter 
5 mm 5 mm 
B. Western blot analysis and microarray analysis 
2 mm / 
3 mm 
2 mm / 
3 mm 
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2.3 Routine histology and immunohistochemistry 
2.3.1 Haematoxylin and Eosin staining (H+E) 
Sections were thawed for 30 minutes at room temperature (RT), and washed x2 in 
PBS. Sections were then immersed in Harris’s Haematoxylin (BDH, Poole, UK) for 5 
mins and washed gently under tap water. Sections were then immersed in Eosin 
(BDH) for 1 min, washed gently under tap water, dehydrated through graded series 
of alcohols, and cleared using 2 changes of Histoclear (National Diagnostics, Atlanta, 
USA) for 1 and 3 mins each. Coverslips were mounted in Vectamount (Vector 
Laboratories, Peterborough, UK) and viewed under a light microscope (Zeiss, 
Hertfordshire, UK). 
 
2.3.2 Fluorescent immunohistochemistry 
Sections were thawed for 30 mins at RT and washed x2 in PBS, permeabilised in 
0.1% Triton X-100 in PBS for 10 mins. After washing sections x3 in PBS, non-specific 
binding was blocked for 30 minutes at RT using PBS containing 0.5% BSA (Sigma) 
and 0.5% Tween 20 (Sigma). Sections were incubated in the relevant primary 
antibody diluted in blocking solution (see relevant sections) and incubated at 4⁰C 
overnight in a humidified chamber (16-18h). Sections were washed x3 in PBS and 
incubated in appropriate Alexa488/594 (green/red, Molecular Probes)/ labelled 
secondary antibodies diluted in blocking solution for 1 hour at RT. Finally, sections 
were washed x3 in PBS and coverslips mounted in the anti-fading agent, Vectashield 
containing DAPI (Vector Labs) and viewed under a Zeiss epi- fluorescent microscope 
(Zeiss).  
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2.3.3 Lesion cavity area 
Although sections throughout the lesion cavity were stained to measure the lesion 
cavity area (Figure 2.4), the middle three sections through each lesion cavity (n = 6 
rats/mice/time-point), determined by cutting sections from the start to the end of the 
DC lesion was used to measure lesion cavity area using ImagePro Analyzer (Media 
Cybernetics, Inc, USA) and relative fluorescent staining intensity to give the amount 
of pixels highlighted in a given area (Ahmed et al., 2014). Cavity areas for mice and 
rats were normalised by recording the ratio of cavity cross-sectional width of the 
spinal cord in the same sections in Adobe Photoshop CS5. One-way ANOVA with 
Dunnett’s post-hoc test was performed (IBM SPSS statistics 20) to detect statistical 
differences. 
 
 
Figure 2.4 Area of acute DC wound cavity at increasing depths from the surface of 
the spinal cord (n = 6 rats represented by different symbols shown in key). Three 
sections chosen at different depths through the lesion were immunostained for 
laminin and GFAP and used to measure the size of the cavity in 6 different rats. 
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2.3.4 Relative fluorescent staining intensity 
All photomicrographs were taken at x 50 magnification with the Zeiss Axioplan 2 
fluorescent microscope using the same standardised exposure settings throughout 
for each antibody. Positive immunostaining was recorded for each antibody in pixel 
counts from a set area of 1851.8µm x 1389.9µm (Figure 2.5) that included the lesion 
site at 0 and 8 dpl. Using ImageJ (NIH, USA), images were thresholded and the 
mean integrated intensity of pixels for each antibody was recorded. Pixel intensities 
at 0 dpl were subtracted from pixel intensities at 8 dpl to remove any background 
fluorescence. Averages and standard deviations were determined and a one way 
ANOVA was performed (IBM SPSS statistics 20) to determine significance. Negative 
antibody controls (primary antibody omitted) were included in each run and used to 
set the background threshold intensity for each antibody and each species. 
 
 
Figure 2.5 A representative picture of the area at x 50 magnification (1851.8µm x 
1389.9µm) containing the entire mouse lesion site (A) and rat lesion site (B) that was 
fluorescently immunostained and used for quantification of fluorescent pixel intensity 
of angiogenic/wound healing-related proteins.   
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2.3.5 Quantification of spared axon density in the dorsal funiculus.  
Photomicrographs of the dorsal funiculus were captured using the Zeiss Axioplan 2 
fluorescent microscope as described above. Using ImageJ (NIH) the relative intensity 
of PKC-γ and NF200+ was measured in the traced area of the entire dorsal funiculi  
after normalisation of the background intensity, obtained with omission of primary 
antibody controls, was subtracted from the intensity value (He et al., 2012). 
Automatic thresholding for each image in ImageJ was performed to determine the 
threshold value for specific immunoreactivity. After setting the threshold, pixel 
intensities above threshold levels were recorded.  
 
2.4 RNA extraction 
Total RNA was extracted from intact control and DC injured rat and mouse tissues 
using TRIzol (Invitrogen, Paisley, UK) RNA extraction reagent according to the 
manufacturer’s protocol. TRIzol was added to 50-100mg of tissue samples and 
homogenised using a bench top tissue homogeniser (Homogenizer Workcenter T10 
basic). Homogenates were centrifuged at 12,000 x g for 10 mins at 4⁰C, the fatty 
layer discarded and the cleared supernatants were transferred to a new tube. 
Chloroform was used to remove contaminating protein and RNA was precipitated 
using isopropanol (propan 2-ol; BDH). After centrifugation at 12,000 x g for 10 mins 
at 4⁰C, the RNA pellet was washed several times with 75% ethanol and the pellet 
was air-dried 5-10 mins at RT. The RNA pellet was resuspended in RNase- free 
water and stored at -20⁰C until required. 
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2.5 Western blot analysis 
 2.5.1 Protein extraction and content assay 
Total protein was extracted from spinal cords by homogenisation in 400µl of ice-cold 
lysis buffer (1M Tris HCL (pH 7.4), 5M NaCl, 0.5M EDTA, 0.25M EGTA, 1% NP-40). 
Homogenates were incubated on ice for 30 mins to allow complete dissociation of 
proteins and clarified by centrifugation at 13,000 x g for 30 mins at 4⁰C. A protein 
inhibitor cocktail (104mM AEBSF, 80mM Aprotinin, 4mM Bestatin, 1.4mM E-64, 2mM 
Leupeptin and 1.5mM Pepstatin A in a dimethyl sulfoxide (DMSO) solution) (Sigma) 
was added to the clarified samples to prevent enzymatic protein degradation. Protein 
content in each sample was assayed using a colorimetric DC protein assay 
according to the manufacturer’s instructions (Bio-Rad, Hertfordshire, UK). Briefly, a 
96 well plate format was used to assay 5µl of sample or a protein standard to which 
reagent A and B were added. The plate was incubated for 15 mins at RT in the dark 
for the colour to develop and read on a spectrophotometer at an absorbance of 
750nm. Protein concentrations were determined in Microsoft Excel using a standard 
curve constructed from the protein standards as a reference point. 
  
2.5.2 Polyacrylamide gel electrophoresis and western blot 
40µg of total protein from each sample were mixed with 2x Laemmli buffer (Sigma), 
boiled for 4 mins and loaded onto pre-prepared 12% Tris-glycine SDS-PAGE gels 
(Invitrogen, UK). Molecular weight standards (5µl of rainbow markers (Invitrogen)) 
were also loaded and proteins were separated for 1hr 50mins at 125V. Resolved 
proteins were transferred onto Immobilon-P polyvinylidene fluoride (PVDF) 
membranes (Millipore, MA, USA) for 2 hours at 25V. Membranes were washed in  
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TBST (0.12% Tris-base, 0.88% NaCl, pH 7.4, 0.05% Tween20) for 5 mins and 
incubated in blocking buffer (TBST, 5% dried skimmed milk (Marvel, Lincolnshire, 
UK)) for 1 hour at RT. Membranes were then incubated with primary antibody (see 
relevant sections) solution (TBST, 5% dried skimmed milk) in a sealed bag on a 
tilting platform overnight at 4°C, washed x3 in TBST before being incubated with 
appropriate secondary antibodies conjugated to HRP (GE Healthcare, 
Buckinghamshire, UK)  for 1 hour at RT.  
Protein bands were detected using an enhanced chemiluminescence (ECL) kit 
according to the manufacturer’s instructions (GE Healthcare) and developed by 
exposure onto Biomax Light film (Kodak, NY, USA). Membranes were stripped in a 
low pH stripping buffer (25mM glycine-HCl, pH 2, 1% SDS) and re-probed as 
required.  
 
2.5.3 Densitometry 
Bands detected by western blot were quantified using densitometry after scanning 
into Photoshop (keeping scanning parameters the same for all blots), and analysed 
using the built-in gel plotting macros in ImageJ (NIH, USA). Each densitometric value 
was derived from three separate blots from three independent experiments and 
normalised to α-tubulin loading control densities. The densitometric values were also 
normalised to the densities of the relevant protein in intact controls for each species 
and presented as mean ± SEM.  
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2.6 Functional test procedures 
SCI induced in our animal models aimed to transect the DC axons and thus disrupt 
the sensory and ascending pathways associated with neuropathic pain after SCI 
(Cruz-Almeida et al., 2012). Infar-Red (IR) plantar heat and Von Frey hair filament 
tests are behavioural analyses that can test these pathways affected in our injury 
model (Baliki et al., 2005; Taguchi et al., 2005). Before carrying out any behavioural 
analyses the plantar surface of both hind limbs on each animal was marked with a 
permanent marker to ensure consistency when testing each hind limb (Figure 2.6A). 
 
2.6.1 Thermal sensitivity 
Using established methods of Plantar heat sensitivity tests described previously 
(Detloff et al., 2012; Hargreaves et al., 1988; Lindsey et al., 2000), animals were 
acclimatised 1-wk before surgery and on -1, 0 (2hr after surgery), 7, 14, 21 and 28 
dpl and data were collected at the same time of day to ensure consistency (n = 10 
rats/mice (5 sham, 5 DC injured)). Animals were acclimatised in clear Perspex 
compartments (230mm x 170mm) for 5 min before testing commenced. Once the 
plantar surface of the hind limbs was placed on the glass with weight support and the 
animal was stationary (Figure 2.6B), the infar-red (IR) heat source (Harvard 
Apparatus, Massachusetts, USA) was placed directly beneath the centre of the 
plantar surface. The beam activated was used to produce a thermal stimulus of same 
heat intensity for both species to start the trial. The reaction time of paw withdrawal 
was recorded for 5 separate tests for each hind limb with a 30s interval before re-
testing on the same paw. The middle three scores for the hind limbs were averaged 
to produce a single score for each animal and presented as mean ± SEM. 
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2.6.2 Mechanical allodynia 
To quantify mechanical sensitivity, hind limb withdrawal responses were quantified 
using Von Frey hair filament tests. Animals were acclimatised 1-wk before surgery 
and on -1, 0 (2hr after surgery), 7, 14, 21 and 28 dpl data were collected at the same 
time of day to ensure consistency (n = 10 rats/mice (5 sham, 5 DC injured)). Animals 
were placed in the Perspex compartment and supplied with food for distraction for 
both species. This was due to animals being placed on a metal grid and therefore 
can identify movement beneath them when applying the monofilament as opposed to 
a glass surface used in the plantar heat test. Animals were allowed to acclimatise for 
10 min before testing commenced. Monofilaments representing specific gram weight 
forces (Stoelting Europe, Dublin) were applied to the plantar surface of each hind 
paw between the foot pads (previously marked with permanent marker) for a 1-2s 
period in a steady manner. A withdrawal response of the hind limb to the particular 
monofilament was recorded as a positive response, while a failure to elicit a 
withdrawal response was recorded as negative. A total of 10 separate trial responses 
were recorded for each hind limb with a 30s interval between each recording. 
Monofilament scores from both hind limbs were averaged to the lowest monofilament 
level used at which 50% or more trials were positive and converted to gram force and 
presented as mean ± SEM. 
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Figure 2.6 Before testing, the plantar surface on each hind limb was marked (A) to 
ensure consistency between each animal. For both behavioural tests (Plantar heat 
and Von Frey test) to commence the animals plantar surface of their hind limbs 
should placed on the ground with full weight support, be stationary and relaxed (B). 
 
2.7 Microarray (Performed by Stephen Kissane, MDS Technology Hub) 
One-colour microarray based gene expression analysis (low input quick amp 
labelling) (Agilent Technologies, Berkshire, UK) was used to identify genes that were 
differentially expressed in mouse and rat after T8 dorsal column (DC) lesion following 
the manufacturer’s instructions (Agilent manual: G4140-90050 version 6.5). One-
A 
B 
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colour RNA spike mix was prepared using serial dilution of 1:20, 1:25 and 1:20 
(Agilent Technologies, refer to Agilent manual regarding serial dilutions depending on 
RNA starting material) and 2µl was added to 100ng of RNA starting material to begin 
the labelling reaction. RNA samples (n = 8 (4 control and 4 injured) per species) were 
denatured and synthesised using T7 promoter primer and labelled with cyanine 3 dye 
by amplifying the samples with T7 RNA polymerase master mix containing cyanine 3 
(Figure 2.7). Each reaction was incubated for 2 hours in a dark circulating water bath 
set at 40⁰C to avoid light exposure. The labelled cRNA was purified using nuclease-
free water, 100% RNA free ethanol, buffer RLT and RPE on RNeasy spin columns 
(Qiagen, Manchester, UK) at 4⁰C, eluting the cleaned cRNA sample in 30µl of 
RNase-free water. cRNA samples were quantified on a Nanodrop (ND-1000 UV-VIS 
Spectrophotometer Version 3.2.1) using the microarray measurement software. 
Measurements including cyanine 3 dye concentration (pmol/µl), RNA absorbance 
ratio (260nm/280nm) and cRNA concentration (ng/µl) were used to determine the 
yield and specific activity before continuing. In this instance for 8-pack microarray a 
yield of 0.825µg and a specific activity of 6pmol Cy3 per µg cRNA was needed before 
going onto the next step (please refer to Agilent manual for recommended yields and 
specific activity depending on the microarray format chosen). Samples were then 
prepared using fragmentation mix (5µl 10X blocking agent, bring total volume to 24µl 
with nuclease-free water and 1µl 25X fragmentation buffer (Agilent Technologies)) 
was added to 600ng of cyanine 3 labelled, linearly amplified cRNA samples following 
the 8-pack microarray formats indicated in the manual. RNA was fragmented for 30 
mins at 60⁰C before the reaction was stopped by addition of appropriate volumes of 
hybridisation mix (2x GEx hybridisation buffer HI-RPM and cRNA from fragmentation 
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mix). 40µl of samples were prepared and loaded onto hybridisation chambers using 
Agilent’s microarray hybridisation chamber user guide (Agilent Technologies, G2534-
90001). Chambers were placed in rotisserie in a hybridisation chamber oven set at 
65⁰C, 10rpm for 17 hours. Time and formation of bubbles was recorded before 
hybridisation chamber disassembly. Slides were submerged in dish 1 containing 
Gene Expression Wash Buffer 1 at room temperature (RT), coverslips was removed 
from the slide and the microarray slide was placed in dish 2 containing Gene 
Expression Wash Buffer 1 at RT for 1 min. Microarray slides were then placed in dish 
3 containing Gene Expression Wash Buffer 2 at 37⁰C for 1 min. Slides were then 
placed in slide holders with Agilent barcode facing up and placed in a nitrogen 
environment. Slides were scanned immediately using Profile AgilentG3_GX_1Colour 
for 8 x 60k microarrays using defined Agilent C scanner settings for one-colour scans 
as indicated in the manual (for 8 x 60k microarrays settings include: dye channel- 
green, scan region- Scan area (61 x 21.6mm), Scan resolution (µm)- 3 and Tiff- 20 
bit). Tiff images are then extracted using Feature Extraction Software and a quality 
control report is generated for each scan. 
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Figure 2.7 A schematic illustration of the amplified cRNA procedure. One-color 
microarray experiments indicate that the sample tested is only cyanine 3 (Cy3)-
labelled. 
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2.7.1 Microarray data analysis (IPA analysis performed by Dr Zsuzsanna 
Nagy, University of Birmingham) 
‘Statistical analysis of microarray’ software (SAM (National Institute of Health, USA)) 
was used to carry out multiclass analysis on raw microarray data between control 
and treated samples off all genes expressed. Genes with an estimated false 
discovery rate (FDR) <10% and p-value = <0.025 were considered to be differentially 
expressed. SAM was carried out with 1000 permutations and the output processed to 
remove duplicates. IPA Ingenuity software was used to interrogate functional 
analysis of those genes that were differentially regulated. IPA Ingenuity software is a 
web-based application that accurately enables the analysis and integration and 
understanding of the biological data from gene expression, providing interactive 
pathway analysis on how genes are related or go on to affect other pathways after 
injury. Cluster and TreeView programs were used to generate heat maps for the 
microarray data (Yates et al., 2013). Genome wide normalisation of raw data files 
was assessed in LIMMA (statistical package) so each treated sample was compared 
to a control sample to show variation between animals of the same species and thus 
biological variation based on average. 
 
2.8 Microarray validation 
2.8.1 cDNA preparation 
High-capacity cDNA reverse transcription Kit (Life Technologies Ltd, Paisley, UK) 
was used to convert RNA to total complementary cDNA following the manufacturer’s 
instructions. 10µl of master mix (10X RT buffer, 25X dNTP mix, 10X random primers, 
RNA-free water, multiscribe RT) was added to each RNA sample that was diluted to 
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500ng in 10µl of RNA-free water. Samples were incubated at 25⁰C for 10 mins and 
further incubated for 2 hours at 37⁰C. Samples were stored at -20⁰C until needed. 
 
2.8.2 Real-time quantitative polymerase chain reaction (qPCR) 
Exiqon universal probe system was used to perform real-time qPCR with forward and 
reverse primers (Table 6.2) designed using a web-based tool produced by Roche 
Applied Science (Roche Diagnostics Ltd, UK). A reaction mix totalling 25µl (12.5µl 2 
x express qPCR supermix (Life Technologies, Paisley, UK), 1µl forward primer 
(10µM), 1µl reverse primer (10µM), 0.25µl of probe (Table 6.2), 0.25µl deionised 
water and 10µl cDNA) was loaded onto a 36-well rotor, qPCR was conducted using a 
Rotor-Gene RG-3000 qPCR machine (Corbett Research Ltd, Australia) and set on 
the following programme (1) 92⁰C for 10 mins, (2) 92⁰C for 15 secs and (3) 60⁰C for 
45 secs, steps 2 and 3 were repeated for a total of 40 cycles for all genes. 
Expression levels were determined using known dilutions of cDNA (1:10, 1:100, 
1:1000) to generate standard curves using Rotor-Gene 6 software (Corbett Research 
Ltd, Australia). All genes were normalised to the expression of housekeeping gene β-
actin to accurately quantify gene expression and compare between samples and 
species. Mean and standard deviations were determined and all statistical 
comparisons were made in SPSS (IBM) using non-parametric Kruskal-Wallis method. 
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CHAPTER 3 
CHARACTERISATION OF THE INJURY RESPONSE IN MICE AND RATS AFTER 
SUB-ACUTE SPINAL CORD INJURY 
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Sections of the introduction are published in the following review: 
Kundi S., Bicknell R., Ahmed Z. (2013). Spinal cord injury: Current mammalian 
models. American Journal of Neuroscience. 4 (1), 1-12. 
Surey S., Berry M., Logan A., Bicknell R., Ahmed Z (2014). Differential cavitation, 
angiogenesis and wound healing responses in injured mouse and rat spinal cords. 
Neuroscience. 275, 62-80. 
 
3.1 Introduction    
 It has been known and accepted that mice and rats display differential 
responses after SCI but research between the two species is limited. However, the 
research available highlights, in particular, the cavity, inflammatory and blood-spinal 
cord barrier (BSCB) responses between mice and rats after SCI. 
 
3.1.1 Differential cavitation and inflammatory responses after SCI 
After SCI, the differential responses of mice and rats have previously been 
documented at a later time-point (28dpl) using MRI analysis after a moderate 
contusion to the thoracic level of the cord (Byrnes et al., 2010). Results demonstrated 
a restricted injury site in mouse tissue with a small area of cavitation surrounded by 
disordered scar tissues, whereas, rat lesion sites displayed multiple cavities, a large 
degree of disordered tissue and significant scar formation around the lesion site. 
Quantification of lesion volume using the Cavalieri method (an accurate volumetric 
calculation that allows organ volumes to be estimated without bias by means of 
consecutive serial sections) showed an increase in lesion volume in rats compared to 
mice (Sonmez et al., 2002, Sahin et al., 2003).  
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Inflammation is part of the body’s natural response to harmful stimuli such as 
pathogens, where vascular tissues aim to remove the harmful stimuli and initiate the 
healing response to bring damaged tissue back to normal. It is a process that needs 
to be closely monitored as chronic inflammation can be detrimental causing 
rheumatoid arthritis, and chronic wound healing for example. Research on the 
inflammatory response comparing the two species has shown that microglia and 
macrophage infiltration is similar after injury, with a marked difference in T-cell 
numbers; in rats T-cell infiltration reached its highest between 3-7 days after injury 
but then declined by 50% at three weeks, whereas in mice T-cell infiltration was not 
evident until 14 days after injury and increased by 50% between 2-6 weeks (Sroga et 
al., 2003). Furthermore, Sroga et al, observed a unique fibroblast-like cell population 
in the newly formed connective tissue matrix in injured mouse spinal cord only. It was 
first under assumption that these cells resembled lymphocytes, however, they did not 
express lymphocyte-specific markers. Immunohistochemical analysis was done to 
see if the nonlymphocytic subpopulation shared the same phenotype as fibrocytes (a 
unique population of blood-derived fibroblast-like cells). Results showed that these 
cells expressed fibronectin, collagen-1, CD43, CD13 and CD45 that extended from 
blood vessels within the tissue matrix. This is characteristic of blood-borne cells 
(fibrocytes) involved in wound healing and immunity.  
It has been shown that there is an increase in the number of white blood cells 
in the cerebrospinal fluid within 7 days after injury with recent studies showing an 
increase in plasma levels of inflammatory mediators in patients with long-standing 
SCI (Segal et al., 1997). It is also thought that the accumulation of activated microglia 
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and macrophages contribute to the progression of secondary injury (Blight, 1992, 
Blight et al., 1995, Bethea et al., 1998).  
 
3.1.2 Differential BSCB responses to SCI 
BSCB (more commonly known as the blood-brain barrier- BBB) is composed 
of specialised endothelial cells that regulate the transport of molecules in and out of 
the CNS, providing a stable environment that is essential for normal neuronal 
function (Mautes et al., 2000). The BSCB is composed of tight junctions between 
adjacent endothelial cells that block intracellular movement of large molecules, 
including plasma proteins (Reese and Karnovsky, 1967). Disruption of BSCB leads to 
vascular permeability due to tight junctions allowing leakage of proteins and 
exposure to toxic effects of inflammatory cells  to the spinal cord which could 
contribute to progression of the secondary injury after SCI (Mautes et al., 2000, 
Whetstone et al., 2003a). The BSCB has been investigated in the two species 28 
days post-injury using sodium fluorescein, showing that after a weight drop injury 
BSCB permeability was apparent at the lesion site of the small cavity in mice with 
little extension to surrounding tissue, whilst in rats the tracer was more diffuse and 
spread rostral and caudal to the injury site (Byrnes et al., 2010). Some reports 
suggest that BSCB permeability at this time-point after SCI may be related to 
inflammation or angiogenesis (Popovich et al., 1996). 
 
3.1.3 Angiogenic and structural extracellular matrix molecule Laminin 
Laminin is a structural, cross-linked, heterotrimeric glycoprotein that is a major 
component of the basement membrane, in particular the basal lamina containing 
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alpha, beta and gamma chains (Cheng et al., 1997) (Figure 3.1). There are currently 
5 alpha, 3 beta and 3 gamma chains that assemble to form the 19 laminin isoforms 
(LN-1 to LN-19) with LN-1 being the most studied isoform consisting of α1, β1 and γ1 
chains (Ekblom et al., 1998, Siler et al., 2000, Koch et al., 1999, Ramadhani et al., 
2012). These chains are binding regions for integrins, collagen and proteoglycans 
whilst also binding to itself to form sheets in the basal lamina of the basement 
membrane. Laminin isoforms are expressed in a tissue-specific manner  located in 
various tissues, nerves and neuromuscular junction (Hallmann et al., 2005).  
In the CNS the presence of laminin has shown regenerative potential ex vivo 
in adult rat and goldfish retinal explants (Ford-Holevinski et al., 1986, Liesi et al., 
1984). Furthermore, it has been demonstrated that laminin γ1 chain in particular is 
important in not only axon regeneration but also axon myelination after injury to both 
the CNS and PNS (Chen and Strickland, 2003, Grimpe et al., 2002, Wallquist et al., 
2002). Laminin expression in chick retina, spinal roots, dorsal root ganglion (DRG), 
and developing rat cerebellum is present in areas where outgrowing axons and 
migrating neurons are present (Cohen et al., 1987, Kalil and Reh, 1979, Rogers et 
al., 1986). An acute injection of polylaminin, a polymeric form of laminin, after 
thoracic compression, partial or complete transection demonstrated improved 
locomotor function (Menezes et al., 2010). Furthermore, polylaminin also 
demonstrated axon regeneration of long and short fibers across the complete 
transection with an unsuspected anti-inflammatory role. This suggested that laminin 
may play a role in SCI and axon regeneration. After ischemic stroke in the CNS 
components of the ECM, in particular laminin was highly upregulated on endothelial 
cells suggesting that ECM remodeling takes places early after ischemic stroke and 
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that the presence of ECM protein expression is an effort to revascularise and 
oxygenate the damaged tissues and thus play a role not only in neuroregeneration 
but also inflammation (Ji and Tsirka, 2012). 
 
 
 
Figure 3.1  Laminins; a heterotrimeric glycoprotein, is a major component of the 
basal lamina of the ECM Laminins contain binding regions for collagen, integrins and 
proteoglycans, it can also bind to itself to form sheets in the basal lamina (Adapted 
from Sigma-Aldrich).  
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3.1.4 Laminin after SCI 
Although reports suggest that laminin expression may be associated with 
outgrowing axons and migrating neurons and thus axon regeneration within the 
nervous system, other reports have contradictory views on this matter. In the PNS, 
Schwann cells express laminin as a major component of the PNS basal lamina 
(Cornbrooks et al., 1983). Laminin immunoreactivity is seen around blood vessels 
and meninges from embryonic to adult rats, the distribution of laminin within the GM 
and WM was very much age-dependent (Sosale et al., 1988). Immunoreactivity of 
laminin in normal spinal cord was present in small amounts in early embryos but 
absent from postnatal animals. However, after injury intense immunoreactivity was 
present at the lesion area in both newborn and adults and was especially prominent 
in the matrix of the lesion, and therefore concluded that the distribution of laminin 
before and after injury did not correlate with axonal growth. The temporal progression 
of angiogenesis and basal lamina deposition after SCI shows an angiogenic 
response with RECA-1 (rat endothelial cell antigen) and SM171 (endothelial barrier 
antigen) with the robust deposition of basal lamina 7 days post lesion within the 
ventral GM epicenter (Loy et al., 2002).  
Motor function after thoracic compression, partial or complete in rats using an 
acute local injection of polylaminin improved 8 weeks post injury, also showing 
neurons of short and long origin to be detected in the spinal cord and brain stem after 
being retrogradely labeled. This indicated regrowth across the complete transection 
site, suggesting its role in promoting axon regeneration after SCI (Menezes et al., 
2010). With laminin demonstrating a contradictory role in axon regeneration in the 
nervous system it also plays a part in endothelial cells and inflammation after injury, 
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this led to the investigation of comparing laminin after sub-acute SCI in mice and 
rats. 
 
 3.1.5 Scar related ECM molecules 
The scar related responses after SCI can be tested using known markers such 
as ED1, fibronectin, GFAP and NG2. Although CD68 (ED-1) was originally identified 
as a marker of macrophages, recent studies demonstrate that CD68 (cluster of 
differentiation 68) is also expressed in human fibroblasts and active endothelial cells 
(Beranek, 2005, Kunz-Schughart et al., 2003, Holness and Simmons, 1993). CD68 
can be used as a marker of active phagocytosis after injury (Perego et al., 2011). 
Fibronectin is a 220 kDa ECM glycoprotein composed of nearly two identical 
disulfide-bound polypeptides. Fibronectin molecule has several distinct domains that 
may bind to collagen, fibrinogen, cell surfaces, heparin, proteoglycans and 
glycoaminoglycans and therefore is a component of the ECM (Meland et al., 2010). 
Fibronectin is a marker of increased fibroblast expression in overgrown lesions 
(Sume et al., 2010).  
Glial fibrillary acidic protein (GFAP) is an intermediate filament protein 
expressed in many cell types in the CNS including ependymal cells during 
development, neural stem cells in the postnatal subventicular zone and astrocytes 
(Liu et al., 2006, Roessmann et al., 1980, Jacque et al., 1978). The increased 
expression of GFAP generally represents activation of astrocytes and glial cells 
during neurodegeneration (Brahmachari et al., 2006). Neural/Glial antigen 2 (NG2) is 
a member of the transmembrane chondroitin sulfate proteoglycan class of inhibitory 
ECM molecules that is highly upregulated after SCI (Jones et al., 2002). NG2 
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expression was not only found in reactive macrophages but also oligodendrocyte 
progenitor cells.  
 
3.2 Rationale 
Unlike humans, mice do not exhibit progressive necrosis, apoptosis and 
cavitation after SCI (Bilgen et al., 2007). Instead, the lesion sites become completely 
filled with ECM molecules, reduced BBB permeability and an adequate balance 
between glial scar and inflammatory markers (Byrnes et al., 2010). Thus, the failure 
of spinal cord cavity formation in mice after injury may be conducive to wound 
healing, leading to ECM deposition and the contraction of the scar with time. This 
differential response between mice and rats was used to investigate cavity lesion 
area, laminin deposition and the local inflammatory response after injury between the 
two species. 
 
3.3 Hypothesis 
Cavitation leads to secondary axonal damage and the presence of cavities in the rat 
SCI model is linked to inadequate wound healing, neo-vascularisation and reduced 
inflammatory responses after SCI, whilst the cavity-free SCI response of mice is 
linked to an adequate balance between scar deposition, wound healing, 
vascularisation and inflammation.  
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3.4 Aims 
• To compare and establish a timeline of cavitation through staining of the lesion 
site after T8 DC crush between the two species. 
• Determine differences in the relative lesion area of the injury site that develops 
after SCI in mice and rats. 
• To compare the localisation of laminin (a surrogate marker of angiogenesis 
and an ECM molecule) over time after SCI, establishing a time-point that 
shows the greatest differences between mice and rats. 
• To establish the local sub-acute inflammatory response between the two 
species after T8 DC crush 8 days post lesion (dpl). 
 
3.5 Materials and Methods   
3.5.1 Experimental design 
Please refer to Materials and Methods section 2.1 Animal surgery and 2.2.1 Tissue 
preparation for histology and immunohistochemistry for standard protocols used. 
Type of analysis N -numbers End-points (days) 
Cavitation timeline 6 (per time point/species) 0, 2, 8, 15 
Laminin timeline 6 (per time point/species) 0, 2, 8, 15 
DC scarring response 6 (per time point/species) 0, 8 
Table 3.1 Experimental design of n numbers and end-points used to assess 
cavitation and laminin over time and DC scarring responses to sub-acute SCI in mice 
and rats. 
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3.5.2 Antibodies used for fluorescent immunohistochemistry 
Please refer to Material and Methods section 2.3.2 Fluorescent 
immunohistochemistry for standard protocol used. Fluorescent 
immunohistochemistry was used to assess laminin deposition and the scarring 
responses after SCI in mice and rats (Laminin (1/200, rabbit polyclonal, L9393, 
Sigma, USA); GFAP (1:400, rabbit polyclonal, G9269, Sigma, USA), fibronectin 
(1:200, rabbit polyclonal, F3648, Sigma, USA), EDI (CD68) (1:400, rabbit polyclonal, 
sc-9139, Santa Cruz Biotechnology, Dallas, Texas, USA), NG2 (1:400, rabbit 
polyclonal, Abcam, ab101807, Cambridge, MA, USA)). 
 
3.6 Results 
3.6.1 Relative proportions of mouse size vs. rat  
Relative proportions between mice and rats were determined using n = 12 
animals/species and calculated by dividing the average width of a mouse cord with 
that of the rat (1036µm / 1443µm = 0.7). This resulted in mouse spinal cords being 
0.7 x smaller than rat and therefore this proportion was taken into consideration when 
determining values in rats. 
 
3.6.2 Acute cavity development 
The histological timeline showed clear pathological differences in the post-
injury response in mice and rats (Figure 3.2 A-H). Little or no differences in gross 
histology were observed at T8 in intact mouse and rat spinal cords (Figure 3.2 A, B). 
At 2 dpl, there was disruption to the normal structure of the cord in the two species 
(Figure 3.2 C, D), but, in rats a large lesion cavity had already begun to develop 
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(Figure 3.2 D). Differences between mice and rat DC lesion sites were more obvious 
at 8 dpl, with tissue disruption in the cord in mice (Figure 3.2 E) but the development 
of a wound cavity in rats filled with haematogenous cells, debris, fibrous material and 
occasional small empty cavities (Figure 3.2 F). Both type I and II cavities were 
present in rat cords at 8 dpl. By 15 dpl, scar tissue had formed at the SCI site but no 
lesion cavities had developed in mouse cords (Figure 3.2 G) while, in rats the wound 
contained Type I cavities consisting haematogenous cells (Figure 3.2 H).  
Differences in wound cavity area were quantified at the various time points in 
defined sections by image analysis using Image ProAnalyzer (Figure 3.3 A) (Please 
refer to Materials and Methods section 2.3.3 Lesion cavity area for detailed 
methodology). The mean pixel intensity count in the defined area showed a marked 
difference between rats and mice (Figure 3.3 B) such that mean wound cavity area in 
the rat was 19 x 10⁴ ± 7.5 x 104 µm² and 26 x 10⁴ ± 4 x 104 µm² at 8 and 15 dpl, 
respectively (Figure 3.3 B). These results confirm that wound cavitation is extensive 
in the rat cord after DC lesion while in the mouse cavities do not develop.   
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Figure 3.2 Histological timeline using a haematoxylin and eosin stain to show the 
development of cavitation at the lesion site at day 0 (A and B) 2 (C and D), 8 (E and 
F) and 15 dpl (G and H), which presented clear post-injury differences between mice 
and rats. Inset picture demonstrates type I cavity at 8 dpl in rats (J) whilst at 15 dpl 
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rats demonstrated type II cavities (H) (n=6/group/time-point; * = lesion epicentre; 
scale bars in A-H = 200µm; arrowheads in D, F and H = cell free areas in rat SCI 
cavities).   
 
 
 
 
Figure 3.3 Quantification of the cavity area in rats at each time-point was achieved 
by drawing around the cavity in Image ProAnalyzer (A) and measuring the mean 
pixel area within the isolated area showed there was a significant increase after 
performing One way ANOVA in lesion area at 0 and 8 dpl, 0 and 15 dpl and 2 and 15 
dpl (B). (n=6/group/time-point; scale bar in A = 200µm).  
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3.6.3 Laminin timeline 
The timeline of laminin deposition after injury was determined using 
fluorescent immunohistochemistry to show the localisation and assess the levels of 
laminin in mice and rats (Figure 3.4 A-H). In the intact cord, the meninges and the 
basal laminae of blood vessels were laminin+ in both mice and rats (Figure 3.4 A and 
B). At 2 dpl, the levels of laminin deposition did not change significantly, compared to 
that observed at 0 dpl in both species (Figure 3.4 C and D), but was enhanced in 
mice compared to rats in the vascular basal lamina and the lining of Type I cavities at 
8 dpl (Figure 3.4 E and F). Enhanced levels of laminin+ immunoreactive vascular and 
glia limitans accessoria remained in 15 dpl mouse lesions (Figure 3.4 G). In rats at 
15 dpl, laminin+ immunoreactivity was primarily associated with the glia limitans 
accessoria (Figure 3.4 H), while the laminin+ immunoreactivity did not change in the 
glia limitans externa of both mouse and rat. 
Quantification of laminin immunoreactivity in ImageJ by thresholding the 
original image (Figure 3.5 A and B) reflected these changes, and following a One 
way ANOVA there was significantly enhanced levels of laminin in mice compared to 
rats at 8dpl (27 x10⁶ ± 2.6 x 106 in mice compared to 7 x 10⁶ ± 1.4 x 106 pixels in rats, 
P<0.002) and 15 dpl (18 x 10⁶ ± 1.1 x 106 in mice compared to 13 x 10⁶ ± 0.5 x 106 
pixels in rats, P<0.003) (Figure 3.5 C). These results demonstrate that fundamental 
differences in injury related parameters are present in mice compared to rats, i.e. 
compared to rats mice SCI sites have greater neovascularisation, do not develop a 
glia limitans accessoria, do not cavitate and deposit higher levels of ECM molecules. 
This time point analysis confirmed that 8 dpl would be the best time-point to 
investigate angiogenic/wound healing-related proteins and gene changes (by 
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microarray analysis) rather than using 15 dpl, since we are interested in the early 
angiogenic response rather during the maturation of scarring that occurs in the spinal 
cord between 12-15 dpl. As opposed to humans maturation of the scar tissue 
normally occurs weeks to months after the initial injury to the CNS, where the 
progressively dense glial scar isolates but does not undergo repair to the injured area 
(Stroncek and Reichert, 2008).  
 
3.6.4 Characterisation of the DC scarring response to injury 
Abundant GFAP+ astrocytes were present in the neuropil and about the lesion 
site in mice (Figure 3.6 A) and in the fibronectin+ lesion core (Figure 3.6 C: inset). In 
rats, fewer GFAP+ astrocytes were localised within the lesion and the lesion core was 
astrocyte-free (Figure 3.6 B and inset). Abundant immunostaining for fibronectin was 
present within the lesion core in mice (Figure 3.6 C and inset) whereas little or no 
immunoreactivity was present in rat SCI sites (Figure 3.6 D and inset). Low numbers 
of ED1+ cells were present in both mice (Figure 3.6 E and inset) and rats (Figure 3.6 
F and inset), and low levels of NG2 were also present in the SCI wounds of both 
species. 
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Figure 3.4 Localisation of laminin in the lesion site over time in DC lesions in mice 
and rats. Expression of laminin in intact controls (A and B) and at 2 (C and D), 8 (E 
and F) and 15 dpl (G and H). The localisation of laminin deposition after DC injury 
displayed clear differences between the two species at 8 and 15 dpl. (n = 
6/group/time-point; * = lesion epicentre; scale bars in A-H = 200 µm; arrowheads = 
glia limitans externa (GLE); arrows = glia limitans accessoria (GLA); open arrows = 
blood vessels).  
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Figure 3.5 Pixel intensities from the original image (A) were calculated in ImageJ by 
thresholding the image (B) and average pixel counts were plotted showing significant 
differences following a One way ANOVA in laminin expression between mice and 
rats at 8 and 15 dpl; with 8 dpl showing the greatest differences in laminin expression 
between the two species (C). (n = 6/group/time-point; scale bars in A and B = 
200µm)  
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Figure 3.6 Acute SCI responses in mice and rats. Immunohistochemistry to show 
changes in GFAP (A and B), fibronectin (C and D), ED1 (E and F) and NG2 (G and 
H) at 8 dpl within and about DC lesions (* = lesion epicentre; scale bars in A-H = 200 
µm).  
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3.7 Discussion 
Our model of T8 sub-acute SCI in mice and rats demonstrates fundamental 
differences seen between the two species early after injury. Cavity development in 
rats begins as early as 2 dpl and continues to expand up until 15 dpl. However, in 
mice only disruption of the cord was evident. Cavity development further coincided 
with a lack of laminin deposition after injury in the lesion epicenter in rats and thus a 
decrease in angiogenesis. However, in mice the lack of cavity development resulted 
in increased laminin deposition in the lesion epicenter after injury and thus an 
increase in angiogenesis.    
 
3.7.1 Differential cavitation expression between mice and rats 
Although our results only extend to 15 dpl, cavity area is thought to continue to 
increase beyond 15 dpl (James et al., 2011, Byrnes et al., 2010). However, by 15 dpl 
the scar tissue around the lesion site is fully mature and the wound-healing response 
is absent beyond this time-point after injury. However, in humans maturation of the 
scar tissue occurs weeks to months after the initial injury to the CNS, where the 
progressively dense glial scar isolates but does not repair the injured area (Stroncek 
and Reichert, 2008). Immunohistochemical studies on human spinal cord after 
traumatic SCI have shown that NG2 and phophacan; members of the CSPGs, are 
present up to a month after injury and thus present in the evolving astroglial scar 
after injury (Buss et al., 2009). Furthermore, GFAP staining in the earlier repair 
stages of wound healing can be observed not only in the lesion epicenter but up to 
400µm outside the lesion (Stroncek and Reichert, 2008). However, when the scar is 
in the remodeling stages, i.e. maturation of scar tissue the GFAP immunoreactivity is 
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more centered to the lesion epicenter. Our intention was to investigate the early 
angiogenic/wound-healing responses that may be responsible for the formation of the 
cavities. Indeed, the mechanisms for the expansion of the cavity area in rats beyond 
15dpl is currently unknown but is thought to occur as a result of maturation of the 
cavity area and secondary mechanisms due to the failure to lay down appropriate 
ECM molecules (James et al., 2011, Byrnes et al., 2010). Although small severity-
dependent injury cavities have been reported in mouse SCI sites, our results confirm 
those of others that ECM deposition without cavitation is a more characteristic 
response (Inman and Steward, 2003, Bilgen et al., 2007). In contrast, rat SCI wounds 
cavitated by 8 dpl and by 15 dpl a large Type II cavity had formed which extended 
rostrally and caudally from the injury epicenter, filled with haematogenous 
macrophages and cellular debris. Cavities may develop after vascular regression and 
endothelial cell loss and their expansion may be exacerbated by hypoxia, necrosis, 
apoptosis and increased vascular permeability (disruption of the blood spinal cord 
barrier (BSCB)) (Loy et al., 2002, Casella et al., 2006). Demyelination and neuronal 
degeneration occur in the surrounding neuropil as the cavity expands (Blight, 2000, 
Mautes et al., 2000, Hunt et al., 2002, Whetstone et al., 2003b, Sandvig et al., 2004, 
Berry et al., 2008, Casella et al., 2006, Fassbender et al., 2011).  
 
3.7.2 Characterisation of lesion laminin expression between mice and rats  
The expression of laminin as a surrogate marker of angiogenesis/wound 
healing  through the early time course mirrored that of cavity area; after injury in mice 
the cavity area was filled with ECM components where laminin levels and protein 
expression was greatly increased correlating angiogenesis and ECM deposition, 
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whereas, in rats after injury cavitation could be seen which increased with time but 
laminin expression was significantly reduced and thus correlated with little 
angiogenesis and reduced ECM deposition.  
 
3.7.3 Inflammatory responses after spinal cord injury 
Cavities may expand as damaged tissues are removed by inflammatory 
macrophages and microglia, explaining the beneficial effects of immunosuppressive 
therapies which probably maintain structural and functional integrity of the spinal cord 
(Giulian and Robertson, 1990, Blight, 1994, Guth et al., 1994, Popovich et al., 1999).  
Although Sroga et al (2003) reported similar responses of macrophages and 
microglia in mouse and rat SCI sites, accumulation of T-cells at the wound is highest  
in rats between 3 and 7 dpl and declines by 50% over the next three weeks, while T-
cell entry is not evident in the mouse until after 14 dpl (Sroga et al., 2003). Dendritic 
cell (normally absent in control rat or mouse spinal cord) infiltrate SCI wounds with T-
cells in rats but not in mice, suggesting another difference in inflammatory reactions 
to SCI between mice and rats (Sroga et al., 2003). Dendritic cells are potent antigen-
presenting cells and have ranging from T-cell activation to T-cell killing (Bernstein, 
1986). Thus, accumulation of dendritic cells in a SCI wound could potentially be 
detrimental by stimulating infiltration of T-cells into the cord or protective by removing 
cytotoxic T-cells. Furthermore, a unique fibroblast-like cell population was observed 
in the newly formed ECM that resembled lymphocytes but did not express 
lymphocyte markers. This phenotype was characteristic of specialised blood-borne 
cells (fibrocytes) that are involved in wound healing and immunity, which are also 
present only in mice (Sroga et al., 2003, Chesney and Bucala, 1997). Although these 
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differential responses may explain why mice do not cavitate, it remains to be 
determined whether they contribute to different injury responsive molecular profiles 
observed in the two species.  The differences in the inflammatory response between 
the two species may thus be a contributing factor to the development of cavities 
within the lesion site in rats. 
 
 
81	  |	  P a g e 	  	  
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
DIFFERENTIAL EXPRESSION OF ANGIOGENIC AND WOUND HEALING 
RESPONSES IN MICE AND RATS AFTER SUB-ACUTE SPINAL CORD INJURY 
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Sections of the introduction are published in the following review: 
Kundi S., Bicknell R., Ahmed Z. (2013). The role of angiogenic and wound-healing 
factors after spinal cord injury in mammals. Neuroscience Research. 76, 1-9. 
Surey S., Berry M., Logan A., Bicknell R., Ahmed Z (2014). Differential cavitation, 
angiogenesis and wound healing responses in injured mouse and rat spinal cords. 
Neuroscience. 275, 62-80. 
 
4.1 Introduction    
 4.1.1 Angiogenesis 
As previously mentioned angiogenesis is a multistep process requiring the 
interaction of the ECM and its component cells that is primarily triggered by tissue 
hypoxia (Chung et al., 2010). Each stage of angiogenesis requires different 
angiogenic molecules to aid in the degradation of the basement membrane, pericyte 
recruitment, outgrowth of endothelial tip-cells, and proliferation of stalk cells and 
migration, proliferation and maturation of the endothelial cells. Dysfunctional 
angiogenesis not only induces cavitation in human cancer, but further results in 
ischemia, haemorrhage and disruption of the blood spinal cord barrier (BSCB) that 
contribute to the detrimental secondary pathogenesis after SCI in rat lesion sites 
(Johnson et al., 2004, Marom et al., 2008, Crabb et al., 2009, Loy et al., 2002, 
Casella et al., 2006). 
 
 4.1.2 Vascular changes after SCI 
Traumatic SCI causes an immediate loss of vascular supply initiating a 
multifaceted response to the injury. This alters the microvascular permeability for 
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days to weeks after injury resulting in neuronal loss and long-lasting damage to 
neuronal elements in the cord. Ischemia is one of the detrimental effects that play a 
part in the vascular changes after SCI that is exacerbated by haemorrhage, edema, 
excitotoxcity and poor perfusion resulting from vasospasm/vasoconstriction (Bullock 
and Fujisawa, 1992, Ducker and Assenmacher, 1969, Yang et al., 1994). Prolonged 
ischemia stimulates neovascularisation and the newly formed vasculature decreases 
glucose transport and increases BSCB permeability and ‘leaky’ tight junctions 
(Benton et al., 2009, Noble et al., 1996, Benton et al., 2008). 
 
 4.1.3 Hypoxia and hypoxia inducible factor (HIF) in SCI 
Hypoxia regulates transcription of hypoxia inducible factor (HIF). HIF has three 
isoforms: HIF-1α, HIF-2α and HIF-3α.  HIF-1 is a heterodimer of two DNA-binding 
proteins; HIF-1α and the aryl hydrocarbon nuclear translocator (ARNT or HIF-1β) 
(Ahmed and Bicknell, 2009). HIF-1α is rapidly degraded in normal oxygen levels and 
binds to ubiquitin ligase; Von Hippel-Lindau protein (pVHL) targeting HIF-1α for 
proteasomal degradation. When oxygen levels drop lower than 2%, HIF-1α is no 
longer degraded, translocates to the nucleus, dimerises with HIF-1β and causes the 
initiation of a complex transcriptional response in genes having specific hypoxia 
response elements (HRE).  
 In the CNS, activation of HIF-1α in the hypoxia-induced ischemia tolerance 
model of brain injury protects the brain from ischemic tissue by preconditioning with 
known activators of HIF-1α, such as cobalt chloride and desferrioxamine, before 
hypoxia induces ischemia (Nordal et al., 2004, Bergeron et al., 1999, Bergeron et al., 
2000, Marti et al., 2000). Ischemia and hypoxia are prominent in the acute phase of 
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SCI and HIF-1α mRNA is expressed 12 hours after injury, peaking at 3 days and 
reducing gradually thereafter to near basal levels (Xiaowei et al., 2006, Yu et al., 
2001). Most HIF-1α mRNA is localised in neurons but is also present in ependymal 
and endothelial cells (Xiaowei et al., 2006). Upregulation of glycolytic enzymes after 
SCI correlates with the expression of HIF-1α mRNA suggesting that active glycolysis 
takes place during these early time-points after SCI (Xiaowei et al., 2006). These 
data suggest that HIF-1α and its target genes such as VEGF limit damage after SCI 
by inducing hypoxia tolerance and neovascularisation in SCI lesions and are 
therefore potential for the treatment of SCI (Kundi et al., 2013). 
 
4.1.4 Angiogenic Factors 
4.1.4.1 Von Willebrand Factor (vWF) 
vWF is a multimeric glycoprotein that was first identified in 1971  playing a vital 
role in haemostasis by functioning as both an anti-haemophilic factor carrier and a 
platelet-vessel wall mediator in the blood coagulation system (Zimmerman et al., 
1971). The synthesis and storage of vWF is found in endothelial cells and 
megakarocytes (platelet precursor haematopoietic cells in the bone marrow) 
(Reininger, 2008). Glycoprotein 1bα (GP1bα); receptor for vWF, is expressed on the 
surface of platelets requiring no activation prior to binding with vWF (Reininger, 2008, 
Monteiro et al., 1999). Upon a vessel becoming injured three processes are activated 
as the first line of defense against bleeding, termed primary haemostasis (Reininger, 
2008). Platelets react with an initial arrest from the flowing blood, followed by 
permanent adhesion and aggregation at the site of injury (Reininger, 2008).  
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Deficiencies or mutations in the protein or gene can result in the Von 
Willebrand’s disease; the most common hereditary bleeding disorder, and 
atherosclerosis (van Galen et al., 2012). It is important to understand that elevated 
levels of vWF are equally as detrimental and have been associated with increased 
risk of ischemic cardiovascular events (van Galen et al., 2012). 
vWF has been highlighted as a possible biomarker in the CNS when detecting 
childhood primary CNS vasculitis due to elevated levels of vWF at diagnosis in 65% 
of the children assessed with this condition (Cellucci et al., 2012). Increased blood-
brain barrier (BBB) permeability is a hallmark of many CNS diseases and 
deficiencies in vWF have shown to promote BBB preservation  in mouse models that 
are presented with increased BBB permeability, hypoxia/re-oxygenation and seizures 
(Suidan et al., 2013). The partial protection in BBB permeability did not provide 
protection but more surprisingly displayed a more severe pathology compared to 
wild-type mice. Given its role in the CNS as a biomarker and potentially reducing 
BBB permeability, research has been instigated to examine the levels of vWF after 
SCI and whether it could be a target for therapeutic options after injury. 
   
4.1.4.2 vWF after SCI 
For many years, vWF has been shown to play a part in the SCI response, but 
few researchers have used this molecule as a therapeutic target in treating patients, 
but more so in recognising the effect of SCI on vWF levels. After acute SCI in 
patients, levels of vWF were high at 6 and 10 days compared to patients who were 
immobilized without paralysis due to a fracture of the cervical spine (Petaja et al., 
1989). Furthermore components of vWF increase after injury causing an increase in 
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platelet aggregability that contributes to hypercoagulation (Mammen, 1992). A major 
cause of morbidity and mortality in patients that suffer from SCI is thromboembolism. 
Following injury there is increase in activity of vWF and its antigen (Green, 1991). 
Contradictory to the earlier reports, levels of vWF and fibronectin remained normal in 
patients with uncomplicated chronic SCI compared to normal patients (Pahl et al., 
1994). SCI has also been associated with coagulation abnormalities and using 
coagulation assays on patients with SCI that either had no deep vein thrombosis 
(DVT) or had DVT, showed no significant differences in the levels of vWF between 
the two groups (Fujii et al., 1992). It may be that due to the contradictory reports on 
vWF researchers have not considered as a target for therapeutic interventions after 
SCI.  
 
4.1.5 Angiogenic Growth Factors 
4.1.5.1 Vascular Endothelial Growth Factor (VEGF) 
VEGF was first described as a tumor-derived factor, approximately 40kDa in 
size and a member of a family of 6 isoforms; VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E and placental growth factor (PGF) (Senger et al., 1983). VEGF-A is 
considered as the most important isoform that stimulates mature angiogenesis, cell 
migration and proliferation whereas VEGF-B, VEGF-C and VEGF-D stimulate 
embryonic angiogenesis and lymphangiogenesis, respectively (Chung et al., 2010, 
Gerhardt et al., 2003, Ruhrberg et al., 2002). VEGF-A has several splice variants; 
VEGF-A 121, 145, 165, 189 and 206, with VEGF-A 165 being the predominant form, 
while VEGF isoforms are expressed in every tissue in adults (Acker et al., 2001, 
Bernini et al., 2002, Maharaj et al., 2006, Robinson and Stringer, 2001). VEGF is 
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upregulated during hypoxia by the action of HIF-1α and stimulates blood vessel 
morphogenesis by binding to VEGF receptor (VEGF-R) located on the cell surface of 
endothelial cells. VEGF is also neuroprotective, axogenic  and supports the survival 
and proliferation of various types of glial cells (Rosenstein and Krum, 2004, Jin et al., 
2000, Matsuzaki et al., 2001, Khaibullina et al., 2004, Mani et al., 2005, Sondell et al., 
1999).  
VEGF is a major angiogenic factor signaling through VEGF-R and many other 
pathways including the RAS/RAF and HIF-1α pathways, thereby restoring oxygen 
supply to tissues with inadequate blood circulation (Ahmed and Bicknell, 2009). Upon 
interaction with VEGF-R, several pathways are activated leading to: (1), gene 
expression and cell proliferation through induction of the MAPK cascade via Raf 
stimulation; (2), cell survival through PI3K and PKB activation; and (3), cell 
proliferation and vasopermeability through activation of PLC-gamma (Figure 4.1). All 
these pathways are angiogenic and regulate endothelial cell function. However, over-
expression of VEGF may contribute to disease, e.g. the formation of metastatic CNS 
tumours, particularly, primary brain tumours that correlate with disease progression 
(Stockhammer et al., 2000; Tassone et al., 2011, Olsson et al., 2006).  
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Figure 4.1 Vascular endothelial growth factor (VEGF) signalling pathway in 
angiogenesis. The building of VEGF to its receptor tyrosine kinase; VEGF-R2 causes 
the activation of various signalling molecules leading to a range of cellular responses. 
VEGF binding causes the activation of SHP-1 and SHP-2 resulting in other 
downstream molecules to become activated such as PLC-γ that goes on to activate 
PIP₂. Once PIP₂ is activated it goes down one of two pathways: DAG, PKC or IP₃, 
Ca²+, NOS and NO, eventually leading to cell proliferation and vasopermeability. The 
activation of Shc, Grb2 and Sos causes activation of the MAPK cascade via Ras, 
Raf, and MEK stimulation resulting in gene expression and cell proliferation. The 
activation of p85 and p110 causes activation of PKB through PI₃K playing a part in 
cell survival. All these different processes lead to angiogenesis through the activation 
of VEGF (Adapted from Sigma-Aldrich). 
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4.1.5.2 VEGF after SCI 
Studies on the role of VEGF in SCI are often contradictory and therefore it is 
difficult to judge the therapeutic utility of VEGF in promoting tissue sparing and 
functional recovery. Contradictory reports exist in the literature about changes in the 
expression of VEGF after SCI. For example, immediately after SCI tissue levels of 
VEGF mRNA and protein rise and eventually normalize by 14 days correlating with 
vascular permeability, rises in HIF-1α and the permeability of the BSCB that can 
have detrimental effects on recovery after SCI (Vaquero et al., 1999, Bartholdi et al., 
1997, Skold et al., 2000, Akiyama et al., 2004, Casella et al., 2002, Loy et al., 2002, 
Benton et al., 2009). Later studies reported a reduction in VEGF isoforms 165, 121 
and 189, in the SCI lesion epicenter where levels remained low for 1 month (Herrera 
et al., 2009). These findings cast doubt on the role of VEGF in regulating vascular 
events after SCI. Moreover, neutralizing VEGF after SCI neither altered the vascular 
density in the lesion epicenter nor exacerbates the histopathology and functional 
recovery after SCI (Benton et al., 2009).  
Furthermore, studies on the use of the predominant form of VEGF; VEGF 165, 
further complicates whether the use of VEGF after SCI is beneficial or detrimental to 
the pathology of the injury. Administration of human recombinant VEGF-A165 via 
intraparenchymal injection into SCI lesions does not affect the microvascular 
architecture but does increase SCI lesion volume, suggesting that intraparenchymal 
injection of VEGF-A165 exacerbates the SCI injury by maintaining vascular 
permeability (Benton and Whittemore, 2003). However, repetitive intrathecal 
administration of VEGF-A165 after SCI neither changes tissue sparing, measures of 
behavioural recovery nor pain hypersensitivity  through plasticity of pain afferents 
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(van Neerven et al., 2010, Deumens et al., 2008, Deumens et al., 2005). Aberrant 
sprouting of primary afferent pathways and rewiring of termination patterns result in 
abnormal processing of sensory stimuli, amplification of nociceptive signals causing 
debilitating chronic pain in >69% of SCI patients (Ondarza et al., 2003, Christensen 
and Hulsebosch, 1997, Finnerup et al., 2001, Siddall et al., 2003). SCI treatments are 
designed to reduce the development of chronic pain and promote maximal functional 
recovery (Deumens et al., 2008, Berger et al., 2011). VEGF165 injection into a SCI 
lesion improves tissue sparing during the acute (early) phase but had no effect on the 
chronic (late) phase after SCI (Sundberg et al., 2011). Furthermore, VEGF165 
treatment enhances sensory recovery and possible remyelination, suggesting that it 
promotes plasticity of the sensory CNS pathways. However, VEGF treated animals 
showed increased incidence of persistent allodynia (a pain stimuli that does not 
normally elicit pain responses) and thus may be an inappropriate treatment for 
human SCI. 
VEGF-A165 increases blood vessel density and tissue sparing in SCI wounds 
significantly enhancing behavioural recovery by 6 weeks (Widenfalk et al., 2003). 
Transplantation of immortalized human neural stem cells into SCI sites, stably 
expressing VEGF, increases blood vessel density, enhances tissue sparing and 
improves Basso, Beattie and Bresnahan (BBB) locomotor scores (Kim et al., 2009). 
While treatment with VEGF-A165 gives conflicting outcomes, it is important to 
recognise that other isoforms of VEGF such as VEGF-A121/189 promote 
neuroprotection (Herrera et al., 2009).  
Administration of engineered zinc finger protein (ZFP) transcription factor, 
which activates all isoforms of VEGF-A, improves outcomes in SCI, stroke, optic 
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nerve injury and traumatic brain injury  probably by induction of angiogenesis (Liu et 
al., 2010, D'Onofrio et al., 2011, Siddiq et al., 2012). Raised VEGF-A mRNA and 
protein levels, increase vascularity, decrease neuronal apoptosis, attenuate axon 
degeneration, and improve both tissue preservation and neurobehavioural outcomes 
after treatment. These results are confirmed using optic nerve injury and cortical pial 
strip ischemia models, through the delivery of adeno-associated vector (AAV) 
encoded VEGF-ZFP’s (D'Onofrio et al., 2011). VEGF-ZFP is neuroprotective, 
inducing angiogenesis and improving functional recovery (Siddiq et al., 2012). 
Sustained release of VEGF in combination with FGF-2 from microfabricated spinal 
cord bridges promotes angiogenesis and axon regeneration within CNS injury sites 
(De Laporte et al., 2011).  
 Administration of a VEGF/PDGF combination provides synergistic modulation 
of inflammatory reactions after SCI and creates a microenvironment that contributes 
to axon preservation and sprouting (Lutton et al., 2012). Co-administration of 
VEGF165 and ANG-1 using viral vectors injected directly into the SCI lesion site 
immediately after injury reduces lesion volume and enhances vascular stabilization, 
improving locomotor recovery, suggesting that combining angiogenesis with vascular 
stabilization might have potential therapeutic applications for SCI lesions (Herrera et 
al., 2010).  
The inconsistent results using VEGF in SCI, may be explained by the short 
half-life of VEGF peptide (3 min in circulation (George et al., 2000)). Hypoxia 
stabilises VEGF and increases its half-life while better outcomes are observed when 
VEGF is injected either exogenously, intraparenchymal or intrathecally  and therefore 
route of administration should be taken into consideration for VEGF as a therapeutic 
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option for SCI (van Neerven et al., 2010, Benton et al., 2009, Levy, 1998, Benton and 
Whittemore, 2003, Yoo et al., 2006).  
 
4.1.5.3 Fibroblast Growth Factors (FGF) 
FGF belong to a family of heparin-binding growth factors with a high affinity for 
heparin sulphate proteoglycans (HSPG) (Cross and Claesson-Welsh, 2001). FGF 
were first purified from bovine pituitary glands, are approximately 18kDa in size and 
have 22 isoforms (Jonker et al., 2012, Ornitz and Itoh, 2001). FGF-1 – FGF-10 are 
the most well studied and bind to one of four tyrosine kinase receptors; FGFR1, 
FGFR2, FGFR3 and FGFR4 (Cross and Claesson-Welsh, 2001). FGF-1 is acidic 
whereas FGF-2 is basic and both are more potent pro-angiogenic factors than VEGF. 
FGF-1 and FGF-2 are normally sequestered in ECM  and regulate endothelial cell 
proliferation (i.e. angiogenesis), cell differentiation and growth, tissue homeostasis 
and wound repair through the MAPK pathway (Jonker et al., 2012, Chung et al., 
2010, Brooks et al., 2012, Cross and Claesson-Welsh, 2001, Abraham et al., 1986b, 
Abraham et al., 1986a). FGF-2 is present in both neuronal and non-neuronal cells 
whereas FGF-1 is confined to neurons (Dono, 2003, Reuss and von Bohlen und 
Halbach, 2003). In addition, FGF-1 and FGF-2 are neuroprotective and improve 
functional recovery in experimental models of head trauma and stroke (Moyer et al., 
1998, Hossain et al., 1998, Madiai and Hackshaw, 2002, Hsu et al., 2009, Hattori et 
al., 1997b, Hattori et al., 1997a, Dono, 2003). 
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4.1.5.4 FGF after SCI 
The levels of FGF-2 mRNA and protein increase adjacent to a SCI epicenter 
over the first 24 hours and peak 4 days later (Eckenstein et al., 1991, Frautschy et 
al., 1991, Follesa et al., 1994, Mocchetti et al., 1996). In models of SCI, FGF-2 
rescues ventral horn neurons from death and by preserving axons it enhances 
functional recovery (Teng et al., 1998). Promising recovery of locomotor function 
occurs after injection of FGF-2 in a completely transected rat SCI model after 6 
weeks, when animals begin to move their hind-limbs (Furukawa and Furukawa, 
2007).  
As mentioned previously, combined FGF-2 and VEGF therapy increases 
endothelial cell infiltration and blood vessel formation and protects grey matter from 
necrosis, improving both motor function and sensory re-innervation (De Laporte et 
al., 2011, Nordblom et al., 2012, Lee et al., 2011). Co-delivery of stem cells derived 
from bone marrow stromal cells (BMSC), amniotic epithelial cells or neural stem cells 
with FGF-1 and FGF-2 improves motor and sensory scores in patients 24 months 
after treatment (Wu et al., 2011, Liu et al., 2011). The delivery of FGF-1 and FGF-2 
to the SCI sites using mononuclear cells, viral vectors and in combination with drugs 
such as Methylprednisolone (MP) promotes myelination and functional recovery 
(Shaimardanova et al., 2011, Huang et al., 2011, Baffour et al., 1995). Although the 
combined treatment of MP with FGF-1/-2 is beneficial in animal models, efficacy in 
human SCI is unproven (Akhtar et al., 2008, Blight, 2000, Hall, 1992, Hugenholtz, 
2003, Hurlbert, 2000). 
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4.1.5.5 Angiopoietins (ANG)  
ANG are a four-member secreted glycoprotein family comprising; ANG-1, 
ANG-2, ANG-3 and ANG-4 of which ANG-1 and -2 are most well characterised 
(Durham-Lee et al., 2012). ANG-1, -2 and -4 are expressed in humans, whereas 
ANG-3 is expressed in mice (Hansen et al., 2008, Valenzuela et al., 1999). ANG 
mediates angiogenesis, maturation and endothelial cell survival in all parts of the 
body including the brain and spinal cord (Valable et al., 2005, Zacharek et al., 2007, 
Kim et al., 2008, Han et al., 2010, Herrera et al., 2010, Ritz et al., 2010, Hansen et 
al., 2008, Thomas and Augustin, 2009). ANG mediate their responses through two 
receptor tyrosine kinases, Tie-1 and -2 (Thomas and Augustin, 2009). ANG-1 
activates Tie-2 by phosphorylation through either the PI3K or RAS pathways to 
promote cell survival, vessel growth and stabilisation, whereas ANG-2 does not 
induce Tie-2 autophosphorylation, but causes destabilisation of mature vessels by 
blocking the stabilising effects of ANG-1 (Procopio et al., 1999, Maisonpierre et al., 
1997). ANG-2 also blocks the effects of ANG-1, promoting neovascularisation in the 
presence of VEGF (Pufe et al., 2005). 
ANG-1 is expressed at low levels in normal brain  and adult vasculature  and 
is present on pericytes and smooth muscle cells, whereas ANG-2 is expressed more 
actively in endothelial cells to counteract ANG-1 signaling (Davis et al., 1996, Nag et 
al., 2005, Kim et al., 2000, Mandriota and Pepper, 1998, Sundberg et al., 2002, Ng et 
al., 2011, Adams and Alitalo, 2007). ANG-2 expression increases in blood vessels in 
hypoxic environments e.g. after stroke and brain injury  and is angiogenic and also 
neurogenic for neural stem cells (Maisonpierre et al., 1997, Zhang et al., 2002, Nag 
et al., 2005, Ward and Lamanna, 2004, Marteau et al., 2011). 
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4.1.5.6 ANG-1 and ANG-2 after SCI 
In normal tissues, ANG-1 maintains BSCB integrity by limiting vascular 
permeability through induction of PECAM1, occludin and ZO-2 tight junction proteins, 
thus strengthening paracellular interactions and reducing the number and size of 
endothelial gap junctions (Lee et al., 2009, Baffert et al., 2006, Hori et al., 2004, 
Gamble et al., 2000, Wong et al., 1997). After SCI, mRNA and protein levels of ANG-
1 are downregulated and therefore the BSCB integrity is compromised (Ritz et al., 
2010, Herrera et al., 2010, Durham-Lee et al., 2012). ANG-1 arrests the progression 
of the CNS injury-induced inflammation by activation of PI3K and Akt, inhibiting 
inflammatory cytokines and adhesion molecules required for inflammatory cell 
migration, thus limiting the infiltration of inflammatory cells from the bloodstream 
(Fuxe et al., 2011, Gamble et al., 2000, Kim et al., 2001, Hughes et al., 2003). 
Although ANG-1 does not contribute to early angiogenic responses, it does play a 
role in the latter stages of migration, stabilisation and maturation of blood vessels 
(Wong et al., 1997). Intravenous injections of ANG-1 after SCI, improves locomotor 
function by rescuing blood vessels in and around the lesion epicenter and reducing 
inflammation (Han et al., 2010). Treatment with ANG-1 and C16 (αvβ3 binding 
peptide) restores almost full functional recovery by acting through αvβ3 integrin to 
promote angiogenesis.  
Whilst ANG-1 is downregulated after SCI, the mRNA and protein levels of 
ANG-2 are upregulated up to 10 weeks after SCI but a role for ANG-2 in endothelial 
barrier breakdown was not supported in this study (Durham-Lee et al., 2012, Ritz et 
al., 2010). ANG-2 is not localised in endothelial cells after SCI but in astrocytes and 
NG2+ oligodendrocyte precursor cells and high levels of ANG-2 correlate with 
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enhanced locomotor recovery, suggesting a beneficial role of ANG-2 in SCI 
(Durham-Lee et al., 2012, Ritz et al., 2010).  
 
4.1.5.7 Transforming growth factor-βetas (TGFβ) 
TGFβs are a superfamily of secreted cytokines of which there are three 
isoforms in mammals: TGFβ-1, TGFβ-2 and TGFβ-3 (Cui and Ackhurst, 1996, Khalil, 
1999). Although Type I and II TGFβ receptor activation leads to phosphorylation of 
signal regulated mothers against decapentaplegic homolog-2 (Smad-2), TGFβ 
complexes with Smad4 allowing translocation to the nucleus and transcription of 
target genes that either stimulate or suppress tumorigenesis. TGFβ regulates cell 
growth, proliferation, tissue homeostasis, wound healing, apoptosis and scarring 
(Lagord et al., 2002, Huang and Huang, 2005, Kohta et al., 2009) (Figure 4.2). TGFβ, 
like many other angiogenic proteins may be tumorigenic when components of the 
signal transduction pathway become mutated (de Caestecker et al., 2000, Massague 
et al., 2000, Culhaci et al., 2005). In the adult mammalian brain, TGFβ-1 is restricted 
to the choroid plexus, meningeal cells and absent in neurons, whereas TGFβ-2 and 
TGFβ-3 is present in neurons in the developing adult brain and in astrocytes of adult 
CNS ((Maharaj et al., 2008, Bottner et al., 2000, Unsicker et al., 1991, Wilcox and 
Derynck, 1988). In the adult mammalian CNS TGFβ-R1 and TGFβ-R2 mRNA and 
protein are present in neurons and astrocytes, with TGF-βR2 being confined to 
several regions that include the choroid plexus particularly the epithelial and 
ependymal cells, cortex, midbrain, brain stem and the hippocampus (Maharaj et al, 
2008, Vivien et al., 1998, Bottner et al, 1996). 
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4.1.5.8 TGFβ after SCI 
In normal human spinal cord tissue TGFβ-1 is confined to the occasional 
blood vessels, motor neurons and intravascular monocytes, whilst TGFβ-2 is only 
found in intravascular monocytes (Buss et al, 2008). However, after traumatic SCI 
TGFβ-1 is localised to neurons, astrocytes and invading macrophages, whilst TGFβ-
2 is localised to macrophages and astrocytes in the injured spinal cord. 
Immunoreactivity of TGFβ-1 was significantly upregulated 2 days post injury 
continuing for the first few weeks with a gradual decline up to 1 year in the human 
samples. Whilst TGFβ-2 was first detected 24 hours after injury and remained 
elevated for up to 1 year (Buss et al., 2008). TGFβ-1 and β-2 mRNA and protein 
levels increase after SCI and have possible roles in angiogenesis, inflammatory 
responses and wound healing (Lagord et al., 2002, Benton et al., 2009, Wang et al., 
2009, Kritis et al., 2010, Aigner and Bogdahn, 2008). The levels of TGFβ-1 mRNA 
are highest 7 days post injury, whereas TGFβ-2 mRNA levels become elevated later 
at 8-14 days post injury (Semple-Rowland et al., 1995, McTigue et al., 2000, Lagord 
et al., 2002, Buss et al., 2008, Ritz et al., 2010).  
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Figure 4.2 Transforming growth factor-beta (TGFβ) pathway and how it signals 
angiogenesis through signal regulated mothers against decapentaplegic homolog-
(Smad)-2. The binding of TGFβ to its cell surface receptor TGFΒ-RII causes the 
phosphorylation of TGFΒ-RI. This allows TGFΒ-RI to phosphorylate and activate 
Smad2 protein. The activation of Smad2 causes it to bind with Smad4, once bound 
the Smad2/Smad4 complex translocates to the nucleus where it recruits various 
transcription factors. The activated Smad complex and transcription factors together 
activate the expression of target genes that regulate the biological effects of TGFβ. 
Some of the target genes act as tumour suppressors through arrested growth and 
apoptosis, whilst some stimulate tumourigenesis through angiogenesis cell mobility 
and cell growth (Adapted from Sigma- Aldrich).  
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However, titres of TGFβ-1 have been reported to decrease after SCI (Konya et 
al., 2008). Nonetheless, delivery of TGFβ-1 to SCI sites affect vascular recovery 
favourably since inhibition with a neutralizing antibody suppresses glial scar 
formation and enhances axon growth and preservation of axons caudal to the site of 
SCI (Kohta et al., 2009). Similarly, intravenous treatment with TGFβ after SCI 
reduces lesion volume by 50% at 48 hours post injury, probably due to the reduced 
accumulation of mononuclear phagocytes in and around the wound (Tyor et al., 
2002). Therefore the decrease of mononuclear phagocyte numbers around the site of 
injury reduced their contribution to the detrimental secondary injury suggesting a 
beneficial role of TGFβ after SCI. 
 
4.1.5.9 Platelet-derived growth factor (PDGF-BB) 
PDGF’s are a family of glycoprotein mitogens for mesenchymal cells  that 
include smooth muscle cells, fibroblast and some populations of neuroectodermal 
origin such as oligodendrocytes (Fredriksson et al., 2004). PDGF's are made up of 
five dimeric isoforms; PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC and PDGF-DD 
with the expression patterns differing between isoforms. PDGF-AA and PDGF-CC 
are mainly expressed in epithelial cells, muscle and neuronal progenitors cells 
(NPC), whilst PDGF-BB are expressed in vascular endothelial cells, megakaryocytes 
and neurons. The expression patterns for PDGF-DD is the less characterized isoform 
but has been known to be found in fibroblasts and smooth muscle cells (Andrae et 
al., 2008).  
 PDGF bind to their tyrosine kinase receptors; PDGF receptor α (PDGFRα) 
and PDGF receptor β (PDGFRβ). Upon receptor binding the ligand-receptor complex 
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undergoes autophosphorylation causing downstream activation of the P13K/Akt and 
PLC-ƴ pathway, similar to that of VEGF, resulting in the regulation of cell growth, 
migration, proliferation, and therefore angiogenesis (Wu et al., 2008, Andrae et al., 
2008). But continuous upregulation of PDGF can result in deleterious effects as 
demonstrated in many CNS diseases including stroke, Huntington’s and Parkinson’s 
disease (Funa and Sasahara, 2014, Ohno et al., 1999, Iihara et al, 1997, Ballagi et 
al., 1994).  
Early research on PDGF-BB demonstrates endothelial proliferation and 
angiogenesis in an in vitro model of bovine aortic endothelial cells (Battegay et al., 
1994). Neutralisation of PDGF-BB reduced cord/tube formation 37 +/- 10%, whilst 
neutralising PDGF-AA had no effect. PDGF-BB DNA synthesis also increased as 
cords and tubes were developed with its receptor; PDGFRβ and thus PDGF-BB 
being specific for cord/tube-forming endothelial cells only. It has been reported that 
PDGF-BB in conditioned medium is important for cell migration and invasion in 
radiation-induced senescence in securing-deficient human breast cancer cells, but 
also conditioned medium promoted angiogenesis in chicken chorioallantoic 
membrane through PDGF-BB (Yu et al., 2013).  
The stimulating research of PDGF-BB led to instigate studies in the CNS. 
Early reports suggested a role of PDGF-BB in the developing cortex of the CNS by 
enhancing protein phosphorylation in neurons and type 1 astrocytes as well as 
inducing migration in vitro in neuroepithelial cells cultured from embryonic rat cortex 
(Forsberg-Nilsson et al., 1998, Zhang and Hutchins, 1997). Furthermore, PDGF-BB 
exerts neurotrophic and neuromodulatory effects in the CNS, whilst restoring 
proliferation and impaired neurogenesis in a rat model of HIV-associated neurological 
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disorder (HAND) after drug use (Yao et al., 2012, Pela et al., 2000, Kastin et al., 
2003). PDGF-BB and its receptor have been suggested to induce angiogenesis and 
neuroprotection in humans after ischemic stroke (Krupinski et al., 1997). 
Contradictory to reports that PDGF-BB has beneficial effects to the CNS, in a recent 
study human serum samples were analysed using microarray analysis and validated 
by immunoassays from patients suffering from neurodegenerative syndromes; 
Parkinson’s disease (PD), multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP) and corticobasal syndrome (CBS). The levels of PDGF-BB increased in 
patients that suffered from these neurodegenerative syndromes, suggesting it as a 
possible biomarker (Mahlknecht et al., 2012). 
 
4.1.5.10 PDGF-BB after SCI 
Although research on PDGF-BB has shown positive yet contradictory results 
in the CNS, the available research on PDGF-BB as a therapeutic strategy after SCI is 
limited. Research has utilized re-vascularisation methods after SCI in an attempt to 
reduce secondary damage and increase the blood supply at the injury site. But 
regulation of the imbalance of pro- and anti-angiogenic factors after injury has shown 
to participate in the failure of blood vessel stabilisation and re-vascularisation 
(Graumann et al., 2011).  Reduced expression of not only PDGF-BB but also VEGF-
A, Ang-1 and PGF at the lesioned area results in vessel reduction at the injury site 2 
days post injury before disappearing into the developing cavity in rats (Graumann et 
al., 2011, Ritz et al., 2010). It is proposed that reduction in pro-angiogenic factors 
also contributes to vessel regression and that applying angiogenic factors to the 
injury site may be a promising therapeutic application in resorting blood flow after SCI 
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(Ritz et al., 2010). As previously mentioned administration of a VEGF/PDGF 
combination provides synergistic modulation of inflammatory reactions after SCI and 
creates a microenvironment that contributes to axon preservation and sprouting 
(Lutton et al., 2012). This suggests that therapeutic application of PDGF-BB after SCI 
may be beneficial to the microenvironment displayed after injury by targeting 
endothelial cells.  
 
4.1.5.11 Angiogenin  
Angiogenin was first characterized in 1985 as a tumour-derived angiogenic 
protein that promotes angiogenesis and neovascularisation (Fett et al., 1985, 
Kishimoto et al., 2005, Tsuji et al., 2005). Human angiogenin is a secreted 123 amino 
acid, 14kDa protein located on chromosome 14q11 that belongs to the ribonuclease 
superfamily sharing 33% sequence homology with pancreatic ribonuclease A 
(Kurachi et al., 1985, Strydom et al., 1985, Weremowicz et al., 1990, Gao and Xu, 
2008). In order for angiogenin-induced angiogenesis to occur four processes are 
necessary. These include ribonuclease activity, basement membrane degradation, 
signaling transduction and nuclear translocation (Gao and Xu, 2008). Whilst the 
ribonucleolytic activity of angiogenin is weak the ribonucleolytic site on angiogenin 
has shown to be essential for its role in angiogenesis (Hu et al., 1994, Moroianu and 
Riordan, 1994, Curran et al., 1993).  
The binding of angiogenin to the endothelial cell surface is crucial for its 
biological function. In endothelial cells the angiogenin receptor is a 42kDa cell 
surface protein that was later discovered to be a smooth muscle type α-actin (Hu et 
al, 1991, Hu et al., 1993).  Upon binding the angiogenin-actin complexes induces 
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degradation of the blood vessel basement membrane and the extracellular matrix 
thus promoting migration of vascular components (Hu et al., 1991, Hu et al., 1993, 
Hu et al., 1994). However in order for signal transduction to occur through angiogenin 
a different receptor is required. It was later identified that a potential angiogenin 
receptor for signal transduction was a 170kDa cell surface receptor located on the 
endothelial cell surface which has shown angiogenin-responsive abilities (Hu et al., 
1997, Liu et al., 2001, Kim et al., 2007, Xu et al., 2001b).  
Upon angiogenin binding it undergoes nuclear translocation where it regulates 
genes responsible for proliferation of endothelial cells by activating various pathways 
that include ERK, Akt, and SAPK/JNK pathways (Hu et al., 1997, Liu et al., 2001, 
Kim et al., 2007, Xu et al., 2001b). Nuclear angiogenin is particularly essential for 
angiogenesis induced by other angiogenic factors such as VEGF (Kishimoto et al., 
2005). Though the expression of angiogenin is predominantly through endothelial 
cells, it is also expressed by a variety of anchorage-dependent proliferating cells that 
include fibroblasts, aortic smooth muscle cells, and tumor cells (Moenner et al., 
1994). Furthermore, the expression of angiogenin is induced by HIF-1α under 
hypoxic conditions and cellular stress (Nakamura et al., 2006, Sebastia et al., 2009).  
In mice angiogenin is expressed strongly in the CNS during development 
(Subramanian and Feng, 2007), whilst, in humans angiogenin is expressed strongly 
in motor neurons but also endothelial cells of normal fetal and adult spinal cords (Wu 
et al., 2007). It has been shown that wild type angiogenin stimulates neurite 
outgrowth and path-finding of motor neurons in culture, whilst mutant angiogenin not 
only lacks these properties but also induces motor neuron degeneration 
(Subramanian et al., 2008). Genetic mutations in angiogenin have been linked with 
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incurable amyotrophic lateral sclerosis (ALS); a progressive neurodegenerative 
disease with specific loss of motor neurons in the brain, brain stem and spinal cord 
(Crabtree et al., 2007, Greenway et al., 2006, Kishikawa et al., 2008, Pasinelli and 
Brown, 2006). It has further been proven that angiogenin plays a key factor to motor 
neuron survival in vitro and in vivo and that knock-down of angiogenin induced 
excitotoxic motor neuron death in mouse models of ALS (Kieran et al., 2008). It has 
been suggested that using angiogenin as therapeutic modulation in the spinal cord 
may be beneficial for patients suffering from ALS (Pasinelli and Brown, 2006, 
Kishikawa et al., 2008).  
 
4.1.5.12 Angiogenin after SCI  
 Given the role angiogenin plays in CNS, the studies that report angiogenin as 
a therapeutic option after SCI is limited. However, the levels of angiogenin have been 
investigated using CSF from  patients with and without SCI (Ng et al., 2011). After 
SCI patients showed significantly lower angiogenin CSF levels between 72 and 84 
hours compared to controls with maximal differences seen at 72 hours, whilst in 
serum there was no change until 60 hours post-injury which continued to increase up 
until 120 hours (Ng et al., 2011). The serum values were not significantly different 
compared to controls. It is thought that using angiogenin as a therapy option after 
injury to the spinal cord may aid in motor neuron survival (Ng et al., 2011). 
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4.1.6 Anti-angiogenic factors 
  4.1.6.1 Tissue inhibitor of metalloproteinase-2 (TIMP-2) 
 TIMPs are natural, regulatory, inhibitors of matrix metalloproteinases apart of 
a four member family (TIMP-1, TIMP-2, TIMP-3 and TIMP-4) of peptidases involved 
in degradation of the ECM and processes required for metastasis and angiogenesis 
(Murphy, 2011, Valente et al., 1998). TIMPs have the ability to suppress proliferation 
of endothelial cells thus playing an essential role in tissue homeostasis. TIMP-1 was 
first cloned in 1985 where it was first recognised that TIMPs are inhibitors of 
metalloproteinases, followed shortly by TIMP-2; 1990/1989, TIMP-3; 1992, and 
TIMP-4; 1996 (Gasson et al., 1985, Docherty et al., 1985, Stetler-Stevenson et al., 
1990, Stetler-Stevenson et al., 1989, Pavloff et al., 1992, Greene et al., 1996). The 
amino-terminal inhibitory domain of TIMPs bind to the active site of MMPs, in 
particular TIMP-2 binds to the active site found on proMMP-2 (Murphy, 2011). TIMP-
2 is unique in that it not only inhibits MMP activity but also selectively interacts with 
membrane type 1 matrix metalloproteinase (MT1-MMP) to induce cell-surface 
activation of proMMP-2. TIMPs show tissue-specific expression which is regulated at 
the transcriptional level by various growth factors and cytokines (Murphy, 2011). The 
molecular mechanism of TIMP-2 expression is controlled through ERK1/2 and p38 
MAPKs and inhibition of ERK1/2 phosphorylation decreases TIMP-2 production, 
whilst downregulation of p38 MAPK activity enhances TIMP-2 synthesis (Munshi et 
al., 2004). 
 Early research on neurological diseases report the presence of TIMPs in the 
CNS particularly TIMP-1 and TIMP-2, for example, in patients with relapsing multiple 
sclerosis significantly higher levels of TIMP-1 and TIMP-2 were found than patients 
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with other neurological diseases compared to healthy controls (Lee et al., 1999). 
During viral and bacterial meningitis in the CNS immunohistochemical analysis from 
autopsy tissue revealed that mononuclear cells are highly immunoreactive for TIMP-2 
in viral meningitis but even higher in bacterial meningitis (Sulik and Chyczewski, 
2008). Whilst in vitro TIMP-2 is constitutively expressed in primary cultures from rat 
brain microvascular endothelial cells and in human neuroepithelial stem cells that 
once differentiated into neurons and glia the expression of TIMP-2 does not change 
(Harkness et al., 2000, Frolichsthal-Schoeller et al., 1999). Human astrocytes 
stimulated by conditioned medium from myobacterium tuberculosis monocytes 
(CoMTB) significantly increase the secretion of TIMP-2 by 3-fold at 120hrs in 
response to CoMTB treatment (Harris et al., 2007).  
 In vivo experiments supports the expression of TIMP-2 in the CNS, for 
example, in normal mice TIMP-2 is expressed in spinal motor neurons and skeletal 
muscle, and TIMP-2 deficient mice displayed motor deficits due to peripheral and 
central defects (Jaworski et al., 2006). In a stab injury model to adult rat brain the 
mRNA expression of TIMP-2 is significantly upregulated after injury in the neurons 
and microglia, also significant  levels of TIMP-2 were seen 5 days after injury 
suggesting that it may play a part in biphasic opening in the BBB permeability after 
injury (Jaworski, 2000, Rosenberg et al., 1998).  
 
  4.1.6.2 TIMP-2 after SCI 
 TIMP-2, especially in the CNS have shown to play a part in BBB permeability, 
inflammation and tissue remodeling in response to injury so the question remains as 
to whether they play a crucial role after SCI. After traumatic SCI in patients with 
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complete injuries, the distribution of TIMP-2 was limited, with the occasional TIMP 
immuno-positive macrophages seen at short survival times. The strong induction of 
MMPs was not accompanied by expression of their inhibitors allowing the MMPs to 
exert their effects on the lesioned spinal cord (Buss et al., 2007). 
 In experimental spinal-cord ischemia-reperfusion injury in rats, TIMP-2 
immunoreactivity at 3 hrs was similar to sham treated controls, that significantly 
increased by 24 hrs, suggesting that the levels may relate to biphasic breakdown of 
BBB permeability and glial scar formation with respect to collagen staining and that 3 
hr perfusion may provide a critical reversible period to the injury response (Anik et al., 
2011b). TIMPs have been investigated to understand whether they contribute the 
failure of regenerating sensory axons after dorsal root injury in rats (Zhang et al., 
2006). TIMP-2 was significantly upregulated in the dorsal root entry zones, 
degenerating dorsal column and also upregulated by microglia/macrophages, 
especially at later postoperative survival times. This suggests that TIMPs may be 
involved in controlling tissue remodeling after dorsal root injury and that manipulation 
of the expression on TIMPs may provide a potential therapeutic option in promoting 
axonal regeneration into the lesioned area. 
 
  4.1.6.3 Semaphorin 3A (Sema 3A) 
Semaphorins; originally named collapsin, were identified originally as axon 
guidance molecules  but more recently they have been thought to be involved in 
other biological functions such as, angiogenesis and cancer (Luo et al., 1993, 
Kolodkin et al., 1993, Neufeld et al., 2005, Capparuccia and Tamagnone, 2009). 
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Semaphorins are grouped into classes; 1-8, depending on the species that they are 
located in (Table 4.1) (Yazdani and Terman, 2006).  
Class Species Members of Semaphorin 
1 Caenorhabditis elegans 
Drosophila melanogaster 
Sema-1a 
Sema-1b 
2 Caenorhabditis elegans 
Drosophila melanogaster 
Sema-2a 
Sema-2b 
3 Danio rerio 
Mus musculus 
Homo sapiens 
Sema 3A, Sema 3B, Sema 3C, 
Sema 3D, Sema 3E, Sema 3F, 
Sema 3G 
4 Danio rerio 
Mus musculus 
Homo sapiens 
Sema 4A, Sema 4B, Sema 4C, 
Sema 4D, Sema 4E, Sema 4F, 
Sema 4G 
5 Drosophila melanogaster 
Danio rerio 
Mus musculus 
Homo sapiens 
Sema 5A 
Sema 5B 
Sema 5C 
6 Danio rerio 
Mus musculus 
Homo sapiens 
Sema 6A, Sema 6B, 
Sema 6C, Sema 6D 
7 Danio rerio 
Mus musculus 
Homo sapiens 
Sema 7A 
V Virus Sema VA 
Sema VB 
Table 4.1 The members of semaphorins, the species that they are generally located 
in and the class that they belong to and are ultimately named after (Yazdani and 
Terman, 2006). 
 
Semaphorin 3A (Sema 3A) binds to plexins indirectly through the help of co-
receptors; neuropilin-1 and neuropilin-2 (NP1 and NP2), and dimerisation of Sema 
3A is important for its activity in growth-cone collapse and repulsive axon guidance  
through the RhoA pathway (Figure 4.3) (Neufeld et al., 2005, Tamagnone et al., 
1999, Klostermann et al., 1998, Koppel and Raper, 1998). NP’s bind to VEGF family 
members and their receptors therefore playing a vital role in angiogenesis rather than 
axon guidance (Rosenstein and Krum, 2004, Soker et al., 2002). Casaza et al, 
showed that Sema 3A does inhibit tumor cell migration in an NP1 dependent manner 
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by inhibiting vessel function without promoting metastasis whilst increasing hypoxia 
and necrosis in multiple mouse tumor models (Casazza et al., 2011). More recently it 
has been shown that Sema 3A suppresses VEGF-mediated angiogenesis in mice 
(Acevedo et al., 2008).  
Sema 3A plays a role in the CNS as repulsive axon guidance molecules in 
demyelinating diseases such as multiple sclerosis (MS). In vitro studies demonstrate 
that in rat models of MS Sema 3A applied to demyelinating lesions resulted in failure 
of remyelination by inhibiting oligodendrocyte precursor cells (OPC), and in an adult 
murine model of MS, Sema 3A impairs OPCs recruitment in the active demyelinated 
area (Piaton et al., 2011, Syed et al., 2011). In a model of optic nerve injury in 
goldfish there was a decrease in Sema 3A in the retina in the early stages after injury 
(Rosenzweig et al., 2010). Intravitreal injections of Sema 3A after optic nerve injury 
led to irreparable damage to several pathways of the regenerative processes that 
include axon growth, survival of retinal ganglion cells and the clearance of myelin in 
the lesioned area. Demyelinating models of the CNS demonstrate that Sema 3A 
plays a detrimental role to the injury response. 
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Figure 4.3 Semaphorin 3A is part of a family of growth cone guidance molecules that 
requires Nrp1 and PlxnA1 complex as the functional receptor. Sema 3A elicits a 
response from two signalling pathways upon binding to Nrp1; (1) Rac1; a small 
GTPase, that results in the depolymerisation of actin filaments and (2) PlxnA1 that 
binds the Rho-family GTPases; Rnd1 and RhoD pathway that results in the loss of 
integrin-mediated substrate adhesion and ultimately the initiation and modulation of 
cytoskeleton collapse. The activation of Nrp1/PlxnA1 complex also stimulates 
phosphorylation of Cofilin that down regulates its ability to promote actin filament 
turnover when phosphorylated by serine/threonine kinase; LIMK (Adapted from 
Qiagen genes and pathways). 
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  4.1.6.4 Sema 3A after SCI 
 Providing the negative role Sema 3A plays in the CNS after injury it's no 
surprise that it provides a detrimental effect after neurodegenerative SCI. The 
expression of Sema 3A is seen in normal rat spinal cord and after T8 hemisection the 
expression decreases rapidly reaching its lowest level 1 day after injury and 
thereafter Sema 3A expression recovered when reaching 28 days. Immunoreactivity 
results revealed that neurons not glia were positive for Sema 3A in the spinal cord 
(Hashimoto et al., 2004). In situ hybridization and qPCR results demonstrated that 
mRNA and active protein of Sema 3A is produced in meningeal cell- conditioned 
medium from neonatal rat DRGs,  further inducing the collapse of DRG growth 
cones, as well as inhibit neurite outgrowth of embryonic DRGs (Niclou et al., 2003). 
 Earlier reports in rats revealed that after complete transection and contusion 
lesions the expression of class 3 semaphorins is induced by fibroblasts in the neural 
scar and distribution through the scar differs between the two different lesions, 
suggesting that class 3 semaphorins contribute to the inhibitory environment of the 
neuronal scar tissue after SCI (De Winter et al., 2002). Inhibition of class 3 
semaphorins, in particular Sema 3A, resulted in better functional recovery that was 
supported by enhanced regeneration and preservation of injured axons in rats after 
SCI (Kaneko et al., 2006). Sciatic nerve pre-conditioning before inducing SCI saw no 
change in Sema 3A levels and results remained the same (Pasterkamp et al., 2001). 
Sema 3A mRNA and protein are upregulated in the scar and motor neurons from 3 
days up to 3 weeks after injury to the lumbar region of rats after intraspinal axotomy 
(Lindholm et al., 2004). The reports all demonstrate that Sema 3A plays a detrimental 
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role to axon regeneration, fibrotic scar tissue and neurite outgrowth and inhibition of 
Sema 3A should be considered as a therapeutic strategy for clinical SCI. 
 
4.1.7 Matrix proteases 
4.1.7.1 Matrix metalloproteinase 1, 2 & 9 (MMP-1, MMP-2 & MMP-9) 
Matrix metalloproteinases (MMPs) are a family of zinc- and calcium-
dependent endopeptidases  that play an essential role in wound healing, repair and 
normal development throughout life via matrix remodeling (Page-McCaw et al., 2007, 
Yong, 2005, Birkedal-Hansen et al., 1993). There are 23 human and 24 murine MMP 
members that are classified into five specific groups dependent on protein structure 
and substrate specificity; (1) collagenases, (2) gelatinases, (3) stromelysins, (4) 
membrane-type and (5) others (Page-McCaw et al., 2007, Yong, 2005). Most MMPs 
are produced and secreted as inactive zymogens containing three structural 
domains; (1) the N-terminal propeptide domain, (2) an internal catalytic domain, and 
(3) a C-terminal hemopexin domain, whilst the membrane-type MMPs also contain a 
transmembrane domain that is linked to a plasma membrane (Zhang et al., 2011a). 
MMPs become activated once the propeptide domain is removed revealing the active 
catalytic site containing the zinc ion. There are a subset of MMPs that are activated 
intracellularly by serine proteases of pro-protein convertase such as MMP-11 and 
MMP-27 (Sternlicht and Werb, 2001). The activity and modulation of MMPs is 
regulated by their inhibitors; TIMPs, binding to their catalytic regions, but it is 
important to remember that their interaction with MMPs does not always lead to 
inhibition (Sternlicht and Werb, 2001, Crocker et al., 2004).  
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Over expression of MMPs can have detrimental effects, for example, the 
expression of MMP-2 correlates with increased angiogenesis by enhancing vascular 
proliferation in brain tumors, therefore enhancing the growth and invasive properties 
within the CNS in lung carcinomas (Rojiani et al., 2010). MMP-1 has shown to be 
upregulated in many cancers including colorectal  and breast cancer, and that 
elevated expression of MMP-1 can promote local growth and formation of brain 
metastases by breast cancer cells (Liu et al., 2012, Sunami et al., 2000) 
The expression and localization of MMPs in the adult CNS varies in humans, 
mice and rats and it is important to take this into consideration when modeling clinical 
SCI especially when comparing the responses of clinical to experimental SCI. The 
localization of MMP-1 in humans is confined to motor neurons of the spinal cord, 
whilst in rats MMP-1 is distributed in the spinal cord (Buss et al., 2007, Zhou et al., 
2014). The localization of MMP-2 is confined to neurons, astrocytes and endothelium 
in the brain and DRGN’s of the spinal cord in rats (Planas et al., 2001, Kawasaki et 
al., 2008). But in humans MMP-2 is confined mainly to astrocytes and microglia in the 
brain (Cuzner et al., 1996, Rosenberg et al., 2001). The localization of MMP-9 is 
confined to the meninges and ventral horn motor neurons in the spinal cord  in mice, 
whilst in rats MMP-9 is confined to the DRGN’s in the spinal cord and confined to 
neurons and myelinated fiber tracts in the brain (Planas et al., 2001, Noble et al., 
2002, Kawasaki et al., 2008). But in humans MMP-9 is confined only to astrocytes 
and microglia in the brain (Cuzner et al., 1996).  
The expression and localization of MMPs suggested that they may play a part 
in the CNS after injury and an early in vitro study comparing rat CNS microvascular 
endothelial cells to endothelial cells derived from rat aorta revealed differences in 
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expression in MMP-2 and MMP-9 between CNS and non-CNS endothelial cells 
(Harkness et al., 1999). Both MMP-2 and MMP-9 were constitutively expressed in 
CNS endothelium, but once CNS endothelium was activated with pro-inflammatory 
cytokines, no significant changes were seen in MMP-2 expression but expression 
was selective to upregulation of MMP-9 levels only. MMP-9 is a potent regulator of 
acute neuroinflammation and in a rat model of intracerebral hemorrhage MMP-9 
levels increased (Hansen et al., 2013). Furthermore, edema and inflammation was 
reduced once MMP-9 was inhibited using Dexamethasone; a drug that is used to 
reduce edema clinically in brain and SCI patients (Yang et al., 2011).  
 
4.1.7.2 MMP-1, MMP-2 and MMP-9 after SCI 
The localization of MMPs after SCI has been investigated and found that the 
localization of MMP-1 was increased predominantly in astrocytes and neurons after 
injury, whilst, MMP-2 and MMP-9 was increased in reactive astrocytes that bordered 
the lesion epicenter (Hsu et al., 2006, Hsu et al., 2008, Zhou et al., 2014). This 
localization of MMPs after SCI differs in humans with MMP1 showing an early 
upregulation in macrophages in the lesion epicenter with a later induction in peri-
lesional activated astrocytes (Buss et al, 2007). Furthermore, MMP-2 and MMP-9 
was predominantly expressed in macrophages at the lesion epicenter only.  
Given the role MMPs have on the microvasculature of the CNS, this lead to 
the effect of MMPs, in particular MMP-1, 2 and 9, have after SCI. After inducing a 
weight drop SCI in rats the expression of not only MMP-1 but also MMP-9 was 
increased in the injured cord and using Methylprednisolone inhibited the expression 
of both MMPs by inhibiting activator protein-1 and nuclear factor kB cascades (Xu et 
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al., 2001a). Human traumatic SCI displayed a lesion-induced bi-phasic expression of 
raised MMP-1 levels that was associated with an early up-regulation of macrophages 
within the lesion epicenter and later the induction of activated astrocytes (Buss et al., 
2007). In response to tissue hypoxia following SCI angiogenesis occurs, and MMP-1; 
found on endothelial cells, is required for endothelial cell migration during 
angiogenesis (Mautes et al., 2000, Hiraoka et al., 1998).  
Neuropathic pain is also a major consequence after SCI, and in a chronic 
constriction injury model in rats increases in MMP-2 were found in the sciatic nerve 
and spinal cord after injury, and using Atorvastatin; an inhibitor of MMP-2, levels 
reduced (Pathak et al., 2013). After partial sciatic nerve injury in mice MMP-9; 
confined to neurons and microglia, was expressed immediately after injury but 
returned to baseline levels 3 day post-injury, whilst MMP-2; confined to glial-like cells, 
was increasingly expressed gradually after nerve injury (Liou et al., 2013). The 
results indicated that MMP-2 should be considered as a therapeutic option when 
managing neuropathic pain after sciatic nerve or SCI. Inhibition of MMP-9 and MMP-
2 activation after SCI in rats improves functional recovery using an ethanol extract; 
Bupleurum falcatum, further more reducing lesion volume (Lee et al., 2010, Lee et 
al., 2012). After photochemically inducing SCI in rats using rose Bengal significant 
upregulation of MMP-9 protein levels in the cord were observed at 6 hours and 
minimal levels were reached by 24 hours after the ischemic insult, whilst MMP-2 was 
not detected at any time point in both injured or control groups (Jang et al., 2011). 
MMPs in particular MMP-2 and MMP-9 are involved in the migration of olfactory 
ensheathing cells (OECs) in vitro on various CNS ECM substrates (Gueye et al., 
2011). 
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The levels of MMP-9 are highly associated with the inflammatory responses 
after SCI due to infiltration of monocytes, and after C57BL/6 and MMP-9 knockout 
mice received lumbar enlargement to the cord, there was an increase in resident 
microglia within 24 hours in wild-type mice and by 7 dpl increases in MMP-9 
expression were evident along with pro-inflammatory TNF-α (Zhang et al., 2011b). 
Deletion of MMP-9 attenuated remote microglia activation and restored TNF-α 
expression to homeostatic levels (Hansen et al., 2013). After spinal cord ischemic 
preconditioning injury in white Japanese rabbits, MMP-9 protein expression was 
reduced after injury which further attenuates increases in BSCB permeability due 
better preservation of tight junctions (Fang et al., 2013a, Lee et al., 2012). It has 
further been shown that traumatic SCI induced with arachnoiditis produced greater 
inflammation, measured by significant increases in MMP-9 activity and BSCB 
permeability, compared to both SCI and arachnoiditis on their own (Austin et al., 
2012). Acute inhibition of MMP-9 using an MMP-9 inhibitor (SB-3CT), for two days 
after T9-T10 spinal cord hemisection produced significant increase in mitosis of 
NG2+ glia cells but not astrocytes, macrophages or microglia and thus causing an 
increase in oligodendrocytes during remyelination (Liu and Shubayev, 2011).  
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcription factor 
against inflammation in the spinal cord, and after SCI in wild type Nrf2 and Nrf2 
deficient mice MMP-9 expression was increased compared to sham controls, 
however in Nrf2 deficient mice there was an increase in edema, and more production 
and activation of MMP-9 compared the Nrf2 wild type mice after SCI (Mao et al., 
2010a, Mao et al., 2010b). Sulforaphane; an anti-inflammatory extract reduced the 
levels and expression of MMP-9 and edema in mice that were treated after SCI than 
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those that simply had SCI with no treatment (Mao et al., 2010c). In rodents and 
humans, injury to the spinal cord triggered the expression of CD95 ligand (CD95L) on 
peripheral blood myeloid cells. Stimulation of CD95 on these cells activated 
phosphoinositide 3-kinase (P13K) and MMP-9 through the recruitment and activation 
of Syk kinase, resulted in increased migration. But deletion of CD95L on myeloid 
cells decreased the infiltration of neutrophils and macrophages into the injury site 
after SCI, ultimately leading to better functional recovery when only the ligand is 
deleted, and thus indicates that CD95L induces tissue damage by increasing the 
inflammatory response after injury (Letellier et al., 2010).  
The effect stem cells have on the levels of MMPs have been investigated 
following spinal cord ischemia-reperfusion injury on white Japanese rabbits using 
bone marrow stromal cells that were injected 2 days before injury (Fang et al., 
2013b). There was reduced expression of MMP-9 and this inhibition of MMP-9 
provided a beneficial effect by stabilising the BSCB. In an in vitro model of axonal 
dieback and adult rat dorsal column crush, using multipotent adult progenitor cells 
(MAPCs) significantly decreased levels of MMP-9 release from macrophages and 
simultaneously prevented the induction of axonal dieback (Busch et al., 2011). 
Although the research may look contradictory, it is clear to see that the expression of 
MMPs after SCI is dependent on the type of injury model produced. MMPs do play a 
fundamental role in matrix remodeling and inflammation after SCI and therefore 
MMP-1 and MMP-2, but not MMP-9 at best should be considered as potential 
therapeutic options.  
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 4.1.8 ECM/scar-related factors 
4.1.8.1 Platelet endothelial cell adhesion molecule-1 (PECAM-1)  
 PECAM-1 is a 130kDa type 1 transmembrane glycoprotein originally cloned by 
Newman and colleagues, is also known as cluster of differentiation 31 (CD31) 
(Newman and Newman, 2003, Newman et al., 1990, Newman et al., 1987). PECAM-
1 is a member of the immunoglobulin supergene family adhesion molecule  found on 
the surface of circulating platelets, monocytes, neutrophils, a subset of T-cells and 
endothelial cells, is involved in various processes that include leukocyte migration, 
angiogenesis and integrin activation (Williams et al., 1996). PECAM-1, located on 
chromosome 17, is encoded by a 75-kb gene of which the extracellular domain 
consists of 574 amino acids organised into 6 immunoglobulin-like homology domains, 
a 19-residue transmembrane domain, and a 118- amino acid cytoplasmic tail 
(Newman and Newman, 2003). It makes up a large portion of endothelial cell 
intercellular junctions and in response to cellular stimulation the serine and tyrosine 
residues in the cytoplasmic domain of PECAM-1 requires regulated phosphorylation 
of signaling complexes and interactions with components of the cytoskeleton 
(Newman and Newman, 2003).  
 Early research has demonstrated that PECAM-1 plays an important role in 
inflammation in the CNS (Williams et al., 1996). In a rat model of experimental 
allergic encephalomyelitis (EAE) the expression of PECAM-1 by CNS endothelial 
cells is not necessary for the initiation of inflammation following the adoptive transfer 
of myelin reactive CD4+ T cells, but that PECAM-1 may play a role in regulating 
antigen-specific T cell trafficking in CNS inflammatory diseases (Williams et al., 1996, 
Qing et al., 2001). Whilst, in a PECAM-1 deficient KO mouse model of EAE 
119	  |	  P a g e 	  	  
infiltration and mononuclear cell extravasation of the CNS occurred at earlier time-
points in PECAM-1-KO mice compared to wild-type and T cell transendothelial 
migration across PECAM-1-KO endothelial cells is enhanced regardless of PECAM-1 
expression (Graesser et al., 2002).  
 Early studies show that PECAM-1 also plays a part in the BBB permeability in 
the developing CNS in mice (Lossinsky et al., 1997). PECAM-1 is expressed on the 
endothelial cell surface in newborn animals which increases at 7-10 days post-
partum and then decreases to weak labeling on endothelial cell surface by 2 weeks 
after birth. The results display active angiogenesis during early brain development in 
the mouse and that upregulation of PECAM-1 may help in the development of an 
'immune' BBB prior to anatomical closure of the BBB (Lossinsky et al., 1997). Brain 
tissue from individuals with HIV encephalitis displayed an accumulation of cleaved, 
soluble form of the extracellular region of PECAM-1 (sPECAM-1) including elevated 
levels in their serum, thus correlating with enhanced transmigration of leukocytes into 
the CNS and the changes in BBB permeability (Eugenin et al., 2006).  
   
4.1.8.2 PECAM-1 after SCI 
 Considering the role PECAM-1 plays in the CNS not only a part of the 
inflammatory response but also the integrity of the BBB in early development, it's 
surprising the amount of research instigated on the effect and response it has on SCI 
is limited. The vascular response during wound healing in adult mice has been 
assessed using PECAM-1 in a weight drop model (Whetstone et al., 2003). There 
was a significant loss of PECAM-1+ blood vessels 1-3 days post injury, but by 3-7 
days there was a significant increase in the number of PECAM-1+ vessels that had 
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returned to control values by 7 days. Within the healing cord at 7 days after injury 
majority of vessels were PECAM-1+, contributing to the wound healing response in 
mice (Whetstone et al., 2003, Goussev et al., 2003).  
 In a spinal cord reperfusion model in rabbits using an intravenous injection of 
ATL-146e; a selective adenosine A(2A) agonist, demonstrated a reduction in spinal 
cord endothelial PECAM-1 expression compared to animals that did not receive ATL-
146e (Cassada et al., 2002). The adenosine agonist reduced spinal cord reperfusion 
injury in animals due to the reduction in spinal cord PECAM-1+ endothelium 
upregulation. 
 The effect of stem cell transplantation using PECAM-1 cells in SCI model has 
been investigated to see whether functional recovery by angiogenesis and 
neurogenesis stimulation is improved. In particular, using three-dimensional cell 
mass of human adipose-derived stem cells (3DCM-ASCs) in vitro confirmed that the 
stem cells differentiated into PECAM-1+ endothelial cells (Oh et al., 2012). 
Furthermore, in vivo experiments where 3DCM-ASCs were transplanted into an 
injured cord model differentiated into PECAM-1+ endothelial cells and remained 
differentiated compared to PBS and adipose-derived stem cell (ASCs) controls. The 
transplantation of 3DCM-ASCs significantly elevated the density of vascular 
formations due to angiogenic factors released by 3DCM-ASCs at the lesion site, 
enhancing axonal growth and functional recovery compared to PBS and ASCs 
controls. Research using PECAM-1 as a therapeutic strategy after SCI shows 
promising results in the wound healing, angiogenic and axonal growth responses that 
ultimately result in better functional recovery. These factors make PECAM-1 
favorable especially when considered for clinical environment.  
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  4.1.8.3 Collagen-1 (Col-1) 
 In the body collagen is the most abundant protein, and with 16 members 80-
90% consists of collagen types I, II and III (Lodish et al., 2000). Being the main 
component of connective tissue and the ECM it's expression, particularly collagen 
type 1, is confined to skin, tendon, bone, dentin, ligaments and interstitial tissues. 
Collagen type 1 was first characterised due to its ease of isolation and high 
abundance in rat tail. Collagen type I is a long, thin protein of which the structural unit 
consists of three coiled subunits: two α1 and one α2 chains. Each chain consists of 
1050 amino acids that wind around each other to form a characteristic right-handed 
triple helix (Shoulders and Raines, 2009). The interruptions in the triple helix and 
other three dimensional structures give each collagen its unique properties.  
 Given that collagen is the main component of the ECM and connective tissue, 
studies in the CNS demonstrate the advantage of using collagen type 1 in tissue 
engineering using scaffolds or gels to assess the repair, regeneration and 
proliferation of cells after injury (Ding et al., 2010, Ma et al., 2004). In a rabbit model 
of sciatic nerve injury nano-silver and collagen type 1 scaffolds were immersed into 
laminin solution and implanted into the lesioned area to repair 10mm of injury. The 
nano-silver containing collagen scaffolds showed higher rate of laminin absorption, 
regenerated nerve with a thick myelin sheath and improved nerve conduction 
compared to control scaffold without nano-silver demonstrating that nano-silver-
collagen scaffolds are essential to the functionality in repair of peripheral nerves 
(Ding et al., 2010). Neural stem and progenitor cells isolated from embryonic rat 
cortical or subcortical neuroepithelium were cultured in 3D collagen gels (Ma et al., 
2004). These 3D gels were first to demonstrate functional synapse and neuronal 
122	  |	  P a g e 	  	  
network formation in a 3D matrix gel in the CNS, suggesting it as a possible 
therapeutic in promoting neuronal regeneration in vivo. 
 
  4.1.8.4 Col-1 after SCI 
 Collagen type 1 has shown to play a role in CNS especially after injury which 
instigated the effect collagen type 1 may have after SCI. Early research has 
demonstrated that application of rat tail collagen type 1 to the lesioned area after SCI 
in rats supports functional recovery despite the absence of corticospinal axons 
(Houweling et al., 1998a, Houweling et al., 1998b). And using rat tail collagen type 1 
as a matrix on cervical spinal injury shows that four weeks after injury provided 
directional re-growth of injured axon tracts into the collagen implant (Joosten et al., 
1995). 
 The expression of collagen type 1 after contusive SCI in adult rats was 
detected in mRNA. Collagen type 1 was observed around blood vessels in the white 
matter at 4 weeks after injury along with an increase in fibroblast immunoreactivity, 
suggesting that collagen type 1 may play a role in angiogenesis after SCI and that 
fibroblast may produce collagen type 1 in rat spinal cord (Okada et al., 2007). 
Confirming that fibroblasts produce collagen type 1, after contusive SCI perivascular 
collagen 1α1 cells were found to be the main source of cellular components of the 
fibrotic scar in transgenic mice. These type 1 collagen cells were identified as 
perivascular fibroblasts that were located around larger blood vessels and were 
distinct from pericytes that are typically located around microvessels (Soderblom et 
al., 2013). Pericytes are important in regulating endothelial cell function including 
vascular formation, stabilization and remodeling (Hirsch and D’Amore, 1996). 
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However, in the brain they contribute largely to BBB permeability and the integrity of 
structural vessels and thus play an important role in the wound healing process and 
therefore scarring after injury (Karén, 2010).  
 Collagen-filament scaffolds have demonstrated to support axonal regeneration 
and functional recovery in transected spinal cord in rabbits at 12 and 24 weeks after 
injury (Yoshii et al., 2009). BBB scores remained high in animals treated with the 
scaffold compared to controls suggesting the possibility of therapeutic application in 
humans. Various studies report that transplantation of neural stem/precursor cells 
(NSPCs) into adult rat injured spinal cord promotes functional recovery and using 
collagen type 1 as a scaffold for NSPC transplantation, or NSPCs in 3D collagen type 
1 gels support cell survival and cell migration under optimal conditions that potentially 
allows NSPCs to differentiate into neurons, astrocytes and oligodendrocytes into the 
injured spinal cord (Watanabe et al., 2004, Watanabe et al., 2007). Using collagen 
type I in SCI especially as a matrix aiding molecule to the lesioned area shows 
promising results as a therapeutic strategy that should be considered clinically. All 
these various factors provide evidence to the effect that they have on the 
microvasculature of the injured cord whether it is beneficial or detrimental when using 
it as a therapeutic application.  
  
4.2 Rationale 
Our model so far has demonstrated differential responses in cavitation, laminin 
deposition and inflammatory responses after sub-acute SCI between mice and rats. 
Mice revealed no cavity formation, increased laminin deposition confined only to the 
lesion area and increased localisation of inflammatory markers 8 dpl after sub-acute 
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SCI. Whilst, rats developed large cavities which were almost devoid of laminin 
deposition within the lesion area and decreased inflammatory response after injury. 
This led to propose that mice may have a more robust wound-healing response and 
are able to overcome the adverse conditions compared to rats after injury. Therefore, 
using 8 dpl as a time point that showed the greatest differences between these 
factors, to investigate early angiogenic responses between the two species using 
other known angiogenic/wound healing-related proteins. 
 
4.3 Hypothesis 
The increased expression and localisation of angiogenic/wound-healing related 
proteins after sub-acute SCI in mice correlates with no cavity development and an 
adequate balance between wound healing, vascularisation and scar tissue. Thus, 
large cavity development in rats is due to an inadequate balance in scar tissue, 
neovascularistion and wound healing and therefore a decrease in the expression and 
localisation of angiogenic/wound healing-related factors. Therefore preventing 
cavitation will spare axons from damage, resulting in better functional recovery. 
 
4.4 Aims 
• To analyse rat and mouse lesion areas using known angiogenic/wound 
healing-related proteins at 8 dpl using immunohistochemistry. 
• To confirm immunohistochemical results by western blot and densitometric 
analysis. 
• To determine the levels of hypoxia using CNS specific carbonic anhydrase 10 
(CA10) between mice and rats after injury. 
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• To examine the levels of axonal sparing in the corticospinal tract using protein 
kinase C and neurofilament 200 between mice and rats at 8 dpl.  
• To determine differences in functional recovery after sub-acute SCI between 
mice and rats using planter heat and Von Frey hair test. 
 
4.5 Materials and Methods   
 4.5.1 Experimental design 
Please refer to Material and Methods section 2.1 Animal surgery, 2.2.1 and 2.2.2 
Tissue preparation for immunohistochemistry and western blotting and 2.6 Functional 
test procedures for standard protocols used. 
Type of analysis N -numbers End-points (days) 
Angiogenic/wound healing 
immunohistochemistry 
6 (per time point/species 0, 8 
Angiogenic/wound healing 
western blot analysis 
6 (per time point/species 0, 8 
Functional tests 5 (per species/group) -1 (day before), 0 (2hrs after 
surgery), 7, 14, 21 
Axonal sparring  6 (per time point/species 0, 8 
 Table 4.2 Experimental design indicating n numbers and end-points used to assess 
angiogenic/wound healing localisation and protein expression after sub-acute SCI in 
mice and rats and the effect this has on functionality and axonal sparring. 
 
4.5.2 Antibodies used for fluorescent immunohistochemistry 
Please refer to Materials and Methods section 2.3.2 Fluorescent 
immunohistochemistry for standard protocol used. Fluorescent 
immunohistochemistry was used to assess the localisation of various 
angiogenic/wound-healing related proteins at 8 dpl (Table 4.3).  
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Angiogenic/Wound-healing related 
proteins 
Dilution 
Factor 
Species Supplier (catalogue no.) 
Primary Antibodies 
Von Willebrand Factor (VWF) 1:200 Rabbit Dako (A0082) 
FGF2 (Fibroblast Growth Factor) 1:200 Rabbit Selective Genetics (7115193) 
Angiopoietin-1 1:200 Rabbit Abcam (ab8451) 
Semaphorin 1:200 Rabbit Abcam (ab23393) 
VEGF-A 1:400 Rabbit Abcam (ab46154) 
Angiogenin 1:100 Rabbit Santa Cruz Biotechnology 
(sc-9044) 
TIMP-2 (Tissue Inhibitor of Matrix 
Metalloproteinases) 
1:200 Rabbit Neomarkers (Rb-1789-P1) 
MMP-1 (Matrix Metalloproteinases) 1:200 Sheep Biogenesis (5980-0111) 
MMP-2 (Matrix Metalloproteinases) 1:100 Rabbit Chemicon International 
(ab37150) 
MMP-9 (Matrix Metalloproteinases) 1:100 Rabbit Santa Cruz Biotechnology 
(sc-10737) 
PECAM-1 (Platelet Endothelial Cell 
Adhesion Molecule)- CD31 
1:100 Rabbit Santa Cruz Biotechnology 
(sc-28188) 
TGFβ-2 (Transforming Growth Factor) 1:200 Rabbit Santa Cruz Biotechnology 
(sc-90) 
PDGF-BB (Platelet-Derived Growth 
Factor) 
1:200 Rabbit Genzyme (AB1487) 
Collagen-1 1:200 Rabbit Abcam (ab292) 
Carbonic Anhydrase X 1:100 Rabbit Abcam (ab91247) 
Protein kinase C 1:250 Rabbit Abcam (ab71558) 
Neurofilament 200 1:200 Rabbit Sigma-Aldrich (N4142) 
Secondary Antibodies 
Alexa 488 1:400 Rabbit Molecular Probes (A11034) 
Alexa 594 1:400 Sheep Molecular Probes (A1105) 
Table 4.3 Primary and secondary antibodies used to label wound 
healing/angiogenic- related proteins by immunohistochemistry. 
 
 4.5.3 Antibodies used for western blotting 
Please refer to Materials and Methods section 2.5 Western blot analysis for standard 
protocol used. Western blot analysis was used to assess the protein expression of 
various angiogenic/wound-healing related proteins at 8 dpl (Table 4.4).  
Angiogenic/Wound-healing related 
proteins 
Dilution 
Factor 
Species Supplier (catalogue no.) 
Primary Antibodies 
Laminin 1:100 Rabbit Sigma (L9393) 
Von Willebrand Factor (VWF) 1:200 Rabbit Dako (A0082) 
FGF2 (Fibroblast Growth Factor) 1:200 Rabbit Selective Genetics (7115193) 
Angiopoietin-1 1:100 Rabbit Abcam (ab8451) 
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Semaphorin 1:200 Rabbit Abcam (ab23393) 
VEGF-A 1:1000 Rabbit Abcam (ab46154) 
Angiogenin 1:100 Rabbit Santa Cruz Biotechnology 
(sc-9044) 
TIMP-2 (Tissue Inhibitor of Matrix 
Metalloproteinases) 
1:200 Rabbit Neomarkers (Rb-1789-P1) 
MMP-1 (Matrix Metalloproteinases) 1:100 Sheep Biogenesis (5980-0111) 
MMP-2 (Matrix Metalloproteinases) 1:100 Rabbit Chemicon International 
(ab37150) 
MMP-9 (Matrix Metalloproteinases) 1:100 Rabbit Santa Cruz Biotechnology 
(sc-10737) 
PECAM-1 (Platelet Endothelial Cell 
Adhesion Molecule)- CD31 
1:1000 Rabbit Santa Cruz Biotechnology 
(sc-28188) 
TGFβ-2 (Transforming Growth Factor) 1:200 Rabbit Santa Cruz Biotechnology 
(sc-90) 
PDGF-BB (Platelet-Derived Growth 
Factor) 
1:200 Rabbit Genzyme (AB1487) 
Carbonic Anhydrase X 1:200 Rabbit Abcam (ab91247) 
Alpha Tubulin 1:2000 Rabbit Abcam (ab125267) 
Secondary Antibodies 
Horseradish Peroxidase (HRP) 1:1000 Sheep GE Healthcare (RPN4201) 
Horseradish Peroxidase (HRP) 1:1000 Rabbit GE Healthcare (NA934) 
Table 4.4 Primary and secondary antibodies used to label wound 
healing/angiogenic- related proteins by western blot. 
 
4.6 Results 
 4.6.1 Comparison of factors in rat and mouse DC wounds at 8 dpl 
Since our results have demonstrated the greatest differences in cavitation, 
laminin and inflammatory (GFAP, fibronectin, ED1 and NG2) immunoreactivity at 8 
dpl, we selected this time point for further analysis using 15 different known 
angiogenic/wound healing-related proteins in mice and rats. 
 
4.6.1.1. Angiogenic factors   
vWF immunoreactivity was present within the lesion area and surrounding white 
(WM) and grey matter (GM) in mice (Figure 4.4A). Although similar observations 
were seen in WM and GM in rats, vWF was confined to the boundaries of the 
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lesioned area (Figure 4.4B). Immunoreactivity quantification was done in ImageJ by 
measuring integrated density in an area containing the lesion site in mice and rats, 
levels were normalised to intact controls revealing no significant difference between 
mouse and rat vWF immunoreactivity levels in the lesion sites 8 dpl (Figure 4.4C).  
To confirm differences observed by immunohistochemistry in mice and rats, 
western blot analysis (Figure 4.4D) followed by densitometry (Figure 4.4F) was used 
to quantify relative levels of proteins in spinal cords after injury. Results confirmed 
that there was no significant difference in the comparison of vWF in mouse and rat 
lesion areas after sub-acute DC injury. 
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Figure 4.4 The localisation of vWF at 8 dpl in DC lesions. Immunohistochemistry for vWF in mice (A) and rats (B) and pixel 
intensities of vWF+ fluorescence (C) revealed no significant differences. Western blot (D) and densitometry (E) corroborated 
the immunohistochemistry results (α-tubulin was used as a protein loading control, image demonstrates a representative 
picture (F); scale bars in A and B = 200 µm, * = lesion epicentre).  
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4.6.1.2. Angiogenic growth factors  
The immunoreactivity of VEGF-A, TGFβ-2, PDGF-BB, FGF2, angiogenin and 
angiopoeitin-1 was observed in mouse and rat lesion areas 8 dpl (respectively, 
Figure 4.5-4.10 A-C). In the mouse these growth factors were localised within the 
lesion site, surrounding neuropil and parenchyma and up to 5 mm either side of the 
lesion epicenter (respectively, Figure 4.5-4.10A), whilst in rats these angiogenic 
growth factors were absent from the lesion site with low levels of immunoreactivity in 
the surrounding neuropil (respectively, Figure 4.5-4.10B). Quantification at 8 dpl 
revealed significantly increased immunoreactivity of VEGF-A, TGFβ-2, PDGF-BB, 
FGF2, angiogenin and angiopoeitin-1 by 0.6-, 3.5-, 3.1-, 0.7-, 1.9-, 0.3-fold, 
respectively, in mice compared to rats (respectively, Figure 4.5-4.10C and Table 4.5).  
Factor Mean Intensity (pixels) (± SEM) 
 
         Mouse                                  Rat 
VEGF-A 15 x102 ± 5 x102 -25x102 ± 7x102 
TGFβ2 28 x 102 ± 6 x102 -8 x 102 ± 4 x 102 
PDGF-BB 31 x 102 ± 3 x 102 10 x 102 ± 4 x 102 
FGF2 6 x 102 ± 2 x 102 -8 x 102 ± 2.5 x 102 
Angiogenin 19.9 x 102 ± 3 x 102 10 x 102 ± 5.4 x 102 
Angiopoeitin-1 8 x 102 ± 3 x 102 -24 x 102 ± 9 x 102 
Table 4.5 Mean fluorescence intensities of angiogenic growth factors in sections of 
spinal cord at 8 dpl after DC injury. 
 
Western blotting (respectively, Figure 4.5-4.10D) and subsequent densitometry 
(respectively, Figure 4.5-4.10E) demonstrated that the levels of angiogenic growth 
factors; VEGF-A, TGF-β2, PDGF-BB, FGF2, angiogenin and angiopoeitin-1, were 
significantly higher in mice compared to rats (Table 4.6).  
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Factor Mean integrated density (arbitrary units)  
(± SEM) 
          Mouse                                 Rat 
VEGF-A 5 x 104 ± 0.8 x 104 -1 x 104 ± 0.6 x 104 
TGFβ2 2 x 104 ± 0.1 x 104 0.5 x 104 x 0.1 x 104 
PDGF-BB -9 x 104 ± 1.2 x 104 -13 x 104 ± 0.2 x 104 
FGF2 17 x 104 ± 5 x 104 1 x 104 ± 0.15 x 104 
Angiogenin 10 x 104 ± 0.2 x 104 -2 x 104 ± 0.12 x 104 
Angiopoeitin-1 4 x 104 ± 0.8 x 104 -3 x 104 ± 0.2 x 104 
Table 4.6 Mean integrated density of angiogenic growth factors in mouse and rat SCI 
sites at 8 dpl, determined by western blotting.  
 
These results confirm that after sub-acute SCI, there is activation of angiogenic 
growth factors that aid in the wound healing, vascularisation responses seen in mice 
8 dpl compared to rats. 
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Figure 4.5 The localisation of VEGF-A at 8 dpl in DC lesions. Immunohistochemistry for VEGF-A in mice (A) and rats (B) and 
pixel intensities of VEGF-A+ fluorescence (C). Western blot (D) and densitometry (E) corroborated the immunohistochemistry 
results (the same α-tubulin was used as a protein loading control as in Figure 4.4F; scale bars in A and B = 200 µm; * = lesion 
epicentre).  
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Figure 4.6 The localisation of TGFβ-2 at 8 dpl in DC lesions. Immunohistochemistry for TGFβ-2 in mice (A) and rats (B) and 
pixel intensities of TGFβ-2+ fluorescence (C). Western blot (D) and densitometry (E) corroborated the immunohistochemistry 
results (the same α-tubulin was used as a protein loading control as in Figure 4.4F; scale bars in A and B = 200 µm; * = lesion 
epicentre).  
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Figure 4.7 The localisation of PDGF-BB at 8 dpl in DC lesions. Immunohistochemistry for PDGF-BB in mice (A) and rats (B) 
and pixel intensities of PDGF-BB+ fluorescence (C). Western blot (D) and densitometry (E) corroborated the 
immunohistochemistry results (the same α-tubulin was used as a protein loading control as in Figure 4.4F; scale bars in A and 
B = 200 µm; * = lesion epicentre).  
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Figure 4.8 The localisation of FGF2 at 8 dpl in DC lesions. Immunohistochemistry for FGF2 in mice (A) and rats (B) and pixel 
intensities of FGF2+ fluorescence (C). Western blot (D) and densitometry (E) corroborated the immunohistochemistry results 
(the same α-tubulin was used as a protein loading control as in Figure 4.4F; scale bars in A and B = 200 µm; * = lesion 
epicentre).  
A 
*"
B 
*"
P<0.001 
-15 
-10 
-5 
0 
5 
10 
M
ea
n 
nu
m
be
r o
f 
pi
xe
ls
 (a
rb
itr
ar
y 
un
its
 x
10
²) 
FGF2 Mouse 
FGF2 Rat 
FGF2 18kDa- 
Mouse Rat 
0 
10 
20 
30 
M
ea
n 
nu
m
be
r o
f 
pi
xe
ls
 ±
SE
M
 
(a
rb
itr
ar
y 
un
its
 x
10
⁴) 
FGF2 Mouse 
FGF2 Rat 
P<0.002 
C 
E 
Rat Mouse 
D 
4.8"
136	  |	  P a g e 	  	  
 
Figure 4.9 The localisation of Angiogenin at 8 dpl in DC lesions. Immunohistochemistry for Angiogenin in mice (A) and rats 
(B) and pixel intensities of Angiogenin+ fluorescence (C). Western blot (D) and densitometry (E) corroborated the 
immunohistochemistry results (the same α-tubulin was used as a protein loading control as in Figure 4.4F; scale bars in A and 
B = 200 µm; * = lesion epicentre).  
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Figure 4.10 The localisation of Angiopoeitin-1 at 8 dpl in DC lesions. Immunohistochemistry for Angiopoeitin-1 in mice (A) and 
in rats (B) and the pixel intensities of Angiopoeitin-1 + fluorescence (C). Western blot (D) and densitometry (E) corroborated 
the immunohistochemistry results (the same α-tubulin was used as a protein loading control as in Figure 4.4F; scale bars in A 
and B = 200 µm; * = lesion epicentre).  
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4.6.1.3. Anti-angiogenic factors 
The immunoreactivity of anti-angiogenic factors; TIMP-2 and Sema 3A was observed 
in mouse and rat lesion areas 8 dpl (respectively, Figure 4.11-4.12A-C). In the 
mouse, there were low levels of immunoreactivity of TIMP-2 in the parenchyma and 
the lesion epicenter, whilst in the rat cord TIMP-2 was distributed in the surrounding 
neuropil but absent in the wound cavity (respectively, Figure 4.11A and B). In 
contrast, Sema 3A immunoreactivity was absent in mice lesion areas but high levels 
were seen in rat lesion cavities and the peri-lesion neuropil (respectively, Figure 
4.12A and B). Quantification at 8 dpl revealed significantly increased 
immunoreactivity of TIMP-2 and Sema 3A by 0.48- and 0.7-fold, respectively, in rats 
compared to mice (respectively, Figure 4.11-4.12C and Table 4.7).  
Factor Mean Intensity (pixels) (± SEM) 
 
          Mouse                               Rat 
TIMP-2 -37 x 102 ± 9 x 102 18 x 102 ± 5.9 x 102 
Sema 3A -23 x 102 ± 7.5 x 102 16 x 102 ± 7.6 x 102 
Table 4.7 Mean fluorescence intensities of anti- angiogenic growth factors in sections 
of spinal cord at 8 dpl after DC injury. 
 
Western blotting (respectively, Figure 4.11-4.12D) and subsequent densitometry 
(respectively, Figure 4.11-4.12E) coincided with immunohistochemical results 
demonstrating that TIMP-2 and Sema 3A levels were significantly higher in rats 
compared to mice (Table 4.8). These results confirm that mice have a robust wound 
healing response after sub-acute SCI due to the decreased expression of anti-
angiogenic factors compared to rats. The increased expression of anti-angiogenic 
factors in rat spinal cord after injury aids in the detrimental cavitation seen. 
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Figure 4.11 The localisation of TIMP-2 at 8 dpl in DC lesions. Immunohistochemistry for TIMP-2 in mice (A) and rats (B) and 
the pixel intensities of TIMP-2
+
 fluorescence (C). Western blot (D) and densitometry (E) corroborated the 
immunohistochemistry results (the same α-tubulin was used as a protein loading control as in Figure 4.4F; scale bars in A and 
B = 200 µm; * = lesion epicentre). 
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Figure 4.12 The localisation of Semaphorin 3A at 8 dpl in DC lesions. Immunohistochemistry for Semaphorin 3A in mice (A) 
and in rats (B) and the pixel intensities of Semaphorin 3A
+
 fluorescence (C). Western blot (D) and densitometry (E) 
corroborated the immunohistochemistry results (the same α-tubulin was used as a protein loading control as in Figure 4.4F; 
scale bars in A and B = 200 µm; * = lesion epicentre). 
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Factor Mean integrated density (arbitrary units)  
(± SEM) 
          Mouse                              Rat 
TIMP-2 -2 x 104 ± 1.1 x 106 5 x 104 ± 0.5 x 104 
Sema 3A -4 x 106 ± 1.8 x 106 27 x 106 ± 0.87 x 106 
Table 4.8 Mean integrated density of anti- angiogenic growth factors in mouse and 
rat SCI sites at 8 dpl, determined by western blotting.  
 
4.6.1.4. Matrix proteases 
MMP-1 MMP-2 and MMP-9 immunoreactivity was observed after sub-acute SCI in 
mice and rats at 8 dpl (respectively, Figure 4.13-4.15A-C). The levels of these matrix 
proteases were higher in mouse lesion sites and surrounding parenchyma compared 
to the rats. The localization of MMPs was found to be in the lesioned area and 
surrounding WM and GM (respectively, Figure 4.13-4.15A and B). Quantification of 
MMP levels revealed significantly higher immunoreactivity levels in mice by 0.36-, 
1.46- and 4.0-fold, respectively, compared to rats (respectively, Figure 4.13-4.15C 
and Table 4.9). 
Factor Mean Intensity (pixels) (± SEM) 
 
          Mouse                                Rat 
MMP-1 16 x 102 ± 7 x 102 -44 x 102 ± 12 x 102 
MMP-2 -19 x 102 ± 8 x 102 -13 x 102 ± 6 x 102 
MMP-9 12 x 102 ± 1.7 x 102 3 x 102 ± 2.9 x 102 
Table 4.9 Mean fluorescence intensities of matrix proteases in sections of spinal cord 
at 8 dpl after DC injury. 
 
Western blotting (respectively, Figure 4.13-4.15D) and subsequent densitometry 
(respectively, Figure 4.13-4.15E) of MMP coincided with immunohistochemical 
results demonstrating  that MMP-1, MMP-2 and MMP-9 levels were greater in mouse 
lesion sites compared to rats (Table 4.10).  
142	  |	  P a g e 	  	  
Figure 4.13 The localisation of MMP-1 at 8 dpl in DC lesions. Immunohistochemistry for MMP-1 in mice (A) and rats (B) and 
the pixel intensities of MMP-1
+
 fluorescence (C). Western blot (D) and densitometry (E) corroborated the 
immunohistochemistry results (the same α-tubulin was used as a protein loading control as in Figure 2.4F; scale bars in A and 
B = 200 µm; * = lesion epicentre). 
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Figure 4.14 The localisation of MMP-2 at 8 dpl in DC lesions. Immunohistochemistry for MMP-2 in mice (A) and rats (B) and 
the pixel intensities of MMP-2
+
 fluorescence (C). Western blot (D) and densitometry (E) corroborated the 
immunohistochemistry results (the same α-tubulin was used as a protein loading control as in Figure 2.4F; scale bars in A and 
B = 200 µm; * = lesion epicentre). 
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Figure 4.15 The localisation of MMP-9 at 8 dpl in DC lesions. Immunohistochemistry for MMP-9 in mice (A) and rats (B) and 
the pixel intensities of MMP-9
+
 fluorescence (C). Western blot (D) and densitometry (E) corroborated the 
immunohistochemistry results (the same α-tubulin was used as a protein loading control as in Figure 2.4F; scale bars in A and 
B = 200 µm; * = lesion epicentre). 
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Factor Mean integrated density (arbitrary units)  
(± SEM) 
 
          Mouse                                   Rat 
MMP-1 4.7 x 104 ± 0.05 x 104 1 x 104 ± 0.8 x 104 
MMP-2 7 x 104 ± 0.5 x 106 2.5 x 104 ± 0.05 x 106 
MMP-9 10 x 104 ± 0.25 x 106 6 x 106 ± 0.07 x 106 
Table 4.10 Mean integrated density of matrix proteases in mouse and rat SCI sites at 
8 dpl, determined by western blotting. 
 
4.6.1.5. ECM/scar-related molecules  
The Immunoreactivity of ECM molecules; Collagen-1 and PECAM-1, have been 
observed between mice and rats after sub-acute SCI at 8 dpl (respectively, Figure 
4.16-4.17A-C). Collagen-1 localisation and its distribution mirrored that of laminin, i.e. 
within the lesion in mice and localised to the GLA in the rat (not shown) (Figure 4.16A 
and B). Whilst, the cell adhesion molecule, PECAM-1, was localised to the lesion site 
and peri-lesion neuropil (not shown) (Figure 4.17A and B). Quantification of 
immunoreactivity levels revealed that levels were significantly upregulated by 10- and 
3.4-fold, respectively, in mice compared to rats (respectively, Figure 4.16-4.17C and 
Table 4.11). 
Western blotting (respectively, Figure 4.16-4.17D) and densitometry (respectively, 
Figure 4.16-4.17E) confirmed that laminin (for immunoreactivity results please refer 
to chapter 3) and PECAM-1 levels were significantly higher in rats compared to mice 
at 8 dpl (respectively, Figure 4.16-4.17E and Table 4.12). 
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Figure 4.16 The localisation of Collagen-1 at 8 dpl in DC lesions. Immunohistochemistry for Collagen-1 in mice (A) and in rats 
(B) and the pixel intensities of Collagen-1 
+
 fluorescence (C). Western blot (D) and densitometry (E) for laminin corroborated 
the immunohistochemistry results seen in chapter 1 (the same α-tubulin was used as a protein loading control as in Figure 
2.4F (Scale bars in A and B = 200 µm; * = lesion epicentre). 
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Figure 4.17 The localisation of PECAM1 at 8 dpl in DC lesions. Immunohistochemistry for PECAM1 in mice (A) and in rats (B) 
and the pixel intensities of PECAM1
+
 fluorescence (C). Western blot (D) and densitometry (E) corroborated the 
immunohistochemistry results (the same α-tubulin was used as a protein loading control as in Figure 2.4F; scale bars in A and 
B = 200 µm; * = lesion epicentre). 
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Factor Mean Intensity (pixels) (± SEM) 
 
          Mouse                                Rat 
Collagen-1 20 x 102 ± 5 x102 -2 x 102 ± 8.5 x 102 
PECAM-1 23 x 102 ± 5.2 x 102 -6.7 x 102 ± 3.5 x 102 
Table 4.11 Mean fluorescence intensities of ECM/scarring-related molecules in 
sections of spinal cord at 8 dpl after DC injury. 
 
Factor Mean integrated density (arbitrary units)  
(± SEM) 
 
          Mouse                                   Rat 
laminin 1.5 x 104 ± 0.05 x 104 3.2 x 102 ± 0.8 x 102 
PECAM-1 6 x 106 ± 0.28 x 106 0.5 x 106 ± 0.01 x 106 
Table 4.12 Mean integrated density of ECM/scarring-related molecules in mouse and 
rat SCI sites at 8 dpl, determined by western blotting.  
 
These results demonstrate fundamental differences in healing of SCI wounds in mice 
compared to rats, i.e. aggressive wound healing in mice marked by increased 
deposition of matrix proteins, pro-angiogenic growth factors correlated with raised 
levels of MMP and reduced TIMP titres. 
 
4.6.2 Induced hypoxia after SCI 
Histological and protein differences in carbonic anhydrase-X (CA10) indicate 
that hypoxia may play a role in mediating the differential responses after SCI (Figure 
4.18A-E). CA10 immunoreactivity was seen in the lesion site and peri-lesion neuropil 
in mice and rats (Figure 4.18A and B). At 8 dpl, there was significantly higher levels 
of CA10 in rats compared to mice (5.6 x10² ± 2.5 x 10² pixels in rats compared to -7.6 
x 10² ± 1.6 x 10² pixels in mice, P<0.001, Figure 4.18C). These results were 
confirmed by western blotting, demonstrating that the protein levels of CA10 were 
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significantly higher in rat compared to mouse DC lesions (5.2 x103 ± 1.2 x 103 pixels 
in rat compared to -5.4 x 103 ± 2.6 x 103  in mice, P<0.021, Figure 4.18D and E). 
These results demonstrate that increased levels of CA10 are induced by hypoxia 
after DC injury in rats.  
 
4.6.3 Behavioural analysis 
The response to thermal stimuli in both rats and mice was significantly 
impaired 2 hr after DC injury compared to sham-treated control animals (Figure 
4.19A and B). For example, the reaction time (paw withdrawal latency) was delayed 
by 3.38s in mice (P<0.041) and by 5.63s in rats (P<0.002). However, by 7dpl the 
response to thermal stimuli had returned to sham-treated control levels and showed 
no further differences in withdrawal latency over the course of the experimental time-
period of 28dpl (Figure 4.19A and B). Unlike thermal responses, mechanical 
allodynia responses were not significantly different in mice or rats, with or without DC 
injury and did not vary over the experimental time-period (Figure 4.20A and B). 
These results indicate that despite the presence of a large wound cavity in rats, DC 
injury did not affect responses to mechanical stimuli but temporarily affected 
responses to thermal stimuli in the early stages after DC injury. However, within 7 
dpl, animals regained normal function response times and were no different to those 
observed in sham-treated control animals.  
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Figure 4.18 The localisation of Carbonic Anhydrase 10 at 8 dpl in DC lesions. Immunohistochemistry for Carbonic Anhydrase 
10 in mice (A) and in rats (B) and the pixel intensities of Carbonic Anhydrase 10
+
 fluorescence (C). Western blot (D) and 
densitometry (E) corroborated the immunohistochemistry results (the same α-tubulin was used as a protein loading control as 
in Figure 2.4F; scale bars in A and B = 200 µm; * = lesion epicentre). 
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Figure 4.19 Comparison of the behavioural deficits observed after T8 DC injury in 
mice and rats over time using IR plantar heat test. Quantification on the average 
reaction time before surgery (-1), 2 hours after surgery (0), 7, 14, 21 and 28 dpl 
showed significant differences in mice (A) and rats (B) at 0dpl only compared to 
sham operated control. 
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Figure 4.20 Comparison of the behavioural deficits observed after T8 DC injury in 
mice and rats over time using Vonfrey hair test. Quantification on the average gram 
force required to elicit paw withdrawal before surgery (-1), 2 hours after surgery (0), 
7, 14, 21 and 28 dpl showed no significant differences in DC lesioned mice (A) and 
rats (B) compared to sham operated control. 
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4.6.4 Greater sparing of PKC-γ+ and NF200+ DC axons in mice compared to 
rats  
 Spared and established axons in the DC of mice and rats after injury were 
assessed by calculating the area occupied by NF200 labeling in the whole dorsal 
funiculi to identify the level of spared axons (smaller axon fibers) left after injury and 
thus plasticity (Bouhy et al., 2011, Butt et al., 1997). In spinal segments T7 (above 
lesion) and T9 (below lesion), normal basal levels of NF200+ immunostaining was 
observed in control mice (Figure 4.21A and B, respectively) and rats (Figure 4.21E 
and F, respectively), in the CST and in interneurons and their axons in the superficial 
dorsal horn. After DC in mice NF200 immunoreactivity was significantly reduced in 
the CST at T7 and T9 compared to intact controls, indicative of retrograde axonal 
dyeback of axons that originate from the motor cortex, respectively (Figure 4.21C 
and D). In rat lesioned DC, reduced NF200 immunohistochemistry was observed in 
spinal segment in the CST from T7 and T9 (Figure 4.21G and H), compared to 
control rats. Pixel intensities were measured in a given area i.e. the dorsal funiculi to 
reveal the reduction in NF200 immunoreactivity in the DC was greater in rat T7 (65 ± 
4% in rat versus 42 ± 3% in mice, P<0.01) and T9 (45 ± 3% in mice versus 20 ± 4% 
in rat P<0.01) segments (Figure 4.22A and B and 4.22I) compared to mice. 
Similar changes were observed with PKC-γ immunostaining (Figure 4.23A and 
B), in the CST and in interneurons and their axons in the superficial dorsal horn 
(Barritt et al., 2006). PKC-γ is an isotope of the classical PKC subfamily, solely 
expressed in the brain and spinal cord and localization is restricted to neurons (Saito 
and Shirai, 2002). After DC injury in mice, PKC-γ immunohistochemistry was 
significantly reduced at T7 and T9, indicative of Wallerian degeneration and 
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retrograde axonal dyeback, respectively (Figure 4.23C and D). In rat lesioned DC, 
reduced PKC-γ immunohistochemistry was observed in spinal segments T7 and T9 
of control rats (Figure 4.22E and F), while after DC injury, reduced PKC-γ 
immunoreactivity was also observed at T7 and T9 segments (Figure 4.23G and H). 
The reduction in PKC-γ immunoreactivity in the DC (Figure 4.24A) was greater in rat 
T7 (14 ± 2% in mice versus 25 ± 3% in rat, P<0.01) and T9 (18 ± 3% in mice versus 
31 ± 1.5% in rat, P<0.01) segments (Figure 4.24B). 
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Figure 4.21 NF200 immunoreactivity as an indicator of axonal sparing at 8 dpl after 
DC injury in spinal segments above and below the lesion. Representative NF200 
staining at T7 (above lesion) in mouse control (A) and injured (C) and at T9 control 
(B) and injured (D) cords. Representative NF200 staining at T7 in rat control (E) and 
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injured (G) and at T9 control (F) and injured (H) cords (Scale bars = 200 µm). A 
representative image outlining the dorsal funiculi that was used for quantification and 
the corticospinal tract (I). 
 
Figure 4.22 Diagram shows dorsal column and corticospinal tract axons quantified 
before and after injury (A). Quantification of the immunoreactivity of NF200 (B) 
demonstrated that NF200 immunoreactivity was reduced in rats compared to mice at 
both T7 and T9 spinal segments.  
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Figure 4.23 PKC-γ immunoreactivity as an indicator of axonal sparing at 8dpl after 
DC injury in spinal segments above and below the lesion. Representative PKC-γ 
staining at T7 (above lesion) in mouse control (A) and injured (C) and at T9 control 
(B) and injured (D) cords. Representative PKC-γ staining at T7 in rat control (E) and 
injured (G) and at T9 control (F) and injured (H) cords. (Scale bars = 200 µm). A 
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representative image outlining the dorsal funiculi that was used for quantification and 
the corticospinal tract (I). 
 
Figure 4.24 Diagram shows dorsal column and corticospinal tract axons quantified 
before and after injury (A). Quantification of the immunoreactivity of PKC-γ (B) 
demonstrated that PKC-γ immunoreactivity was reduced in rats compared to mice at 
both T7 and T9 spinal segments.  
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4.7 Discussion 
In our animal model of sub-acute T8 DC injury at 8 dpl demonstrates that 
there are fundamental differences in angiogenic/wound healing-related proteins 
between mice and rats, confirming that mice have a robust wound healing response 
that correlates with the no cavity development compared to rats. But the cavity free 
response seen in mice did not aid in better functional recovery as originally 
hypothesised, but did have increased axonal sparing.  
However, using other endpoints such as MRI/gadolinium (a contrast medium 
that improves the clarity of internal structures) would allow for a more accurate 
determination of cavity development and lesion volume between mice and rats after 
SCI. Furthermore, blood vessels and scarring could also be assessed in the animals.  
If time permitted, earlier time points would also be useful in determining the early 
angiogenic/wound healing responses between the two species after sub-acute SCI. 
 
 4.7.1 Angiogenic factors 
Although there were no significant differences in expression of vWF after T8 
sub-acute SCI in mice and rats at 8dpl, there is evidence to demonstrate that vWF is 
upregulated after injury to the CNS  and more importantly after SCI in humans 
(Petaja et al., 1989, Mammen, 1992, Cellucci et al., 2012, Suidan et al., 2013). But 
conflicting results indicate that no changes are seen in vWF levels after injury to the 
cord in patients (Fujii et al., 1992, Pahl et al., 1994). Due to inconsistent results in the 
literature vWF is not considered as an appropriate therapeutic option after SCI. 
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4.7.2 Angiogenic growth factors 
VEGF-A; a potent stimulator of angiogenesis and formation of new vessel 
sprouts, is up-regulated in many cancers and is important in the angiogenic 
processes in particular cell migration and proliferation (Gerhardt et al., 2003, 
Ruhrberg et al., 2002, Ito et al., 2007, Chung and Ferrara, 2010). In our model there 
was a significant upregulation of VEGF-A in mice compared to rats at the lesion 
epicenter. Although VEGF is neuroprotective, the levels reported after SCI are 
inconsistent   along with the use of VEGF-A165 isoform (Bartholdi et al., 1997, Skold 
et al., 2000, Jin et al., 2000, Matsuzaki et al., 2001, Benton and Whittemore, 2003, 
Akiyama et al., 2004, Rosenstein and Krum, 2004, Deumens et al., 2005, Herrera et 
al., 2009, van Neerven et al., 2010, Berger et al., 2011). However, the use of VEGF-
A121/189 isoforms has demonstrated to be neuroprotective and in combination with 
spinal cord bridges and viral vectors induces angiogenesis and thus axon 
regeneration (Herrera et al., 2009, D'Onofrio et al., 2011, Siddiq et al., 2012, De 
Laporte et al., 2011). 
In our model the levels of FGF-2 was increased in mice compared to rats after 
sub-acute SCI. In  experimental models of CNS injury, FGF-2 has demonstrated a 
role in  neuroprotection and functional recovery (Dono, 2003, Hattori et al., 1997b, 
Hattori et al., 1997a, Hossain et al., 1998, Hsu et al., 2009, Madiai and Hackshaw, 
2002). This phenomenon has also been observed in animal models of SCI  and in 
clinical situations where patients  treated with stem cells co-delivered with FGF-2 to 
the injured site, improved motor and sensory scores were observed 24 months after 
treatment (Teng et al., 1998, Furukawa and Furukawa, 2007, Liu et al., 2011, Wu et 
al., 2011). Furthermore, FGF-1 induced the stimulation of blood vessels via 
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proliferation of endothelial cells and smooth muscle cells that resulted in enhanced 
mitotic activity of the neural stem cells and thus promote cell differentiation and 
survival. The decrease in deficit seen after plantar heat test in mice compared to rats 
may be supported by the increase in FGF-2 and thus improve functional outcome in 
our model. 
ANG-1 not only promotes endothelial cell survival, vessel stabilisation and 
maturation, but also inhibits and reduces inflammation that results in tissue loss after 
SCI  and therefore promotes angiogenesis (Thurston et al., 2005, Thurston et al., 
2000, Fleming et al., 2006, Chung and Ferrara, 2010, Han et al., 2010). Our 
immunohistochemical results showed that there was an increase in expression of 
ANG-1 after SCI in mice compared to the rats. This may imply that the upregulation 
of reactive astrocytes as a result of inflammatory response causes secondary 
damage and decreases the chances of angiogenesis occurring in and around the 
lesion site but also the BSCB integrity is compromised in rats due to down regulation 
of ANG-1 after SCI (Durham-Lee et al., 2012, Herrera et al., 2009, Ritz et al., 2010). 
The localization and levels of ANG-2 was not investigated in this study despite the 
beneficial role it has shown after SCI due to previous studies showing an 
upregulation 10 weeks after injury (Durham-Lee et al., 2012, Ritz et al., 2010). Our 
study investigated the early angiogenic/wound healing effects at 8 dpl after sub-acute 
SCI, therefore if time permitted and later time points were to be investigated then 
ANG-1 vs. ANG-2 would be considered.  
TGFβ-2 regulates many processes including angiogenesis, inflammation and 
wound-healing (Khalil et al., 1989). It also induces generalised scar tissue formation 
but has also been demonstrated to correlate with the deposition of the scar in the 
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CNS (Lagord et al., 2002, Shah et al., 1995). Our results show that there is 
significantly higher localisation of TGFβ-2 around the lesion site in mice whilst in rats 
it was present in lower levels. The higher levels of TGFβ-2 in mice supports our 
hypothesis that mice have a better wound healing response due to an adequate 
balance of angiogenesis and scar deposition. 
PDGF is responsible for  recruitment of pericytes in promoting tumour 
angiogenesis  and vessel maturation during angiogenesis along with MMPs and 
TGFβ (Abramsson et al., 2003, Chung and Ferrara, 2010). In our studies there was a 
significant upregulation of PDGF-BB in and around the lesion site after injury in the 
mouse where low levels were observed in rats. It has been reported that human 
dermal wounds and patients with chronic neuropathic diabetic ulcers treated with 
recombinant PDGF-BB (rPDGF-BB) increases wound healing with fibroblast 
activation and granulation tissue formation by increasing the expression of PDGF-AA 
isoform which is present in endothelial cells, capillaries and smooth muscle. 
Therefore, treating chronic wounds with exogenous rPDGF-BB maybe a promising 
therapeutic application of wound healing (Pierce et al., 1995, Wieman et al, 1998). 
More recently it has been demonstrated that using a peri-ulcer injection of a 
replication-incompetent adenoviral construct expressing PDGF-BB in patients with 
venous leg ulcers (a disease responsible for chronic lower extremity wounds), was 
able to increase wound healing and have a systemic effect on parts of the wound that 
were not injected (Margolis et al., 2009). The multifaceted role that PDGF-BB plays in 
the CNS instigated studies that utilise PDGF-BB as a therapeutic strategy after SCI. 
Angiogenin is well characterized in the pathogenesis of amyotrophic lateral 
sclerosis (ALS), a motor neurodegenerative disease of the CNS that was first 
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characterised by Fett et al. as a tumour-derived angiogenic protein (Fett et al., 1985, 
Boillée et al., 2006, Kishikawa et al., 2008). In our hands, angiogenin was 
significantly increased in and around the lesion site in mice. Although there is 
angiogenin expression around the lesion after following injury in rats there was no 
positive immunoreactivity in the lesion site. It is thought that using angiogenin as a 
therapy option after SCI may aid in motor neuron survival  and that the increase seen 
in the mouse correlates with increased angiogenesis and thus wound healing (Ng et 
al., 2011). Angiogenesis and wound healing are two closely liked dynamic processes 
that demonstrate a strong correlation particularly after injury where impaired 
angiogenesis can delay or accelerate wound healing (Guo and Dipietro, 2010, 
Gosain and DiPietro, 2004, Zhou et al., 2004, Echtermeyer et al., 2001, Nanney et 
al., 2001, Swift et al., 1999, Lee et al., 1999). 
 
4.7.3 Anti-angiogenic factors  
In order for successful angiogenesis to occur after injury, a balance in pro- and 
anti-angiogenic protein expression is required. TIMP’s regulates MMPs but high 
levels of TIMP-2 have shown to inhibit MMP-2 in which TIMP-2 strongly binds to and 
controls degradation of collagen-1 (Anik et al., 2011a). High levels of TIMP-2 have 
been observed in the degenerating dorsal column suggesting that TIMP-2 may be 
used as a therapeutic strategy after SCI (Zhang et al., 2006). This supports our data 
in which higher levels of TIMP-2 were localised to rat lesion areas compared to lower 
levels in mice, suggesting mice have an equal balance in the levels of pro- and anti-
angiogenic factors.  
164	  |	  P a g e 	  	  
Due to NP’s binding to VEGF family members and its receptors, semaphorins 
play a vital role in angiogenesis rather than axon guidance (Soker et al., 2002). Sema 
3A does inhibit tumor cell migration in an NP1 dependent manner by inhibiting vessel 
function and increasing hypoxia and necrosis in multiple mouse tumor models 
(Casazza et al., 2011). Our fluorescent immunohistochemistry results confirm the 
role of Sema3A as an inhibitory molecule in and around the lesion site after SCI in 
rats by displaying a significant increase in localisation of Sema 3A compared to mice. 
Sema 3A was almost absent in mice lesions and further supports the idea that cavity 
free response seen in the mouse after SCI is conducive to angiogenesis, wound-
healing and a better balance of scar deposition which we originally hypothesised 
from preliminary results that showed an increase in laminin deposition in the mouse 
compared to that of the rat lesion site. It is important to note that whilst the mice in 
our model seemed to recover fully after mild sub-acute SCI this may not be that case 
if a more severe model was to be inflicted, such as the weight drop model, which 
would result in increased functional deficits. 
 
4.7.4 Matrix proteases 
MMP-1 is required for cell migration during angiogenesis and is upregulated in 
many cancers and in humans MMP-1 levels are associated with an early up-
regulation of macrophages (Hiraoka et al., 1998, buss et al, 2007). Our results show 
that MMP-1 was significantly higher in mouse lesion sites compared to rat lesion 
sites after sub-acute SCI. This suggests that there is induction of angiogenesis after 
SCI in mice supporting our hypothesis but also an early induction of inflammation to 
remove debris after injury. 
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Whilst, MMP-2 and MMP-9 are associated with angiogenesis and  
inflammation reaction after injury  and is thought they play a part in BBB disruption, 
edema, migration and infiltration of inflammatory cells (Mautes et al., 2000, Biddison 
et al., 1997, Di Girolamo et al., 1998, Romanic et al., 1998). It is reported that 
expression of VEGF up-regulates MMP-9 expression, which correlates with our 
immunohistochemical observations that show significant expression of VEGF and 
MMP-9 in mouse lesions compared to rats (Wang and Keiser, 1998). Whilst there 
was no significant difference in the levels of MMP-2 after injury between mice and 
rats and it has been demonstrated that in the CNS MMP-2 is constitutively expressed 
in the endothelium. But once activated with pro-inflammatory cytokines no changes 
were seen in MMP-2 expression coinciding with our results (Harkness et al., 1999).  
 
4.7.5 ECM/scar-related molecules 
PECAM-1 plays a key role in removing aged neutrophils, aids leukocyte 
migration, activates integrins and promotes angiogenesis (Newman, 1997). Our 
results showed that there was a significant increase in PECAM-1 localisation around 
the lesion site in rats and mice. PECAM-1 has been demonstrated to play a role in 
the integrity of the BBB in the CNS (Lossinsky et al., 1997). However in a weight drop 
model in mice there was a significant increase in PECAM-1+ vessels at 3-7 days 
suggesting that it contributes to wound healing (Goussev et al., 2003, Whetstone et 
al., 2003). This supports our data seen and thus our hypothesis that mice have a 
robust wound healing response correlating with angiogenesis compared to rats.  
Laminin and collagen-1 localisation in both species mirror each other’s 
response. In the sub-acute stage, one would expect there to be an adequate balance 
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between angiogenesis (i.e. laminin expression) and scar deposition (i.e. collagen-1 
deposition) in order for damaged tissue and neurons to effectively repair the lesion 
site. However in the chronic stages one would expect there to be more collagen-1 
deposition than laminin due to the scar maturing. It has been demonstrated that 
using collagen type 1 scaffolds in the CNS promotes neuronal regeneration  but more 
importantly after SCI provides directional axonal growth and functional recovery (Ma 
et al., 2004, Ding et al., 2010, Watanabe et al., 2007, Joosten et al., 1995). However, 
our results showed that only mice are able to fill the lesion site with laminin and 
collagen-1 while the response by rats was poor, failing to fill the lesion site with these 
molecules. This may reflect the difference in cavitation observed between mice and 
rats. 
 
4.7.6 Behavioural testing 
We originally hypothesised that mice have a robust wound healing response 
resulting in increased angiogenesis and better functional recovery than rats, 
correlating with little or no cavity formation while a large cavity in rats correlate with 
little angiogenesis and poorer functional outcomes. After observing significant 
differences in pro-angiogenic and anti-angiogenic protein localisation and levels after 
DC injury between mice and rats, part of our hypothesis was vindicated. However, 
our hypothesis that behavioural deficits would be present correlating with little 
angiogenesis and large cavities in rats was not borne out by our behavioural 
assessments. Our behavioural tests showed that despite post-injury deficits, animals 
regained normal responses within 7 days even though the cavity is still forming and 
expanding in rats beyond 1 month when cavities are fully established (Byrnes et al., 
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2010, Sroga et al., 2003, James et al., 2011). A similar unaffected behavioural 
response was shown by Hill et al (2009) where they used a LISA-Vibraknife to 
generate precise dorsal lacerations at varying depths from 0.5, 0.8, 1.1 to 1.4mm in 
mice (Hill et al., 2009). Using similar behavioural assessments to that used by us, the 
authors showed that a comparable 0.8mm laceration of the dorsal spinal cord at the 
same T8 lesion site, produced no significant differences in behavioural assessment 
parameters, in injured mice compared to control mice. However as the lesion depth 
increased to 1.1 and 1.4mm, behavioural deficits were observed. Previous studies 
have shown that lesion severity correlates with the extent of behavioural deficits in 
mouse SCI models (Farooque, 2000, Seki et al., 2002, Ma et al., 2001). Similar 
results were shown in rats using small lesions at T8 within the corticospinal tract, 
similar to our model, rats reached recovery within a week (Majczynski and Slawinska, 
2007, Muir and Whishaw, 2000). In our SCI model, lesion depth of 0.8mm is 
therefore considered a mild injury and therefore slight behavioural deficits were seen 
only 2 hours after injury in both mice and rats returning back to baseline control 
levels. Our results demonstrate that despite the presence of a large cavity in rats, 
behavioural deficits are not observed suggesting remarkable spinal plasticity in the 
rat. After injury the spinal cord is capable a degree of injury-induced spinal plasticity 
and therefore the ability of the animal to regain an apparent degree of functional 
recovery increases (Dietz, 2006). Activity dependent training to enhance limb 
movement and reinforce appropriate connections have shown to result in better 
functional recovery through spinal plasticity in both humans and animal models after 
SCI (Edgerton and Roy, 2002, Dietz, 2002, Dietz, 2006, Krajacic et al., 2010). 
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Another explanation as to why an acute deficit was observed only 2 hours 
after injury in both species could be a result of the model itself. Our aim was to 
transect only the DC axons to produce a SCI in both mice and rats and to use 
mechanical and thermal stimuli to assess neuropathic pain. However, the 
spinothalamic tract, located in the lateral section of the spinal cord is the central pain 
pathway that would show true pain deficits once injured (Purves et al, 2001). 
Therefore the deficits seen could be due to the Buprenorphine; an analgesic opioid 
used to relieve pain, wearing off after surgery as opposed the model itself.  
Although we have used an inbred mouse (C57Bl6) and outbred rat (Sprague-
Dawley) strain to investigate cavitation, equivalent responses to DC injury have been 
observed in other outbred rat strains such as Long Evans and Wistar rats as well as 
inbred strains such as Lewis rats (Jimenez Hamann et al., 2005, Byrnes et al., 2010, 
Schwartz et al., 1999, Poon et al., 2007, Lagord et al., 2002, Figley et al., 2014, 
Sroga et al., 2003). The extent of cavitation however, is dependent in the severity of 
the initial injury (Poon et al., 2007). Furthermore, there is no consistency across 
inbred and outbred strain to indicate that cavitation would be different in one group of 
animals versus the other group. For example, SCI in inbred and outbred strains of 
mice that are either resistant or susceptible to excitotoxcity all showed increases in 
lesion size over the first 7 days followed by decreases in cavity and wound healing 
from 7 to 56 days, although animals susceptible to excitotoxcity showed larger lesion 
sizes across all strains (Inman and Steward, 2003). Therefore, our results are valid 
across a range of rat and mouse strains and highlights the differences in cavity 
formation, matrix deposition and wound healing responses. 
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In summary, this data for known pro-angiogenic/wound healing-related 
proteins supports the notion that the cavity free response seen after SCI in mice is 
due to an adequate balance of scar deposition, wound-healing and vascularisation 
but do not correlate with acute functional deficits but a reduced amount of axonal 
sparing. The injury response observed in rats correlates with the presences of cavity 
formation after injury very much the same as what has previously been documented 
in humans after SCI (Fleming et al., 2006). However, in our animal model of mild T8 
sub-acute SCI, the observation of functional deficits was minimal and therefore did 
not correlate with our injury response and histological data observed in rats. 
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CHAPTER 5 
DISTINCT INFLAMMATORY-INDUCED ANGIOGENIC RESPONSES DISPLAYED 
AFTER SUB-ACUTE SPINAL INJURY IN MAMMALS 
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5.1 Introduction 
5.1.1 Inflammation 
Inflammation is part of the body’s natural response to harmful stimuli such as 
pathogens, where vascular tissues aim to remove harmful stimuli and initiate the 
healing response bringing damaged tissue back to normal. The acute phase of 
inflammation requires a rapid influx of blood granulocytes, typically neutrophils, 
followed shortly by monocytes that mature into inflammatory macrophages. The 
process of acute inflammation results in redness, swelling and pain, symptoms 
typically associated with inflammation, around the sight of infection/injury (Ricciotti 
and FitzGerald, 2011). Once the harmful stimulus is removed via phagocytosis, the 
inflammatory reaction begins to resolve allowing macrophages and lymphocytes to 
return back to pre-inflammatory levels. Successful inflammation results in repair and 
resolution of tissue damage but it is a process that needs to be closely monitored as 
persistent inflammation can typically result in scarring and loss of organ function thus 
leading to excessive tissue damage and chronic inflammation (Nathan, 2002). 
Chronic inflammation can be detrimental resulting in the cause of autoimmune 
demyelinating diseases of the central and peripheral nervous system such as 
multiple sclerosis (MS) and chronic demyelinating polyradiculoneuropathy (CIDP) 
(Melzer and Meuth, 2014).   
 
 5.1.2 Inflammation and cavitation 
Many studies report that inflammation contributes to cavitation which also aids 
in the deleterious pathology seen in many pathological conditions and diseases. 
Clinical intra-operative pathology of the salivary/parotid gland swelling revealed 
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granulomatous inflammation accompanied by central cavitation (Ho et al., 2013). 
Whilst in cases of congenital cystic adenomatoid malformation massive amounts of 
cavitation containing multiloculated cysts of vary size was observed with noticeable 
inflammation (Kim et al., 2013). Uncontrolled inflammation in tuberculosis can lead to 
excessive tissue remodelling, causing fibrosis and/or cavitation (Perez et al., 2003). 
Inflammation-induced cavitation not only plays a dual role in organs but also other 
areas of the body. An infection in soft tissue and joints demonstrates that 
inflammation proceeds through necrosis to cavitation (Wilson, 2004). 
Previous studies have demonstrated that inflammation may contribute to 
secondary injury and therefore cavitation after injuries to the CNS. Inducing 
inflammation using zymosan; a macrophage activator, into the corpus callosum of 
rats initiates a cascade of secondary tissue damage, progressive cavitation and glial 
scarring in the CNS (Fitch et al., 1999). In models of traumatic brain injury vascular 
fluid cavitation and cell death, are both exacerbated by the progression of 
neuroinflammation (Abdul-Muneer et al., 2013, Atkins et al., 2013). Patients 
developing spinal arachnoiditis after peridural anaesthesia developed meningeal 
inflammation that later induced ischemia and cavitation (Torres et al., 1993). 
Inflammatory cells and in particular macrophages, participate not only in tissue 
destruction but also cavity enlargement and thus contribute to the secondary 
pathology response after SCI (Glaser et al., 2006). In models of SCI, rats receiving 
dural repair after cervical laceration to the spinal cord resulted in reduced infiltration 
of macrophage/microglial into the lesioned area that further reduced lesion volume 
and cystic cavitation (Iannotti et al., 2006). The use of self-assembling peptides 
combined with neural/progenitor cells in rats after cervical SCI reduces cystic 
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cavitation volume whilst attenuating peri-lesional inflammation (Iwasaki et al., 2014). 
Interestingly endogenous expression of interleukin-4 regulates macrophage 
activation but also confines cavity formation after traumatic SCI in rats (Lee et al., 
2010). The presence of a large cavity in the rat is proposed to be the result of the 
presence of macrophages and microglia removing debris, whilst mice fail to 
demonstrate cavitation (Inman and Steward, 2003, Gonzalez-Lara et al., 2009). The 
lesioned area in mice is normally filled with ECM and inflammatory cells (Inman and 
Steward, 2003). 
 
 5.1.3 Inflammation after SCI 
After human SCI neutrophils entered the injured spinal cord between 1-3 days 
and were detectable for up to 10 days after SCI. There were significant numbers of 
CD68 microglia but few monocytes/macrophages in the injured tissue 1-3 days after 
injury and remained in the cord up to weeks and months after SCI. Through the time 
periods tested only a few CD8+ lymphocytes were observed (Fleming et al., 2006). It 
has been shown that there is an increase in the number of white blood cells in the 
cerebrospinal fluid within the 7 days after injury showing an increase in plasma levels 
of inflammatory mediators in patients with long-standing SCI (Segal et al., 1997). The 
accumulation of activated microglia and macrophages may contribute to the 
progression of secondary injury (Blight, 1992, Blight et al., 1995, Bethea et al., 1998).  
As previously mentioned the inflammatory response between mice and rats 
has previously been investigated showing marked differences in T-cell numbers 
between the two species (Sroga et al., 2003, Byrnes et al., 2010). However, the 
difference in the pathological progression after SCI in rats and mice appears to be 
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the formation of a cavity near and around the lesioned area and the extent of 
inflammation (Byrnes et al., 2010). The differences in the inflammatory response 
between the two species may thus be a contributing factor to the development of 
cavities within the lesion site. 
 
 5.1.4 Inflammatory markers 
 The localisation and protein expression of inflammatory mediators can be 
tested using known inflammatory markers, in particular, OX-42, CD68, CD4, CD8, 
fibronectin and GFAP after SCI. OX-42 (CD11b) is a β-integrin marker of activated 
microglia and macrophages that can be used to mark the activation and recruitment 
after injury especially after neurodegenerative inflammation (Roy et al., 2006, Perego 
et al., 2011). As previously mentioned (Chapter 3 introduction) CD68 (ED-1) was 
originally identified as a marker of macrophages and active phagocytosis and  is also 
expressed in human fibroblasts and active endothelial cells (Holness and Simmons, 
1993, Kunz-Schughart et al., 2003, Beranek, 2005, Perego et al., 2011).  
CD4 and CD8 (cluster of differentiation 4 and 8) are transmembrane 
glycoprotein’s used as a marker of T-cells after injury (Luckheeram et al., 2012). CD4 
are known as the ‘helper’ T-cells that activate B cells, whilst CD8 are known as the 
‘cytotoxic’ T-cells that kill other ‘target’ cells, and are used to identify T-cells involved 
in the injury response (Alberts et al., 2002). 
 As previously mentioned (Chapter 3 introduction) Fibronectin is an ECM 
glycoprotein and is a marker of increased fibroblast expression in overgrown lesions 
(Sume et al., 2010). However, glial fibrillary acidic protein (GFAP) is an intermediate 
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filament protein where increased expression of GFAP represents activation of 
astrocytes and glial cells during neurodegeneration (Brahmachari et al., 2006). 
  
5.2 Rationale 
After sub-acute SCI, mice and rats displayed distinct differences in cavitation, laminin 
deposition and inflammatory/angiogenic responses. The increased angiogenic 
responses at 8 dpl supported no cavity formation in mice after sub-acute SCI, whilst 
rats developed large cavities that coincided with decreased angiogenic responses. 
Many studies have shown that inflammation along with other mechanisms can 
contribute to the secondary damage after injury and that inducing inflammation in rats 
can potentiate cavitation. This led us to propose that inducing inflammation 
immediately after injury in mice may cause cavity formation similar to that seen in 
rats after SCI at 8 dpl; a time point that has demonstrated the greatest difference 
between the two species.  
  
5.3 Hypothesis 
In vivo induction of inflammation using an acute injection of zymosan; a macrophage 
activator, directly to the lesioned area immediately after injury would increase 
inflammatory cell infiltration, resulting in wound cavities in the microenvironment of 
the mouse SCI site similar to those seen in rat SCI at 8 dpl compared to control PBS 
treated animals.  
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5.4 Aims 
• To compare histological analyses after PBS and zymosan injection into the 
mouse lesion site with PBS and zymosan injected rat lesion sites after T8 DC 
crush. 
• To determine cavity development in PBS and zymosan injected mouse and rat 
lesion sites using Image ProAnalyzer. 
• To analyse mouse and rat lesion sites using known inflammatory markers at 8 
dpl using immunohistochemistry. 
• To determine the effect that induced inflammation has on angiogenesis in 
mouse and rat lesion sites using known angiogenic markers. 
• To confirm immunohistochemical results by western blot and densitometric 
analysis. 
 
5.5 Material and Methods 
 5.5.1 Experimental design 
Please refer to Material and Methods section 2.1 Animal surgery, 2.2.1 and 2.2.2 
Tissue preparation for immunohistochemistry and western blotting for standard 
protocols used. To induce inflammation after sub-acute SCI, DC were crushed and 
immediately after injury mice and rats received either injection of PBS or zymosan 
directly to the lesioned area (stock concentration 12.5µg/ml (Fitch et al., 1999), 3µL 
or 5µl, respectively (maximum volume injected into mouse and rat previously used in 
the lab) (Table 5.1).  
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Type of analysis N -numbers End-points (days) 
Inflammatory/angiogenic 
immunohistochemistry 
3 (species/treatment group) 0, 8 
Inflammatory/angiogenic 
western blot analysis 
3 (species/treatment group) 0, 8 
Table 5.1 Experimental design of n numbers and end-points used to assess 
inflammatory/angiogenic localisation and protein expression after sub-acute SCI in 
mice and rats. 
 
 5.5.2 Antibodies used for fluorescent immunohistochemistry 
Please refer to Materials and Methods section 2.3.2 Fluorescent 
immunohistochemistry for standard protocol used. Fluorescent 
immunohistochemistry was used to assess the localisation of inflammatory and 
angiogenic related proteins (Table 5.2). 
Inflammatory and wound 
healing/angiogenic-related proteins 
Dilution 
factor 
Species Supplier (catalogue no.) 
Primary antibodies 
Glial fibrillary acidic protein (GFAP) 1:400 Rabbit Sigma (G9269) 
Fibronectin 1:200 Rabbit Sigma (F3648) 
ED1 (CD68) 1:400 Rabbit Santa Cruz 
Biotechnology (sc-9139) 
OX-42 (CD11b) 1:100 Rabbit Abcam (ab28664) 
CD8 1:400 Rabbit Novus Biologicals 
(NBP1-42051) 
CD4 1:400 Rabbit Novus Biologicals 
(NBP1-19371) 
Laminin 1:200 Rabbit Sigma (L9393) 
VEGF-A (Vascular Endothelial 
Growth Factor-A) 
1:400 Rabbit Abcam (ab46154) 
MMP-1 (Matrix Metalloproteinases) 1:200 Sheep Biogenesis (5980-0111) 
TIMP-2 (Tissue Inhibitor of Matrix 
Metalloproteinases) 
1:200 Rabbit Neomarkers (Rb-1789-
P1) 
Semaphorin 3A 1:200 Rabbit Abcam (ab23393) 
Secondary Antibodies 
Alexa 488 1:400 Rabbit Molecular Probes 
(A11034) 
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Alexa 488 1:400 Sheep Molecular Probes 
(A1105) 
Table 5.2 Primary and secondary antibodies used to label inflammatory and wound 
healing/angiogenic-related proteins by immunohistochemistry. 
 
 5.5.3 Antibodies used for western blotting  
Please refer to Materials and Methods section 2.5 western blot analysis for standard 
protocol used. Western blot analysis was used the protein expression of various 
inflammatory/angiogenic-related proteins at 8 dpl (Table 5.3) 
Inflammatory and wound 
healing/angiogenic-related proteins 
Dilution 
factor 
Species Supplier (catalogue no.) 
Primary antibodies 
Glial fibrillary acidic protein (GFAP) 1:500 Rabbit Sigma (G9269) 
Fibronectin 1:200 Rabbit Sigma (F3648) 
OX-42 (CD11b) 1:400 Rabbit Abcam (ab28664) 
CD8 1:400 Rabbit Novus Biologicals 
(NBP1-42051) 
CD4 1:400 Rabbit Novus Biologicals 
(NBP1-19371) 
Laminin 1:100 Rabbit Sigma (L9393) 
VEGF-A (Vascular Endothelial 
Growth Factor-A) 
1:1000 Rabbit Abcam (ab46154) 
MMP-1 (Matrix Metalloproteinases) 1:100 Sheep Biogenesis (5980-0111) 
TIMP-2 (Tissue Inhibitor of Matrix 
Metalloproteinases) 
1:200 Rabbit Neomarkers (Rb-1789-
P1) 
Semaphorin 3A 1:200 Rabbit Abcam (ab23393) 
Secondary Antibodies 
Horseradish Peroxidase (HRP) 1:1000 Rabbit GE Healthcare (NA934) 
Horseradish Peroxidase (HRP) 1:1000 Sheep GE Healthcare 
(RPN4201) 
Table 5.3 Primary and secondary antibodies used to label inflammatory and wound 
healing/angiogenic-related proteins by western blot. 
 
 5.5.4 Lesion cavity area 
Please refer to Material and Methods section 2.3.3 Lesion cavity area for standard 
protocol used. Due to micro-cavities being present in the zymosan injected mouse 
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spinal cord after injury, cavities were determined using GFAP immunostaining in 
mouse and rat lesion sites. Cavities were considered to be free of GFAP+ astrocytes 
whilst the border was surrounded by GFAP+ astrocytes (Figure 5.1). 
 
 5.5.5 Relative fluorescent staining intensity 
Please refer to Material and Methods section 2.3.4 Relative fluorescent staining 
intensity for standard protocol used for quantification of antibody immunoreactivity. 
Mice and rats injected with PBS were considered as controls whilst those injected 
with zymosan were the treatment groups. Quantification of pixel intensities were 
measured within a set area in ImageJ by thresholding the original image as 
described in previous chapters (Please refer to Chapter 2 Figure 2.5, Chapter 3 
Figure 3.6 and Chapter 4). 
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Figure 5.1 Lesion cavity area of mice and rats injected with PBS or zymosan was 
determined using GFAP stained sections (A). The lesion area was measured in 
Image ProAnalyzer by drawing around the edge of the astrocyte free cavity (B) using 
the middle section of each cavity in mice and rats. (n = 3/species/treatment group; 
scale bars in A - B = 200µm; arrowheads in A-B = GFAP positive astrocytes; * = 
astrocyte-free areas). 
* 
* 
* 
* 
A 
B 
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5.6 Results 
 5.6.1 Microenvironment responses after induced inflammation 
 After receiving an acute injection of control PBS, the microenvironment of the 
spinal cord in both mice and rats at 8 dpl displayed what is typically seen after SCI 
i.e. no cavitation seen in the mouse lesion area compared to wound cavities present 
in the rat (Figure 5.2A and B, arrows). Zymosan injection caused a greater degree of 
tissue disruption around the lesion epicentre (Figure 5.2C and D) when compared to 
their representative PBS controls, such that a larger cavity was apparent. In the rat 
cord this disruption continued rostrally and caudally after zymosan injection 
compared to PBS controls (Figure 5.2B and D). It is also apparent that small wound 
cavities, not normally present in PBS treated lesions, had developed around the 
lesion epicentre in mice treated with zymosan (Figure 5.2A and C, arrow).  
Quantification of the lesion/micro-cavity area in mice (Figure 5.3A) and the 
lesion/micro-cavity area in rats (Figure 5.3B) at 8 dpl demonstrated significant 
difference in animals that were injected with PBS compared to those injected with 
zymosan. The cavity area in zymosan injected mice and rats were significantly higher 
(P<0.040 and P<0.005, respectively) compared to their controls. These results 
confirm that there is a greater degree of tissue damage and cavitation after zymosan 
injection compared to PBS controls in both mice and rats at 8 dpl. 
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Figure 5.2 Histological differences in wound cavitation after SCI in mice treated with PBS (A) or zymosan (C) and rats treated with 
PBS (B) or zymosan (D) at 8dpl. Tissue disruption was examined by haematoxylin and eosin staining of the middle section of each 
cavity to understand the greatest difference between PBS or zymosan treated cords in mice and rats. (n = 3/species/treatment 
group; * = lesion epicentre; scale bars in A-D = 200 µm; arrows in B, C and D = cell free areas in mouse and rat SCI cavities; dotted 
black line in D = extent of tissue damage after zymosan injection). 
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Figure 5.3 Accumulative mean micro-cavity area in mice (A) and accumulative mean 
micro-cavity area in rats (B) was compared in animals injected with PBS and 
Zymosan using GFAP
+
 staining in the middle section of each cavity at 8 dpl. (n = 
3/species/treatment group). 
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 5.6.2 Characterisation of the inflammatory response to sub-acute SCI  
1. Microglia. OX-42+ quiescent and activated microglia were localised mainly to the 
lesion site and surrounding tissue after PBS injection with no apparent change after 
zymosan injection in mice (Figure 5.4A and B: inset), whilst in rats after zymosan 
injection there was slight decrease compared to PBS controls (Figure 5.4C and D: 
inset). OX-42+ microglia immunoreactivity showed significant increase in rats 
compared to mice in PBS controls only (Figure 5.4E). Western blotting (Figure 5.4F) 
and subsequent densitometry (Figure 5.4G) demonstrated that OX-42 protein 
expression was significantly higher in rats compared to mice in PBS controls only at 
8 dpl, coinciding with immunohistochemistry results.  
2. Macrophages. The immunoreactivity of CD68+ (ED1) activated macrophages was 
confined not only to the lesion site but surrounding tissue with a slight increase in 
CD68+ macrophages after zymosan injection compared to PBS control  in mice at 8 
dpl (Figure 5.5A and B: inset). In PBS injected rats CD68+ macrophages were 
present and once treated with zymosan there was an increase in CD68+ 
macrophages that were confined mainly to the lesioned area (Figure 5.5C and D, 
arrow: inset). Immunoreactivity of CD68+ macrophages revealed significant increase 
in zymosan injected rats compared to zymosan injected mice and their representative 
PBS controls (Figure 5.5E).  
3. Resident T-cells. CD4+ resident T-cells followed a similar pattern to CD68+ ; no 
significant differences were observed in PBS/zymosan injected mice (Figure 5.6A 
and B; inset), whilst there was an increase in zymosan injected rats compared to 
their PBS controls (Figure 5.6C and D, arrow: inset) with the localisation confined 
only to the lesioned area. Immunoreactivity of CD4+ cells were significantly increased 
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after zymosan injected rats compared to mice (Figure 5.6E).  Western blotting (Figure 
5.6F) and subsequent densitometry (Figure 5.6G) confirmed immunoreactivity levels; 
an increase in protein expression of CD4+ cells after zymosan injected rats compared 
to zymosan injected mice.  
Whilst CD8+ resident T-cells revealed a decrease after zymosan injection in 
mice compared to PBS controls (Figure 5.7A and B: inset). However, in rats there 
was an increase in CD8+ T-cells after zymosan injection compared to PBS controls 
where CD8+ staining was confined mainly to the lesioned area (Figure 5.7C and D: 
inset). Quantification of immunoreactivity levels confirmed that there was an increase 
in CD8+ cells in rats compared to mice after zymosan injection (Figure 5.7E). Western 
blot and subsequent densitometry confirmed that there was not only a significant 
increase in CD8 protein expression in rats compared to mice after zymosan injection, 
but that there was also a significant increase in CD8 protein in mice compared to rats 
after PBS injection (Figure 5.7F - G). 
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Figure 5.4 The localisation of OX-42 at 8dpl in DC lesions after induced 
inflammation. Immunohistochemistry for OX-42 in mice either treated with PBS (A) or 
zymosan (B) and rats either treated with PBS (C) or zymosan (D) and the pixel 
intensities of OX-42
+ 
fluorescence (E). Western blot (F) and densitometry (G) 
corroborated the immunohistochemistry results (α-tubulin was used as a protein 
loading control, image demonstrates a representative picture (F); n = 
3/species/treatment group; * = lesion epicentre; scale bars in A - D = 200µm). 
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Figure 5.5 The localisation of CD68 (ED1) at 8dpl in DC lesions after induced 
inflammation. Immunohistochemistry for CD-68 in mice either treated with PBS (A) or 
zymosan (B) and rats either treated with PBS (C) or zymosan (D) and the pixel 
intensities of CD68
+ 
fluorescence (E). (n = 3/species/treatment group; * = lesion 
epicentre; scale bars in A - D = 200µm; arrow in D = CD68
+
 macrophages). 
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Figure 5.6 The localisation of CD4 at 8dpl in DC lesions after induced inflammation. 
Immunohistochemistry for CD4 in mice either treated with PBS (A) or zymosan (B) 
and rats either treated with PBS (C) or zymosan (D) and the pixel intensities of CD4
+ 
fluorescence (E). Western blot (F) and densitometry (G) corroborated the 
immunohistochemistry results (α-tubulin was used as a protein loading control, image 
demonstrates a representative picture (F); n = 3/species/treatment group; * = lesion 
epicentre; scale bars in A - D = 200µm; arrow in D = CD4+ T-cells). 
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Figure 5.7 The localisation of CD8 at 8dpl in DC lesions after induced inflammation. 
Immunohistochemistry for CD8 in mice either treated with PBS (A) or zymosan (B) 
and rats either treated with PBS (C) or zymosan (D) and the pixel intensities of CD8
+ 
fluorescence (E). Western blot (F) and densitometry (G) corroborated the 
immunohistochemistry results (α-tubulin was used as a protein loading control, image 
demonstrates a representative picture (F); n = 3/species/treatment group; * = lesion 
epicentre; scale bars in A - D = 200µm).  
Mouse/PBS 
injection 
Mouse/Zymosan 
injection 
Rat/Zymosan 
injection 
Rat/PBS 
injection 
A C D
E 
50kDa- α-Tubulin 
F 
Mouse/PBS  Mouse/Zym Rat/Zym Rat/PBS 
39kDa- 
50kDa- 
CD8 
G
* 
* * 
0 
5 
10 
15 
20 
CD8 
Mouse 
CD8 
Rat 
M
ea
n 
nu
m
be
r o
f 
pi
xe
ls
 (a
rb
itr
ar
y 
un
its
 
x1
0²
) PBS injection 
Zymosan 
injection 
P<0.012 
0 
10 
20 
30 
40 
50 
60 
CD8 Mouse CD8 Rat 
M
ea
n 
nu
m
be
r o
f 
pi
xe
ls
 ±
S
E
M
 
(a
rb
itr
ar
y 
un
its
 x
10
²)
 
PBS injection 
Zymosan 
injection 
P<0.001 
P<0.027 
B
* 
190	  |	  P a g e 	  
	  
5.6.3 Characterisation of the DC scarring response to injury 
  After injury, fibronectin+ ECM filled the lesion core in mice when injected with 
PBS or zymosan showing similar responses (Figure 5.8A and B, arrows: inset), 
whereas in rats injected with PBS, very little or no fibronectin was present in the SCI 
wounds but after zymosan injection fibronectin+ ECM material filled the lesion core in 
rats (Figure 5.8C and D, arrow: inset). Quantification of immunoreactivity revealed a 
significant increase in fibronectin+ immunohistochemistry in rats after zymosan 
injection compared to mice (Figure 5.8E). Western blot and subsequent densitometry 
not only confirmed that there is a significant increase in fibronectin+ protein 
expression after zymosan injection in rats compared to mice but that there was also a 
significant increase in fibronectin+ protein expression in mice compared to rats after 
PBS injection (Figure 5.8F - G).  
 GFAP+ astrocytes were abundant in the neuropil around the lesion site and 
invading the lesion core in mice injected with either PBS or zymosan (Figure 5.9A 
and B, arrows: inset). In rats injected with PBS, fewer GFAP+ astrocytes were 
localised within the lesion and virtually absent in the lesion core, but there was an 
increase around the lesion site of GFAP+ astrocytes in rats that were injected with 
zymosan (Figure 5.9C and D: inset). Pixel intensities demonstrated there was no 
significant difference in GFAP+ astrocytes in mice injected with PBS or zymosan 
compared to rats treated with PBS or zymosan (Figure 5.9E). However, western blot 
and subsequent densitometry confirmed that no difference was seen between the 
two treatment groups for both mice and rats for GFAP+ protein expression (Figure 
5.9F and G). 
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Figure 5.8 The localisation of FN 8dpl in DC lesions after induced inflammation. 
Immunohistochemistry for FN in mice either treated with PBS (A) or zymosan (B) and 
rats either treated with PBS (C) or zymosan (D) and the pixel intensities of FN
+ 
fluorescence (E). Western blot (F) and densitometry (G) corroborated the 
immunohistochemistry results (α-tubulin was used as a protein loading control, image 
demonstrates a representative picture (F); n = 3/species/treatment group; * = lesion 
epicentre; scale bars in A - D = 200µm; fibronectin = FN; arrows in A, B and D = FN
+
 
cells confined to lesioned area).  
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Figure 5.9 The localisation of GFAP 8dpl in DC lesions after induced inflammation. 
Immunohistochemistry for GFAP in mice either treated with PBS (A) or zymosan (B) 
and rats either treated with PBS (C) or zymosan (D) and the pixel intensities of 
GFAP
+ 
fluorescence (E). Western blot (F) and densitometry (G) corroborated the 
immunohistochemistry results (α-tubulin was used as a protein loading control, image 
demonstrates a representative picture (F); n = 3/species/treatment group; * = lesion 
epicentre; scale bars in A - D = 200µm; glial fibrillary acidic protein = GFAP; arrows in 
A and B = GFAP
+
 astrocytes invading the lesion core). 
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 4.6.4 Characterisation of angiogenic response to induced inflammation 
1. Pro-angiogenic molecules. The immunoreactivity of VEGF-A did not differ after 
sub-acute injury in mice whether treated with PBS or zymosan (Figure 5.10A and B: 
inset), whilst in rats there was a slight reduction in VEGF-A once treated with 
zymosan compared to the PBS control (Figure 5.10C and D: inset). Quantification of 
immunoreactivity revealed a significant increase in VEGF-A+ staining in mice once 
injected with zymosan compared to rats injected with zymosan (Figure 5.10E). 
Western blot and subsequent densitometry correlated with the immunohistochemical 
results (Figure 5.10F and G), demonstrating a significant increase in VEGF-A protein 
expression in mice compared to rats injected with zymosan after injury.   
 The immunoreactivity of MMP-1, like VEGF-A levels did not alter in the mouse 
regardless of injection received after injury (Figure 5.11A and B: inset), whilst in rats 
there was an increase in MMP-1 after being injected with zymosan compared to PBS 
controls, particularly localised to the lesion area (Figure 5.11C and D, arrow: inset). 
Quantification of immunoreactivity levels revealed a significant decrease in MMP-1+ 
cells in rats injected with PBS compared to mice, whilst, after zymosan injection there 
was a significant increase in MMP-1+ staining in rats compared to mice (Figure 
5.11E). Western blot and subsequent densitometry correlated with 
immunohistochemical results showing a significant increase in MMP-1 protein 
expression in rats injected with zymosan compared to mice injected with zymosan 
only (Figure 5.11F and G). 
 After injury to the DC the lesioned area in mice becomes highly enriched with 
LN+ staining and regardless of the mouse being injected with PBS or zymosan the 
outcome remains the same (Figure 5.12A and B: inset), whereas with rats after being 
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injected with PBS the lesioned area is mostly devoid of LN+ ECM but once injected 
with zymosan there is an increase in LN+ ECM mainly confined to the lesioned area 
(Figure 5.12C and D: inset). Quantification of immunoreactivity revealed there was a 
significant increase in laminin in rats after zymosan injection compared to mice 
injected with zymosan (Figure 5.12E). Western blot and subsequent densitometry not 
only confirmed that there was a significant increase in LN+ protein expression in rats 
in injured cords injected with zymosan compared to mice but also revealed a 
significant increase in LN+ protein expression in PBS control mice compared to PBS 
control rats (Figure 5.12F and G). 
2. Anti-angiogenic molecules. The immunoreactivity of TIMP-2 was localised to the 
lesioned site and surrounding tissue in mice injected with PBS or zymosan (Figure 
5.13A and B: inset), whereas in rats injected with PBS the lesion site was mostly  
devoid of TIMP-2 immunoreactivity but is localised to the boundaries of the SCI 
wound and surrounding tissue (Figure 5.13C and arrow: inset). Rats injected with 
zymosan displayed an upregulation of TIMP-2 confined mainly to the lesion epicentre 
compared to PBS controls with surrounding tissue devoid of immunoreactivity for 
TIMP-2 (Figure 5.13D and arrow: inset). Quantification of pixel intensities revealed no 
significant differences between the treatment groups (Figure 5.13E). However, 
western blot and subsequent densitometry demonstrated a significant increase in 
TIMP-2 levels in PBS injected mice compared to PBS injected rats after SCI (Figure 
5.13F and G). 
 Semaphorin 3A immunoreactivity was mainly confined to the lesion site in 
mice treated with PBS or zymosan (Figure 5.14A and B: inset), whereas rats 
receiving a PBS or zymosan injection at the lesion site were devoid of Semaphorin 
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3A immunoreactivity and was localised to the boundaries of the wound cavity (Figure 
5.14C and D, arrows: inset). Following quantification of pixel intensities, a significant 
increase in Semaphorin 3A protein expression was observed in mice injected with 
zymosan compared to rats injected with zymosan (Figure 5.14E). Western blot and 
subsequent densitometry confirmed what was observed immunohistochemically; 
significant increase in semaphorin 3A protein levels in mice compared to rats injected 
with zymosan (Figure 5.14F and G). 
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Figure 5.10 The localisation of VEGF-A (21 and 28 kDa proteins detected in the gel 
correspond to VEGF isoforms 165 and 189, respectively (Jauhianinen et al., 2011)) 
8dpl in DC lesions after induced inflammation. Immunohistochemistry for VEGF-A in 
mice either treated with PBS (A) or zymosan (B) and rats either treated with PBS (C) 
or zymosan (D) and the pixel intensities of VEGF-A
+ 
fluorescence (E). Western blot 
(F) and densitometry (G) corroborated the immunohistochemistry results (α-tubulin 
was used as a protein loading control, image demonstrates a representative picture 
(F); n = 3/species/treatment group; * = lesion epicentre; scale bars in A - D = 200µm; 
vascular endothelial growth factor- A = VEGF-A). 
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Figure 5.11 The localisation of MMP-1 8dpl in DC lesions after induced inflammation. 
Immunohistochemistry for MMP-1 in mice either treated with PBS (A) or zymosan (B) 
and rats either treated with PBS (C) or zymosan (D) and the pixel intensities of MMP-
1
+ 
fluorescence (E). Western blot (F) and densitometry (G) corroborated the 
immunohistochemistry results (α-tubulin was used as a protein loading control, image 
demonstrates a representative picture (F); n = 3/species/treatment group; * = lesion 
epicentre; scale bars in A - D = 200µm; matrix metalloproteinase 1 = MMP-1; arrow in 
D = MMP-1
+
 cells confined to the lesioned area).  
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Figure 5.12 The localisation of LN 8dpl in DC lesions after induced inflammation. 
Immunohistochemistry for LN in mice either treated with PBS (A) or zymosan (B) and 
rats either treated with PBS (C) or zymosan (D) and the pixel intensities of LN
+ 
fluorescence (E). Western blot (F) and densitometry (G) corroborated the 
immunohistochemistry results (α-tubulin was used as a protein loading control, image 
demonstrates a representative picture (F); n = 3/species/treatment group; * = lesion 
epicentre; scale bars in A - D = 200µm; laminin = LN). 
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Figure 5.13 The localisation of TIMP-2 8dpl in DC lesions after induced inflammation. 
Immunohistochemistry for TIMP-2 in mice either treated with PBS (A) or zymosan (B) 
and rats either treated with PBS (C) or zymosan (D) and the pixel intensities of TIMP-
2
+ 
fluorescence (E). Western blot (F) and densitometry (G) corroborated the 
immunohistochemistry results (α-tubulin was used as a protein loading control, image 
demonstrates a representative picture (F); n = 3/species/treatment group; * = lesion 
epicentre; scale bars in A - D = 200µm; Tissue inhibitor of matrix metalloproteinase 2 
= TIMP-2; arrow = TIMP-2
+
 cells confined to the lesioned area). 
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Figure 5.14 The localisation of Sema-3A 8dpl in DC lesions after induced 
inflammation. Immunohistochemistry for Sema-3A in mice either treated with PBS (A) 
or zymosan (B) and rats either treated with PBS (C) or zymosan (D) and the pixel 
intensities of Sema-3A
+ 
fluorescence (E). Western blot (F) and densitometry (G) 
corroborated the immunohistochemistry results (α-tubulin was used as a protein 
loading control, image demonstrates a representative picture (F); n = 
3/species/treatment group; * = lesion epicentre; scale bars in A - D = 200µm; 
Semaphorin 3A = Sema-3A). 
P<0.004 
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5.7 Discussion 
We report here that significant differences in the inflammatory response exist in mice 
and rats after T8 sub-acute SCI following exacerbation of inflammation using 
zymosan. In both mice and rats, the degree of tissue damage and cavitation seen at 
8 dpl after zymosan injection was greater compared to PBS controls. Of note, the 
cavity free response normally seen in mice was challenged by the injection of 
zymosan into the lesion site such that micro-cavities were now present in and around 
the lesion site. An influx of macrophages and resident T-cells, but not microglia was 
observed in zymosan injected rats compared to mice that correlated with a 
deleterious, rich fibronectin+ scar tissue but not GFAP+ astrocytes. In addition, the 
expression of pro-angiogenic MMP-1 and laminin were significantly up-regulated 
within the lesioned area in response to induced inflammation in rats compared to 
mice.  
 
 5.7.1 Inflammatory responses 
 Zymosan injected into the corpus callosum in the brain, was first used as a 
model of cavitation in 1999 (Fitch et al., 1999). This model removed the presence of 
the inflammatory response that may result from primary direct tissue damage and 
thus allowed assessment of progressive cavitation commonly found after CNS 
injuries. Their results demonstrated that injection of zymosan resulted in persistent 
inflammation causing a significant increase in astrocyte-free cavities that was 
maintained up to 2 weeks after initial injection. Whilst our inflammation induced injury 
was direct it still demonstrated that the lesioned areas in both mice and rats 
displayed larger cavities that were devoid of GFAP+ astrocytes. 
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 The inflammatory response between mice and rats has previously been 
documented to show marked differences in T-cell numbers (Sroga et al., 2003). In 
rats T-cell infiltration was highest between 3-7days after injury but then decline by 
50% after three weeks, whereas in mice T-cell infiltration was not evident until 14 
days after injury and increased by 50% between 2-6 weeks. However, at an earlier 
time point, our results demonstrated similar outcomes after zymosan injection i.e. T-
cell infiltration was significantly increased in rats compared to mice.  
 Activated microglia after thoracic SCI has been shown to play a role in chronic 
pain by contributing to the maintenance of pain-related behaviours and hyper-
responsiveness (Hains and Waxman, 2006). Furthermore using an anti-inflammatory 
treatment, Minocycline, in an adult rat model of SCI demonstrated reduced microglia 
activation along with reduced lesion size and increased functional recovery (Stirling 
et al., 2004). In our mouse model of SCI, the presence of activated microglia 
immunoreactivity observed after zymosan injection may contribute to the 
microcavities present. Therefore, if the injury produced was severe enough to 
damage the sensory pain pathways, hypersensitivity and chronic pain may be 
observed. Furthermore, after injury microglia adopt an activated state in response to 
neurodegeneration and multiply (Perry and Holmes, 2014). This is a process known 
as priming that result in the microglia becoming more susceptible to the inflammatory 
stimulus and thus further result in an exaggerated inflammatory response. This may 
explain the detrimental inflammatory response documented after SCI. 
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 5.7.2 Macrophages and their responses to SCI 
Macrophages are heterogeneous cells that have the ability to switch phenotypes and 
alter their functions by local factors present in the inflammatory microenvironment 
after SCI (Ren and Young, 2013). There are a range of macrophage subtypes that 
are distinguished from one another based on their distinct functions. These include 
classically activated macrophages (M1 macrophages), alternatively activated 
macrophages (M2 macrophages), ‘regulatory’ macrophages, tumour-associated 
macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) (Murray and 
Wynn, 2011). M1 macrophages function to mediate defence of the host from a 
variety of viruses, bacteria, and protozoa whilst M2 macrophages regulate wound 
healing and have anti-inflammatory functions (Murray and Wynn, 2011). ‘Regulatory’ 
macrophages are able to secrete large amounts of interleukin-10 (a monocyte / 
macrophage-derived cytokine involved in the immune response) in response to 
macrophage receptor ligation (Sutterwala et al, 1997, Sutterwala et al., 1998). TAMs 
play a role in suppressing anti-tumour immunity with MDSCs being linked to TAMs. 
Furthermore, MDSCs have been suggested as precursors for TAMs (Murray and 
Wynn, 2001, Mosser and Edwards, 2008). 
 As mentioned and documented previously by various studies inflammation 
plays a detrimental role to the secondary pathogenesis after SCI (Kim et al., 2013, 
Perez et al., 2003). After SCI M1 macrophages, activated by Th1 cytokines, produce 
proinflammatory cytokines, NO and reactive oxygen species (ROS) that contribute to 
tissue inflammation and therefore contribute the deleterious effects seen after SCI 
(Shechter et al., 2013, Kigerl et al., 2009). However, M2 macrophages, activated by 
Th2 cytokines, produce anti-inflammatory factors and demonstrate a reduced 
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capacity to produce proinflammatory molecules and therefore contribute more to 
wound healing and tissue remodelling (Ren and Young, 2013). M2 macrophages can 
be further subdivided into three classes; M2a, M2b and M2c subtypes, that are 
dependent on the type of stimulation and expression of surface molecules and 
cytokines (Mantovani et al., 2004). 
 Many studies into the inflammatory responses after SCI in animal models has 
been aimed at blocking the detrimental M1 activation pathway to demonstrate a 
reduction in tissue damage, an induction of myelin regeneration and improved 
locomotor recovery (Wang et al., 2013, Chen et al, 2011). However, it has been 
suggested that the potential therapeutic application of reprogramming macrophages 
to the M2 phenotype may control and resolve the inflammation after SCI (Ren and 
Young, 2013). Currently there are many ongoing clinical trials that are investigating 
the potential therapeutic utility of treatments that alter macrophages from M1 to M2 
phenotype, cell transplantation of macrophages into the injured area or inhibition of 
M1 pathway to aid in the beneficial effects that M2 macrophages possess after SCI 
(Gensel et al., 2011). But it is important to note that whilst it has been documented 
that the immune systems between mice and humans are quite similar and as animal 
models of human diseases they do demonstrate limitations due to a few differences 
in their immunology (Mestas and Hughes, 2004, Haley, 2003). Many studies in the 
literature demonstrate potential clinical therapies in mice but fail to provide beneficial 
results in the clinic (Shepherd and Sridhar, 2003, Oehler and Bicknell, 2000, Panitch 
et al., 1987).  
Distinguishing between the levels of M1 and M2 macrophages in this model of 
sub-acute SCI at 8 dpl using zymosan would help establish the inflammatory 
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response to induced inflammation further. A proposed hypothesis would be that 
inducing inflammation directly after SCI using zymosan in mice and rats would result 
in a higher proportion of M1 macrophages in the rat microenvironment compared to 
mice and thus contribute to cavitation. Whilst a higher proportion of M2 macrophages 
would be observed in mice compared to rats and thus aid in the beneficial wound 
healing responses that mice have previously demonstrated after SCI. Due to mice 
and rats demonstrating differences in inflammatory responses after SCI, the 
difference in M1 and M2 macrophages between the two species would add 
knowledge to the inflammatory research in SCI and the already ongoing clinical trials. 
 
 5.7.3 Inflammatory-induced angiogenic response 
 In response to tissue damage, it is important to accept that angiogenesis and 
inflammation are two separate, but closely linked multi-complex pathways (Ono, 
2008, Granger and Senchenkova, 2010, Naldini and Carraro, 2005). They interact in 
3 main ways: (1) playing a dual role in particular diseases such as cancer; (2) in the 
inflamed areas inflammatory cells interact with endothelial cells, ECM and fibroblasts; 
and (3) the same molecular events and particular cytokines, growth factors, 
proteases and adhesion molecules promote and trigger both processes (Costa et al., 
2007, Ono, 2008). But mediators of the inflammatory response such as monocytes 
and macrophages are sufficient to induce angiogenesis alone (Koch et al., 1986, 
Sunderkotter et al., 1994). Chronic inflammation results in large areas of hypoxia that 
can cause inflammatory mediators to either directly or indirectly promote 
angiogenesis  and thus further contribute to the prolonged inflammatory pathology 
therefore intensifying the response in disease states (Jackson et al., 1997, 
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Koutroubakis et al., 2006, Nagy et al., 2008). Inflammation-induced angiogenesis can 
have 2 distinct fates: persistence of vasculature and chronic inflammation or vascular 
regression and tissue repair (Arroyo and Iruela-Arispe, 2010). However, in a model of 
EAE, angiogenesis induced by CNS inflammation promoted neuronal remodelling 
(Muramatsu et al., 2012, Arroyo and Iruela-Arispe, 2010). This may explain the 
increase in angiogenic protein expression in rats compared to mice in response to 
induced inflammation in our results. 
 
5.7.4 Vascular permeability and inflammation 
 Vascular permeability is one of the hallmarks of inflammation that is induced 
by an upregulation of VEGF, allowing plasma components and inflammatory cells to 
exit the bloodstream (Arroyo and Iruela-Arispe, 2010). The resulting acute 
inflammation can induce angiogenic responses, producing a highly vascularised 
granulated tissue, that would normally occur during wound healing (Singer and Clark, 
1999). During tissue repair, vascular regression helps to restore homeostatic control 
after inflammation, but the absence of vascular regression can cause further 
exacerbation in the inflammatory response (Mazzone et al., 2009). This is the cases 
in many diseases such as, atherosclerosis, rheumatoid arthritis and psoriasis, in 
which the decision between sustained inflammation or tissue repair is significantly 
influenced by the composition and turnover of the ECM (Jackson et al., 1997, Costa 
et al., 2007, Arroyo and Iruela-Arispe, 2010). This may suggest that mice can restore 
their homeostatic control providing vascular regression during tissue repair after 
injury, whilst rats may not be able to restore vascular regression efficiently thus 
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further exacerbation of the inflammatory response occurs leading to large cavity 
formation. 
Our mouse and rat model of inflammation indicates distinct inflammatory-
induced angiogenic responses between the two species 8 dpl. Whilst zymosan 
caused further tissue damage and micro-cavities in the CNS environment of mice 
and rats, it is clear that inflammation alone is not the only mechanism that contributes 
to cavitation after SCI. 
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CHAPTER 6 
GENOME WIDE ANALYSIS OF SCI-INDUCED ANGIOGENIC/WOUND HEALING-
RELATED GENES IN MICE AND RATS 
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6.1 Introduction 
6.1.1 Introduction to microarray analysis 
Microarray analysis is a 2D array that can assess large amounts of biological 
material and therefore as a research tool, has become popular in recent years due to 
various analyses that can be carried out post array. These include variation detection 
within the gene sequence of a given sample, sequence determination, gene mapping 
and most importantly gene expression or genetic variation analysis. There are many 
different microarrays available on the market that include, DNA microarray, protein 
microarray and tissue microarray amongst many more. There are two types of 
microarrays based on the fluorescent dyes used known as one-colour or two colour 
microarrays. Cyanine 3 (Cy3) and Cyanine 5 (Cy5) are the two dyes commonly used 
that label the cDNA from the samples tested, Cy3 is detected at a wavelength of 
570nm (green section of the light spectrum), whilst Cy5 is detected at 670nm (red 
section of the light spectrum). The advantages of using one-colour microarray is that 
each array chip is exposed to only one sample thereby reducing sample 
contamination and the ease of data comparison between different experiments. 
However, the disadvantage when compared to a two-colour microarray is double the 
amount of microarrays are needed to compare samples within a given experiment. 
Using one-colour microarray reduces the cost by 50% and results in 94% genes 
correctly annotated compared to the 98% using the two-colour microarray, therefore 
resulting in only a moderate decrease in overall specificity and sensitivity (Schwarz et 
al., 2010).  
The first large-scale gene expression study in acute SCI in rats revealed 
changes in mRNA levels associated with inflammatory signals and neuronal loss, 
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with in vivo studies in rats at early time points showing increased transcription, 
neurotransmitter dysfunction, ionic imbalance  and changes in genes that may play a 
role in tissue damage or repair after SCI (Carmel et al., 2001, Song et al., 2001, 
Nesic et al., 2002, Tachibana et al., 2002, Xiao et al., 2005, Velardo et al., 2004).  
 
6.1.2 Angiogenesis and wound healing  
Wound healing is a dynamic process like angiogenesis, by which the 
damaged skin/organ-tissue repairs itself after injury. Haemostasis, inflammation, 
proliferation and tissue remodelling and resolution are the four main overlapping, 
precisely programmed phases that occur after injury in order for successful wound 
healing to occur (Guo and Dipietro, 2010, Gosain and DiPietro, 2004). Haemostasis 
is induced immediately after injury to stop the initial bleeding at the site of injury by 
vascular constriction and platelet aggregation to form a clot. The damaged tissue and 
clot release pro-inflammatory factors causing infiltration of neutrophils, monocytes 
and lymphocytes to remove the cellular debris. Followed closely after the 
inflammatory phase is the proliferative phase, mainly characterised by re-
epithelialisation (epithelial proliferation), angiogenesis (blood vessel capillary growth), 
collagen synthesis and ECM formation. Finally the remodelling phase is a critical 
phase allowing collagen remodelling, vascular maturation and regression of newly 
formed capillaries.  
There are various factors that can affect wound healing and therefore result in 
impaired tissue repair (Guo and Dipietro, 2010). Local factors such as oxygenation 
and infection are factors that directly influence the characteristics of the wound, whilst 
systemic factors such as age, gender, medications, obesity and alcohol for example, 
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are factors that affect the individual’s ability to heal. Angiogenesis plays an important 
role in wound healing and therefore impaired angiogenesis can affect and potentially 
delay wound healing (Zhou et al., 2004, Echtermeyer et al., 2001, Swift et al., 1999, 
Lee et al., 1999). In SCI aberrant inflammatory angiogenesis that occurs as a 
consequence of secondary damage can impair wound healing, and that using  an 
anti-pathoangiogenic polysaccharide can inhibit the impaired angiogenesis and 
accelerate the rate of wound healing (Nanney et al., 2001). 
In our study, we performed intricate analysis combing the use of microarray, q-
PCR and immunohistochemical analysis to characterise the genome wide expression 
profile changes focussing on angiogenic/wound healing-related genes induced after 
acute SCI in mouse and rat 8 dpl. 
 
6.2 Rationale 
Previous research has demonstrated that mice and rats exhibit differences in wound 
healing, scarring and inflammatory responses after SCI. Furthermore, our model of 
T8 sub-acute SCI supports the differential wound cavitation and inflammatory 
responses between the two species but also demonstrates differential angiogenic 
protein expression and localisation as well as acute functional differences. This led 
us propose that other angiogenic/wound healing-related genes may be involved in 
the robust wound healing response seen in mice after SCI compared to rats. 
Therefore using 8 dpl as a time point that has previously shown the greatest 
differences between the two species, to investigate genome wide known and 
unknown early angiogenic/wound healing-related genes using microarray analysis. 
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6.3 Hypothesis 
Mice have a robust wound healing response compared to rats after SCI which enable 
them to present a cavity free response that coincides with increased angiogenic 
expression. Known angiogenic/wound healing-related genes may be involved the 
early stages in preventing cavitation after SCI in mice that will be detected using 
microarray gene expression and thus contribute to the sparing of axons from 
damage. 
 
6.4 Aims 
• To compare mouse and rat control (0 dpl) and injured (8 dpl) spinal cord 
samples using microarray analysis. 
• To compare the raw data of each species compared to controls using 
‘Statistical analysis of microarray’ software (SAM) and IPA Ingenuity software. 
• To determine all angiogenic/wound healing-related genes that are up- or 
downregulated after T8 DC crush in mice and rats compared to species 
matched controls. 
• Search through the genes that are unique to mouse and rat and identify any 
that are angiogenic/wound healing-related. 
• Validate a number of angiogenic/wound healing-related genes that are 
mapped and differentially regulated between mouse and rat after SCI using 
qPCR, and immunohistochemistry. 
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6.5 Materials and Methods 
6.5.1 Experimental design 
Type of analysis N -numbers End-points (days) 
Microarray analysis 4 per species/group 0, 8 
Validation by qPCR  3 per species/group 0, 8 
Angiogenic/wound healing 
immunohistochemistry 
3 per species/group 0,8 
Table 6.1 Experimental design to assess angiogenic/wound healing-related genes by 
microarray analysis, qPCR and immunohistochemistry. 
 
6.5.2 RNA Extraction (Performed by Stephen Kissane) 
Please refer to Materials and Methods section 2.4 RNA extraction for standard 
protocol used. Once RNA was extracted from control and injured mouse and rat 
samples (n = 8 (4 control and 4 injured) per species), they were the tested on a 
Bioanalyzer (Agilent) to ensure RNA Integrity Number (RIN) values were above 7 
before continuing to ensure repeatability of experiments (Appendix 1.1 and Appendix 
1.2). Samples were then analysed individually through microarray analysis that 
resulted in 16 arrays in total and the quadruplets were then analysed in SAM 
software. 
 
 6.5.3 Real-time polymerase chain reaction (qPCR) 
Please refer to Materials and Methods section 2.8.2 Real-time quantitative 
polymerase chain reaction for standard protocol used. The genes chosen from 
microarray analysis were only considered if they were more than 2-fold upregulated 
or downregulated for validation of gene expression by qPCR (Table 6.2 and 6.3).  
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Gene Log ratio Comments  
Alpha-2-Adrenergic 
receptor beta (α2B-AR) 
3.317 (Rat) An angiogenic gene that was shown 
to be regulated after SCI in rat only. 
Annexin A3 (ANXA3) -1.93 (Mouse) 
-5.119 (Rat) 
An angiogenic gene that was shown 
to be regulated in both species after 
SCI. 
CD44 -3.608 (Mouse) 
-6.069 (Rat) 
An angiogenic/wound healing gene 
that was shown to be regulated in 
both species after SCI. 
H2.0-like homeobox 
(HLX-1) 
-10.707 (Rat) An angiogenic gene that was shown 
to be regulated after SCI in rat only. 
Integrin beta 2 (ITGβ2) -4.437 (Rat) An angiogenic/wound healing gene 
that was shown to be regulated after 
SCI in rat only. 
Metallothionein (MTIH) -11.075 (Rat) A wound healing gene that was 
shown the regulated after SCI in rat 
only. 
Protein kinase C-eta 
(PRKCH) 
-4.797 (Rat) A wound healing gene that was 
shown the regulated after SCI in rat 
only. 
Retinoic acid receptor 
beta (RARβ) 
3.136 (Mouse) An angiogenic gene that was shown 
to be regulated after SCI in mouse 
only. 
Transforming growth 
factor beta receptor 1 
(TGFβR1) 
-2.202 (Mouse) 
-2.745 (Rat) 
An angiogenic/wound healing gene 
that was shown to be regulated in 
both species after SCI. 
Table 6.2 The angiogenic/wound healing-related genes chosen for validation from 
the raw microarray data. 
 
Gene Probe 
No. 
Forward 
primer 
Reverse 
primer 
Reference 
number 
Mus musculus (mouse) 
Alpha-2-Adrenergic receptor 
beta (α2B-AR) 
#83 gtggccaaggct
gattagaa 
aagcctgcctgtt
ggctta 
NM_00963
3.3 
Annexin A3 (ANXA3) #17 gcagtaccaagc
agcgtatg 
gccagagagat
cacccttca 
NM_01347
0.2 
CD44 #49 tccttctttatccgg
agcac 
cctggagtccttg
gatgagt 
M27130.1 
H2.0-like homeobox (HLX-1) #85 ccttaagctccaa
cccaaga 
tggcatggtgtcc
ttagtga 
NM_00825
0.2 
Integrin beta 2 (ITGβ2) #32 cccagtgtgagt
gtcagtgc 
tcccaatgtagcc
agactca 
NM_00840
4.4 
Metallothionein (MTIH) #18 caagtgcacctc
ctgcaa 
ttcgtcacatcag
gcacag 
NM_01360
2.3 
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Protein kinase C-eta 
(PRKCH) 
#52 ccacagggatcc
tcaagtct 
aaagggtgtctc
aggatctcat 
NM_00885
6.3 
Retinoic acid receptor beta 
(RARβ) 
#69 caccggcatact
gctcaa 
caaacgaagca
gggcttg 
NM_01124
3.1 
Transforming growth factor 
beta receptor 1 (TGFβR1) 
#70 gcagctcctcatc
gtgttg 
agaggtggcag
aaacactgtaat 
NM_00937
0.2 
Rattus (rat) 
Alpha-2-Adrenergic receptor 
beta (α2B-AR) 
#60 gagagagagcg
ccttttcg 
tgcaggacgcac
agaact 
NM_13850
5.2 
Annexin A3 (ANXA3) #62 ggagaattatctg
ggcattttg 
ggggtgttcctcg
tacagc 
NM_01282
3.2 
CD44 #75 gagaaaactgg
acccaggaac 
ttaggatctgccc
aggttgt 
NM_01292
4.2 
H2.0-like homeobox (HLX-1) #85 caacatcaattcc
aagacacg 
ttgtacgtctgtgg
catggt 
NM_00107
7674.1 
Integrin beta 2 (ITGβ2) #66 tccacaaaaagt
gacccttaact 
cgtcggaaagtc
acattgaa 
NM_00103
7780.2 
Metallothionein (MTIH) #15 caccagatctcg
gaatggac 
aggagcagcag
ctcttcttg 
NM_13882
6.4 
Protein kinase C (PRKCH) #84 aaccaccccttc
ctcacc 
actccatgacaa
agaacagacg 
NM_03108
5.2 
Retinoic acid receptor beta 
(RARβ) 
#70 agcaccggcata
ctgctc 
cagacgaagca
gggcttg 
NM_03152
9.1 
Transforming growth factor 
beta receptor 1 (TGFβR1) 
#53 aaggccaaatat
tcccaaca 
attttggccatcac
tctcaag 
NM_01277
5.2 
Table 6.3 The angiogenic/wound healing-related genes chosen from microarray 
analysis gene lists that were either 2-fold upregulated/downregulated for validation by 
qPCR for mouse and rat, the probe number, forward and reverse primer sequences 
and their reference number.  
 
6.5.4 Fluorescent immunohistochemistry 
Please refer to Materials and Methods section 2.3.2 Fluorescent 
immunohistochemistry for standard protocol used to assess the localisation of 
chosen known angiogenic/wound healing-related proteins. Primary antibodies used; 
retinoic acid receptor beta (1:500, rabbit polyclonal, Abcam, ab53161, Cambridge, 
MA, USA), PKC (1:100, rabbit polyclonal, Abcam, ab4134), Annexin A3 (1:100, rabbit 
polyclonal, Abcam, ab127924), integrin β2 (1:100, rabbit polyclonal, Santa Cruz 
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Biotechnology, SC-28661, Dallas, Texas, USA); HLX-1 (1:100, rabbit polyclonal, 
Santa Cruz Biotechnology, SC-133657); α2B-AR (1:100, rabbit polyclonal, Santa Cruz 
Biotechnology, SC-10723). 
 
6.6 Results 
 6.6.1 Microarray data analysis  
Following microarray analysis on mouse and rat control and injured samples 
after T8 sub-acute SCI, 55821 probes in the mouse (Appendix 2.1) and 30507 
probes in the rat (Appendix 2.2) were expressed at 8 dpl. Multiclass analysis was 
then performed in SAM on the raw data files to reduce the amount of false positives 
that may be detected using a false discovery rate (FDR) at <10% and significance 
level set at <0.025 for any genes to be deemed as significant (Figure 6.1A and B). 
This resulted in 1090 genes showing significant regulation in mice and 1616 genes in 
rats. Pathway analysis was then performed using IPA Ingenuity software to 
interrogate this data further. We determined genes that were: (1), differentially 
expressed in mouse/rat control versus mouse/rat injured tissues; (2) mapped and 
differentially regulated genes (874 and 721 genes, respectively) in mouse versus rat; 
and (3) unmapped genes that were differentially regulated in mouse and rat (388 and 
98 genes, respectively) (Figure 6.1C). Separate to this, the whole array of gene 
expression was analysed and we found 562 genes that were unique to the mouse 
and 689 that were unique to the rat.  
From the raw data files for mouse and rat, a full list of genes that were 
common (Appendix 2.3), mapped (Appendix 2.4 and Appendix 2.5), un-mapped 
(Appendix 2.6) and unique (Appendix 2.7 and Appendix 2.8) were extracted. We 
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determined that 31 genes were common between mouse and rat, 670 and 795 
genes, respectively, that were mapped in mouse and rat, 388 and 97 genes, 
respectively, that were un-mapped in mouse and rat and 562 and 689 genes, 
respectively, that were unique to either mouse or rat only. Further to this a full list of 
known angiogenic and wound healing genes (Appendix 2.9) to date was used to 
extract angiogenic (Appendix 2.10) and wound healing (Appendix 2.11) genes that 
are expressed after SCI in the mouse and rat from these lists and those that were 
either 2-fold upregulated or downregulated were deemed as significant. From this 
data 9 angiogenic/wound healing genes were selected based on expression levels 
for further validation by qPCR. 
Raw microarray data was also analysed using cluster analysis and results 
viewed with TreeView software (Figure 6.2). Cluster analysis allows genes to be 
grouped together into the same family of molecules with similar functions and to 
show how they are regulated after SCI. Figure 6.2 shows the known 
angiogenic/wound healing genes in the mouse and rat, and genes that are red are 
upregulated and those in green are downregulated. The higher intensity of the colour 
represents higher expression of those genes. Following IPA analysis genes that were 
mapped and differentially expressed were grouped into similar functions for both 
mouse (Figure 6.3) and rat (Figure 6.4). 
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Figure 6.1 Multiclass analysis in SAM software produced q-values that had a false 
discovery rate of <10% and p-value of 0.025 resulting in 1090 genes in mice (A) and 
1616 genes in rat (B). IPA analysis of these q-values revealed genes that were 
unique, mapped and unmapped between mouse and rat (C).  
Genes Mouse  Rat 
Unique 562 689 
Mapped and differentially 
regulated  
874 721 
Unmapped 388 98 
C 
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Figure 6.2 Heat maps for angiogenic/wound healing genes expressed in mouse (A) 
and rat (B) control (0 dpl) and injured (8 dpl) samples, generated using Cluster and 
TreeView analysis.  
B. Rat A. Mouse 
Control Injured Control Injured 
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Figure 6.3 The molecular functions of mapped and differentially regulated genes expressed in mice after DC lesion at 8dpl 
following multiclass analysis using SAM software. 
Inflammatory Response, 
Cancer, Tumor Morphology 
Embryonic Development, 
Organismal Development, 
Cellular Development 
Gene 
Expression, 
Cell Cycle, Cell 
Death and 
Survival 
Cellular Growth and 
Proliferation, Cellular 
Assembly and 
Organization, Cellular 
Function and 
Maintenance 
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Figure 6.4 The molecular functions of mapped and differentially regulated genes expressed in rats after DC lesion at 8dpl 
following multiclass analysis using SAM software. 
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6.6.2 Known canonical pathways after SCI 
IPA Ingenuity software was used to assess known canonical pathways between mice 
and rats after sub-acute SCI at 8 dpl using the Molecular Activity Predictor (MAP) 
(Figure 6.5A and B for key legend). The IL8 signalling pathway demonstrated key 
changes between mice and rats after SCI (Figure 6.6 and 6.7, respectively). Mice 
demonstrated a predicted activation of cadherin E through the highly inhibited 
cytokine CXCR1/R2 that leads to cell adherence, however, in rats this same 
relationship is inconsistent with the state of the downstream molecule. Moreover, 
angiogenic molecules such as VEGF, EGFR and MMP2 are highly inhibited through 
the IL8 pathway in mice after SCI (Figure 6.6). Whilst in rats it is predicted that IL8 
leads to slight activation of these angiogenic molecules suggesting that after SCI 
there is abnormal upregulation of angiogenesis (Figure 6.7). 
The NGF signalling pathway which plays a role in neurite outgrowth and 
differentiation displayed specific differences between mice and rats after SCI (Figure 
6.8 and 6.9, respectively). In mice there is inhibition of NF-kB presumably due to the 
predicted slight downregulation of TRAF6 and thus inhibits neurite outgrowth and 
differentiation after SCI, whilst no change was seen in molecules that are responsible 
for apoptosis (Figure 6.8). However, in rats there is a slight predicted upregulation of 
P75 that further causes the predicted activation of molecules such as BAX and p53 
that lead to apoptosis after SCI (Figure 6.9). There is a highly predicted upregulation 
of NF-kB that ultimately leads to neurite outgrowth and differentiation in rats after SCI.  
this however,  could be counteracted by the aberrant upregulation of apoptosis after 
SCI as seen in the predicted MAP pathway. 
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 PDGF plays a role in cell proliferation and cell survival in angiogenesis 
particularly in the later stages of the angiogenic process and after SCI there are key 
differences between mice and rats (Figure 6.10 and 6.11, respectively). In mice the 
predicted effect of the relationships between PDGF molecules and the molecules that 
lead to cell proliferation and mitogenesis are not predicted in this instance (Figure 
6.10). However there is slight upregulation of P13K phosphatase and a slight down 
regulation of the CRK complex in mice after sub-acute SCI. However, various 
predicted relationships resulted from the activation of PDGF receptor; PDGFR are 
highly activated in rats compared to mice after SCI (Figure 6.11). These relationships 
include activation of mitogenesis through the CRK complex and cell proliferation via 
STAT1 and STAT3 transcription regulators. This could again be a result of aberrant 
upregulation of various molecules of the PDGF signalling pathway that result in the 
detrimental effects such as cavitation seen in rats after SCI compared to mice.  
Finally, the VEGF signalling pathway demonstrated specific differences in the 
hypoxic and angiogenic responses between mice and rats after sub-acute SCI 
(Figure 6.12 and 6.13, respectively). In mice there is slight upregulation of P13K and 
Bcl-2 that lead to cell survival and angiogenesis after injury with no effect on hypoxic 
VEGF and HIF-1α molecules (Figure 6.12). However, in rats there is upregulation 
and activation of the VEGF receptor; VEGFR but this has little effect on the activation 
of its downstream molecules like Bcl-2 and P13k that result in cell survival, 
angiogenesis, cell proliferation and cell migration. More over there is a strong 
prediction in the activation of HIF-1α that leads to the activation of slight upregulated 
VEGF mRNA as a result of the hypoxic environment and therefore causing VEGF to 
activate its receptor VEGFR after SCI (Figure 6.13). However in the results already 
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seen in the previous chapters i.e. downregulation of angiogenic markers after sub-
acute SCI in rats, these results could indicate that the mechanism for an increase of 
angiogenesis is present after injury but aberrant upregulation could lead to the 
detrimental effects seen after SCI in rats.  
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Figure 6.5 IPA legend for Molecule Activity Predictor (MAP) that allows the prediction 
of upstream and/or downstream effects of activation or inhibition and allows for 
interactions and relationships between molecules (A) and the network shapes used 
in canonical pathways (B) (Legend adapted from Ingenuity Pathway Analysis).  
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Figure 6.6 Molecular Activity Predicator (MAP) using IPA analysis of IL8 mediated 
regulation of angiogenesis and tumour growth canonical pathway in mice after T8 
sub-acute SCI 8 dpl. The predicted activation of cadherin E and its predicted 
relationship is inhibited by complex CXCR1/R2 in the IL8 pathway (MAP Prediction 
Legend adapted from Ingenuity Pathway Analysis). 
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Figure 6.7 Molecular Activity Predicator (MAP) using IPA analysis of IL8 mediated 
regulation of angiogenesis and tumour growth canonical pathway in rats after T8 sub-
acute SCI 8 dpl. The predicted relationship between complex CXCR1/R2 
demonstrates inconsistent findings with the state of the downstream molecule in the 
IL8 pathway (MAP Prediction Legend adapted from Ingenuity Pathway Analysis).  
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Figure 6.8 Molecular Activity Predicator (MAP) using IPA analysis of NGF signalling 
for neurite outgrowth and differentiation canonical pathway in mice after T8 sub-acute 
SCI 8 dpl. The NGF pathway causes a slight downregulation of TRAF6 that result in 
the highly predicted inhibition of NF-kB and thus neurite outgrowth and differentiation 
(MAP Prediction Legend adapted from Ingenuity Pathway Analysis). 
Extracellular space 
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Figure 6.9 Molecular Activity Predicator (MAP) using IPA analysis of NGF signalling 
for neurite outgrowth and differentiation canonical pathway in rats after T8 sub-acute 
SCI 8 dpl. NGF causes the predicted upregulation of p53 and BAX; two molecules 
that play a part in apoptosis particularly in rats after SCI potentially aiding to the 
detrimental secondary pathology seen after injury (MAP Prediction Legend adapted 
from Ingenuity Pathway Analysis).  
Extracellular space 
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Figure 6.10 Molecular Activity Predicator (MAP) using IPA analysis of PDGF 
signalling for cell proliferation and survival canonical pathway in mice after T8 sub-
acute SCI 8 dpl. After SCI not many changes are seen in the PDGF pathway in mice, 
however there was a slight activation in PI3K and a slight downregulation of complex 
CRK. Moreover no predicted effects on the relationships were observed in this 
instance (MAP Prediction Legend adapted from Ingenuity Pathway Analysis).  
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Figure 6.11 Molecular Activity Predicator (MAP) using IPA analysis of PDGF 
signalling for cell proliferation and survival canonical pathway in rats after T8 sub-
acute SCI 8 dpl. After SCI the PDGF receptor; PDGFR, are strongly activated 
causing a vast amount of other downstream  molecules to become activated that play 
a role in cell proliferation and survival and mitogenesis  (MAP Prediction Legend 
adapted from Ingenuity Pathway Analysis).  
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Figure 6.12 Molecular Activity Predicator (MAP) using IPA analysis of VEGF 
signalling for hypoxia and angiogenesis canonical pathway in mice after T8 sub-
acute SCI 8 dpl. After SCI in mice there is no predicted effect on the relationship 
between hypoxia and angiogenic VEGF (MAP Prediction Legend adapted from 
Ingenuity Pathway Analysis).  
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Figure 6.13 Molecular Activity Predicator (MAP) using IPA analysis of VEGF 
signalling for hypoxia and angiogenesis canonical pathway in rats after T8 sub-acute 
SCI 8 dpl. After SCI in rats HIF-1α is strongly upregulated where it dimerises with 
ARNT under hypoxic conditions to further cause an increase in VEGF mRNA (MAP 
Prediction Legend adapted from Ingenuity Pathway Analysis).  
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6.6.3 Screening of angiogenic/wound healing genes by qPCR  
qPCR was conducted to determine whether angiogenic/wound healing-related α2B-
AR (Figure 6.14A), ANXA3 (Figure 6.14B), CD44 (Figure 6.14C), HLX-1 (Figure 
6.18A), ITGβ2 (Figure 6.18B), MT1H (Figure 6.18C), PRKCH (Figure 6.22A), RARβ 
(Figure 6.22B) and TGFβR1 (Figure 6.22C) genes are truly expressed in mice and 
rats after T8 sub-acute SCI at 8 dpl. The representative data and standard curve for 
each gene and treatment group are shown in α2B-AR (Figure 6.15), ANXA3 (Figure 
6.16), CD44 (Figure 6.17), HLX-1 (Figure 6.19), ITGβ2 (Figure 6.20), MT1H (Figure 
6.21), PRKCH (Figure 6.23), RARβ (Figure 6.24) and TGFβR1 (Figure 6.25).  All 
expression values were normalised to mouse control 1 to show true biological 
variability between different treatment groups. In this instance α2B-AR was 
upregulated after SCI in mice compared to control and when compared to injured rats 
but no change was observed between normal and injured rat (Figure 6.14A). This 
same pattern was also seen in ANXA3 (Figure 6.14B), CD44 (Figure 6.14C), MT1H 
(Figure 6.18C), PRKCH (Figure 6.22A) and RARβ (Figure 6.22B). The expression of 
HLX-1 was slightly increased after SCI in mice but in rats it was decreased after 
injury, and when comparing injured species, the expression of HLX-1 was slightly 
increased in mice compared to rats (Figure 6.18A). The expression of ITGβ2 gene 
was increased after SCI in both species but on a whole was higher in rats compared 
to mice after injury (Figure 6.18B). The expression of TGFβR1 was upregulated in 
rats after injury compared to control whilst no change was seen in the mouse after 
injury compared to control, but as a whole the expression of TGFβR1 was higher in 
rats compared to mice after injury (Figure 6.22C). Whilst some groups showed 
significant differences (Table 6.4, highlighted in bold) only ANXA3, CD44 and 
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PRKCH showed an overall significance with the variability highly dependent on 
treatment and species.  
 
Angiogenic 
gene 
NM vs. IM NR vs. IR NM vs. NR IM vs. IR Overall significance 
and variability  
α2B-AR 0.127 0.246 0.127 0.653 0.147; 49% 
ANXA3 0.184 1.000 0.046 0.072 0.037; 77% 
CD44 0.127 0.034 0.037 0.637 0.028; 83% 
HLX-1 0.513 0.037 0.658 0.037 0.080; 61% 
ITGβ2 0.827 0.050 0.050 0.275 0.077; 62% 
MT1H 0.513 0.121 0.037 0.050 0.027; 84% 
PRKCH 0.513 0.184 0.050 0.275 0.110; 55% 
RARβ 0.127 0.513 0.275 0.513 0.376; 28% 
TGFβR1 0.827 0.050 0.050 0.513 0.108; 55% 
Table 6.4 Significance of gene expression between groups was determined using 
non-parametric Kruskal-Wallis method. The variability means that the overall values 
are dependent on species and treatment (P value = < 0.05).  
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Figure 6.14 The expression of alpha-2-adrenergic receptor beta was validated by 
qPCR revealing that its expression was high in injured mice compared to normal 
mouse, whilst in rats the expression did not alter much (A). The expression of 
annexin A3 revealed that its expression was high in injured mice compared to normal 
mouse, whilst in rats the expression did not alter much (B). The expression of CD44 
revealed that its expression was high in injured mice compared to normal mouse, 
whilst in rats the expression did not alter much (C).    
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Figure 6.15 A representative quantification data and standard curve from each 
treatment group for alpha-2-adrenergic receptor beta gene.  
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Figure 6.16 A representative quantification data and standard curve from each 
treatment group for annexin A3 gene.  
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Figure 6.17 A representative quantification data and standard curve from each 
treatment group for CD44 gene.  
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Figure 6.18 The expression of HLX-1 was validated by qPCR revealing that its 
expression was slightly higher in injured mouse compared to normal mouse, whilst in 
rats the expression decreased after injury (A). The expression of integrin beta 2 
revealed that its expression was higher in injured mice compared to normal mouse, 
whilst in rats the expression was higher compared to normal rat (B). The expression 
of metallothionein 1H revealed that its expression was high in injured mice compared 
to normal mouse, whilst in rats the expression did not alter much (C).   
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Figure 6.19 A representative quantification data and standard curve from each 
treatment group HLX-1 gene.  
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Figure 6.20 A representative quantification data and standard curve from each 
treatment group integrin beta 2.  
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Figure 6.21 A representative quantification data and standard curve from each 
treatment group metallothionein 1H gene.  
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Figure 6.22 The expression of protein kinase C-eta was validated by qPCR revealing 
that its expression was high in injured mice compared to normal mouse, whilst in rats 
the expression did not alter much (A). The expression of retinoic acid receptor beta 
revealed that its expression was high in injured mice compared to normal mouse, 
whilst in rats the expression did not alter much (B). The expression of transforming 
growth factor beta receptor 1 revealed that its expression did not alter between 
normal and injured mouse, whilst in rats the expression increased after injury (C).  
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Figure 6.23 A representative quantification data and standard curve from each 
treatment group for protein kinase C-eta gene.  
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Figure 6.24 A representative quantification data and standard curve from each 
treatment group for retinoic acid receptor beta gene. 
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Figure 6.25 A representative quantification data and standard curve from each 
treatment group for transforming growth factor beta receptor 1 gene. 
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 6.6.4 Localisation of angiogenic/wound healing-related genes 
The localisation of angiogenic/wound healing-related proteins was determined by 
fluorescent immunohistochemistry (Figure 6.26 and 6.27). The localisation of α2B-AR 
in normal mouse tissue displayed base line levels before injury in mice (Figure 
6.26A) and after SCI there is an increase in α2B-AR particularly around the lesioned 
area (Figure 6.26B). This same phenomenon was observed with ANXA3 (Figure 
6.26C and D), HLX-1 (Figure 6.26E and F), ITGβ2 (Figure 6.26G and H) and PRKCH 
(Figure 6.26I and J) which all coincided with gene expression results. However, the 
gene expression of RARβ was increased after SCI in mice but immunoreactivity did 
not represent this expression (Figure 6.26K and L). This could be due to biological 
variability between samples of the same species. 
 Whilst in rats there was no comparable change seen in the immunoreactivity 
of α2B-AR between control and injured animals (Figure 6.27A and B), and this same 
pattern was also observed for ANXA3 (Figure 6.27C and D), HLX-1 (Figure 6.27E 
and F) and RARβ (Figure 6.27K and L) which matched the gene expression results. 
However, this could not be said about ITGβ2 (Figure 6.27G and H) and PRKCH 
(figure 6.27I and J). The immunoreactivity of ITGβ2 was decreased after SCI and 
therefore did not match the gene expression results that showed increased gene 
expression. The expression of PRKCH showed no comparable change before and 
after injury, but the immunoreactivity levels of PRKCH was increased. Again these 
variations in data could be accounted for by the biological variation between samples 
of the same species.  
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Figure 6.26 The localisation of angiogenic/wound healing-related proteins using 
fluorescent immunohistochemistry at 8 days after DC lesion. Pictures taken in 
AxionVision (x100 magnification) (n=3/group/antibody). Scale bars in A-L = 100µm.  
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Figure 6.27 The localisation of angiogenic/wound healing-related proteins using 
fluorescent immunohistochemistry at 8 days after DC lesion. Pictures taken in 
AxionVision (x100 magnification) (n=3/group/antibody). Scale bars in A-L = 100µm.  
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6.6.5 Genome wide normalisation 
Biological variation is one of the main pitfalls of comparing two species against one 
another and whilst microarray analysis provides average gene expression in the 
samples, the qPCR validation resulted in huge error bars indicating that not all 
samples express a specific gene at the same level. To confirm the biological variation 
the raw data was analysed in Linear Models for Microarray Data (LIMMA) which is a 
statistical package that allows the analysis of microarray data. It uses linear models 
to assess differential expression in the designed experiment and thus, each injured 
mouse and rat sample can be compared to their representative control samples 
using various codes within the package for global normalisation (Figure 6.28 and 
Appendix 3). The genes validated by qPCR were assessed in this manner to 
establish huge variation between samples of the same species and in this instance 
both mouse and rat showed marked variation in genes HLX1, ITGβ2 and TGFβR1, 
whilst MT1H and PRKCH was only variable in rat and mouse, respectively (Table 
6.5). The top 20 and 20 bottom genes expressed in both mouse (Table 6.6) and rat 
was analysed (Table 6.7) to determine if any genes were expressed on the same 
level. In this manner Gpnmb, Serpina3n, Ccl3 and cd68 genes were in the top 20 
genes that were highly expressed in the treated samples compared to control in both 
species. However, there were no genes that were in the bottom 20 that were 
common in both species. 
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Figure 6.28 A flow diagram representation of the commands and codes used in the 
LIMMA package to assess the raw microarray data to estimate the variability 
between the arrays. 
 
 
 
Raw data 
LIMMA package 
Background correction Code: normexp (by using negative control probes) 
Normalise between arrays Code: quantile (normalises to ensure the arrays have the same empirical distribution) 
Contrast treated to 
control 
Compares treated samples to control samples 
eBayes Estimates variability between arrays  
Output data 
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Number Probe number  Gene symbol Sample 1 
logFC 
Sample 2 
logFC 
Sample 3 
logFC 
Sample 4 
logFC 
Sample mean 
logFC 
Mus musculus (mouse) 
1 A_55_P1994027 
 
Alpha-2-Adrenergic 
receptor beta  
-1.23390972 -0.17175395 -0.38623904 -0.26532275 -0.520083727 
2 A_55_P2056325 annexin A3 2.56079809 2.53740130 2.15727629 2.20185159 2.407680747 
3 A_55_P2064043 CD44 0.40792437 0.85920411 1.15568355 0.52691227 0.735762741 
4 A_51_P179701 H2.0-like 
homeobox 
-1.88933495 0.06036528 -1.10351221 -0.66534948 -0.887394054 
5 A_51_P262208 Integrin beta 2 1.32069049 1.56898064 2.32291897 1.63846431 1.725674778 
6 A_66_P111660 Metallothionein -0.00557403 -0.10017106 0.21036148 0.33741974 0.117770373 
7 A_51_P355852 Protein kinase C-
eta 
1.16996187 1.36053779 -0.20682296 -0.03805165 0.625270584 
8 A_55_P2084807 
 
Retinoic acid 
receptor beta 
0.08773170 0.16002007 -0.54127186 0.13814893 -0.004963839 
9 A_55_P2137211 
 
Transforming 
growth factor beta 
receptor 1 
1.82474528 0.83875293 0.18243684 1.27208182 1.114244834 
Rattus (rat) 
10 A_64_P138008 
 
Alpha-2-Adrenergic 
receptor beta  
-0.56471 -0.83458 -0.80746 -0.57817 -0.693340228 
11 A_44_P325508 annexin A3 1.367028 0.711145 1.055104 1.553076 1.166203155 
12 A_64_P080817 CD44 0.718257 0.921977 0.677076 1.44472 0.927787969 
13 A_42_P460351 H2.0-like 
homeobox 
0.750358 0.530825 1.677066 2.545135 1.34657912 
14 A_42_P591344 Integrin beta 2 1.80609 0.998719 2.960178 1.958429 1.910085321 
15 A_64_P123603 Metallothionein 1.238768 0.530675 3.106903 2.327902 1.751289343 
16 A_64_P019638 Protein kinase C-
eta 
0.615275 0.499325 0.91402 0.94893 0.735108794 
17 A_64_P016249 Retinoic acid 
receptor beta 
-0.18279 0.04831 0.439737 0.739502 0.20735347 
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18 A_64_P045651 
 
Transforming 
growth factor beta 
receptor 1 
0.346688 0.649364 0.4809 0.959905 0.601934197 
Table 6.5 A list of the chosen genes validated by qPCR and the individual expression values for each sample compared to 
their representative controls and the average of those values for both mouse and rat. 
Number Probe number  Gene symbol / 
Target ID 
Mouse 1 
logFC 
Mouse 2 
logFC 
Mouse 3 
logFC 
Mouse 4 
logFC 
Mouse mean 
logFC 
1 A_51_P438967 Gpnmb 5.89198506 5.70245996 7.04679567 6.58607612 6.346912445 
2 A_51_P137419 Cst7 5.18645776 5.28253262 6.21365721 4.58712959 5.344085985 
3 A_51_P139678 Sprr1a 4.31786049 4.70115880 6.02285310 4.66825812 4.967096054 
4 A_51_P205779 Cd5l 4.80519630 3.84617646 6.24002043 3.40562024 4.589421311 
5 A_51_P246653 Clec7a 4.22027374 4.38594099 6.10922248 3.67233205 4.578915286 
6 A_55_P1957459 Lilrb4 3.97648500 3.57444249 5.92867472 4.56533732 4.52666022 
7 A_51_P303424 Itgax 4.50650332 4.17068552 5.41352796 3.77876176 4.514777894 
8 A_55_P1958165 Ms4a7 3.72280098 3.24972728 6.33393221 3.37125409 4.130264913 
9 A_55_P2171116 Lgals3 3.82387252 3.71153291 5.31750148 3.48317787 4.049111794 
10 A_55_P2008987 Ch25h 3.99581439 3.46650580 5.04147643 3.20032468 3.969106822 
11 A_51_P321150 Lyz2 4.46160685 3.42680898 4.21473631 3.70027281 3.966706352 
12 A_51_P159453 Serpina3n 4.47385527 3.41767669 3.45719993 3.96586618 3.878583389 
13 A_55_P1985850 Timp1 4.33356164 2.49976759 5.52239169 3.10954919 3.817485153 
14 A_51_P390804 Wisp2 3.23174289 2.92092873 5.33333254 3.36409558 3.710914599 
15 A_51_P140710 Ccl3 3.16714559 3.46699671 4.54943268 3.46754414 3.667707425 
16 A_55_P1961943 Cd68 2.95631320 3.03324106 4.76665106 3.41986205 3.540201653 
17 A_51_P509573 Ccl4 3.08088928 3.66455819 3.99111875 3.24667892 3.523629922 
18 A_51_P390538 Mpeg1 3.40789024 3.28950858 4.35053542 3.00453264 3.510343718 
19 A_55_P2016462 Cxcl10 3.40698882 3.59642904 4.55382287 2.33295926 3.464584124 
20 A_55_P1962937 Trem2 3.36895576 3.26565512 4.06565373 2.65653662 3.338456774 
21 A_30_P01019700 chr18:3003075- -3.70394860 -2.18050164 -2.98479172 -2.29518378 -
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3016150_F 2.801454175 
22 A_55_P2208682 B230334C09Rik -3.47204997 -1.80024556 -2.54957359 -3.37048896 -
2.817081071 
23 A_30_P01027915 chr19:54011403-
54018978_F 
-3.95513763 -3.15152115 -1.85667473 -2.11191713 -
2.829760602 
24 A_52_P188042 Trat1 -1.04771229 -1.06196747 -9.96536217 0.35766663 -
2.845310757 
25 A_30_P01024761 chr5:15146475-
15170100_F 
-4.09403809 -3.55986540 -1.65382983 -1.89045844 -
2.876934281 
26 A_30_P01032085 chr10:82074600-
82085425_F 
-8.22497129 -1.82810194 -1.48349064 -0.95040127 -
3.109743631 
27 A_30_P01022919 chr18:3003075-
3016150_R 
-3.27326914 -2.77135806 -3.91574508 -2.65891809 -
3.149356408 
28 A_30_P01032775 chrX:92149320-
92151107_R 
-4.40636708 -2.79420035 -3.25575599 -2.42936925 -
3.236106373 
29 A_55_P2050747 4930557B15Rik -3.87338472 -3.56712539 -3.47768217 -2.10791381 -
3.259800879 
30 A_55_P2089398 TC1709339 -4.61772973 -2.91686519 -3.30658156 -2.68433217 -3.35508493 
31 A_30_P01028043 chr4:3009566-
3009932_R 
-3.50172909 -3.14724880 -3.30924986 -3.50737751 -3.3776035 
32 A_30_P01033617 chrX:92139043-
92140820_R 
-4.53248666 -3.10229217 -3.62012190 -2.32714929 -
3.403957091 
33 A_55_P1957865 Unknown -4.86401918 -4.59927795 -2.56706150 -2.62065037 -
3.720866815 
34 A_30_P01017834 chr5:15146475-
15170100_F 
-4.79686176 -4.82521838 -2.50539711 -3.01293501 -
3.770900917 
35 A_55_P2279498 4933438K21Rik -4.68399199 -3.54177705 -3.89665981 -3.15881507 -
3.841871908 
36 A_30_P01029005 chr5:14943275-
14944205_F 
-4.73949414 -5.07511057 -2.67789485 -2.99856524 -
3.859425273 
37 A_30_P01023020 chr18:3003075- -4.21080020 -4.70045875 -4.60877863 -3.61383246 -
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3016150_R 4.283062796 
38 A_30_P01031842 chr5:15146475-
15170100_F 
-5.00549672 -5.62376375 -3.37373773 -3.80572856 -4.4290566 
39 A_30_P01018533 chr5:15146475-
15170100_F 
-5.33960833 -5.22639512 -3.62109536 -3.82758312 -
4.468591972 
40 A_30_P01019442 chr5:14943275-
14944205_F 
5.41487528 -5.30993106 -3.80898660 -3.79752440 -
4.531068753 
Table 6.6 A list of the top 20 and bottom 20 genes in each mouse injured sample compared to its representative control 
indicating the level of expression for that particular gene.  
Number Probe number  Gene symbol / Target 
ID 
Rat 1 
logFC 
Rat 2 
logFC 
Rat 3 
logFC 
Rat 4 
logFC 
Rat mean 
logFC 
1 A_44_P990376 Gpnmb 4.154838 2.666411 4.521813 4.9884 4.027771723 
2 A_64_P059728 TC597252 2.994824 2.278056 3.301945 4.992649 3.365957969 
3 A_64_P019260 Cd68 2.930126 1.669075 2.926219 4.363112 2.931408127 
4 A_44_P1023538 C3 2.290524 1.878488 3.893855 2.58147 2.616035051 
5 A_42_P714311 Ccl3 2.205907 2.163499 2.376008 3.434482 2.529210581 
6 A_64_P149280 Vegfb -0.03244 4.93425 5.126778 1.287988 2.511129445 
7 A_44_P1000653 Serpina3n 2.315075 2.836115 1.009049 3.42614 2.369845254 
8 A_64_P119127 Unknown 1.01392 2.459927 1.426598 4.483438 2.322098839 
9 A_43_P12698 Lgals3 1.981876 2.211423 2.085039 2.69779 2.23892154 
10 A_42_P686879 Siglec1 1.426674 1.480708 2.231108 3.95273 2.22498532 
11 A_44_P1039128 Cxcl10 1.647039 1.080097 3.944641 2.154608 2.158587681 
12 A_42_P567268 Mt2A 1.966689 1.444918 2.531827 2.766486 2.142133969 
13 A_64_P026316 C4a 1.267121 1.989006 2.647144 2.746835 2.122519743 
14 A_44_P115116 Mpeg1 1.098664 2.86058 3.076251 1.984928 2.100357939 
15 A_64_P019790 Cyp2d1 1.197507 1.887371 1.90169 3.559268 2.095199779 
16 A_64_P036725 Gpr63 0.483037 2.035594 3.394641 2.62822 2.039815229 
17 A_64_P001211 Cyp2d5 1.104044 1.853117 1.825171 3.479227 2.02154868 
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18 A_64_P058336 Ucn 1.466213 1.684027 2.431743 2.43484 1.968147628 
19 A_64_P039693 Unknown 0.938036 0.956756 4.162889 1.832246 1.944354676 
20 A_42_P591344 Itgb2 1.80609 0.998719 2.960178 1.958429 1.910085321 
21 A_64_P049738 Unknown -2.47931 -1.88494 -2.36692 -1.66452 -
2.068562861 
22 A_64_P074544 Ankrd61 -1.65037 -1.40274 -3.78067 -1.6348 -
2.102764221 
23 A_64_P017473 Chmp4bl1 -1.48364 -1.97589 -2.61163 -2.46863 -
2.110169207 
24 A_44_P552452 RT1-Bb -3.41722 -4.86162 -0.14356 0.01438 -
2.129867032 
25 A_64_P089410 LOC367436 -0.52206 -0.97178 -3.60203 -3.99501 -
2.173922537 
26 A_64_P121091 Acoxl -1.37307 -1.0136 -4.1215 -2.35871 -2.19689634 
27 A_64_P122168 Lhx6 -1.76206 -1.31402 -3.94155 -1.76785 -
2.204759175 
28 A_64_P001301 Unknown -1.31435 -1.53917 -3.7107 -2.34074 -
2.226466678 
29 A_64_P100669 E2f8 -2.02178 -1.30411 -3.86626 -2.07665 -
2.313368742 
30 A_64_P020531 TC600364 -2.37602 -1.26157 -3.86074 -1.99291 -
2.338446142 
31 A_64_P053411 ENSRNOT00000044462 -2.21067 -1.074 -3.48051 -2.83507 -
2.353114623 
32 A_64_P043546 Unknown -1.60005 -1.34514 -4.44055 -2.24304 -
2.398442543 
33 A_64_P166168 ENSRNOT00000051988 -2.21085 -1.51288 -3.62255 -2.71833 -
2.489797379 
34 A_64_P137734 ENSRNOT00000052393 -1.556 -1.83267 -4.14567 -2.98483 -
2.579600407 
35 A_43_P17464 TC628549 -2.54863 -1.09049 -4.61122 -2.34216 -
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2.616442246 
36 A_64_P127173 Unknown -2.5613 -1.54302 -4.31685 -2.43696 -
2.686336704 
37 A_64_P080179 Unknown -0.2428 -0.1439 0.013226 -11.8417 -2.76728462 
38 A_64_P105550 Unknown -2.58876 -1.87724 -4.24234 -2.48592 -
2.805829696 
39 A_64_P286599 Vwf -4.05406 -2.17121 -5.35609 -3.482 -
3.716496849 
40 A_64_P015163 Unknown -1.63945 -4.95575 -4.23493 -4.23801 -
3.728893926 
Table 6.7 A list of the top 20 and bottom 20 genes in each rat injured sample compared to its representative control indicating 
the level of expression for that particular gene.  
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6.7 Discussion 
Multiclass analysis revealed 1090 genes in mice and 1616 genes in rats that 
were deemed as significantly expressed after SCI. IPA analysis on these values 
revealed that in mice and rats 562 and 689 genes, respectively, were unique whilst 
874 and 721 genes, respectively, were mapped and differentially regulated whilst 388 
and 98 genes, respectively, were un mapped after SCI. Known canonical pathways 
were used to assess IL8 mediated regulation of angiogenesis and tumour growth, 
NGF signalling for neurite outgrowth and differentiation, PDGF signalling for cell 
proliferation and survival and VEGF signalling for hypoxia and angiogenesis 
pathways that showed significant differences between mice and rats after SCI. 
Known angiogenic/wound healing-related genes that were either 2-fold up or down 
regulated after sub-acute SCI at 8 dpl were extracted from the raw data sets, and of 
those 9 genes were chosen to be validated by qPCR. Whilst alpha-2-adrenergic 
receptor beta, annexin A3, CD44, metallothionein 1H, protein kinase C-eta and 
retinoic acid receptor beta gene expression was increased in injured mouse 
compared to other treatment groups, HLX-1 gene expression was reduced in injured 
rat compared to other treatment groups. Integrin beta 2 and transforming growth 
factor beta receptor 1 gene expression was increased in injured rat compared to 
other treatment groups; with only annexin A3, CD44 and metallothionein 1H showed 
overall significance.  
 Whilst microarray analysis provides average gene expression in the samples, 
true biological variation is not accounted and therefore large variations in gene 
expression were observed. Each injured sample was compared to a control sample 
indicating that there was marked variation in HLX-1, integrin beta 2 and transforming 
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growth factor beta receptor 1 in both species, whilst metallothionein 1H and protein 
kinase C-eta in rat and mouse, respectively. The top 20 and bottom 20 genes 
expressed in both mouse and rat was analysed to determine if genes were 
expressed on the same level. In this manner Gpnmb, Serpina3n, Ccl3 and cd68 
genes were in the top 20 genes that were highly expressed in the treated samples 
compared to control in both species. However, there were no genes that were in the 
bottom 20 that were common in both species.  
 
6.7.1 Angiogenic/wound healing-related genes chosen for validation 
6.7.1.1 Alpha-2-adrenergic receptor beta (α2B-AR) 
Catecholamines are neurotransmitters of the sympathetic nervous system that 
respond by binding to their adrenergic receptors (adrenoreceptors) (Figure 6.29) 
(Kanagy, 2005). Adrenoreceptors are members of the G protein-coupled family that 
is formed of a 7-transmembrane domain, typically found throughout vertebrates, that 
have a critical role in regulating neurotransmitter release from sympathetic nerves 
and from adrenergic neurones in the CNS (Aris-Brosou et al., 2009, Wang et al., 
2002). Whilst there are a total of nine known isoforms, alpha-2-adrenoreceptor has 3 
highly homologous isoforms; alpha2A, alpha2B and alpha2C that are expressed 
within the CNS, kidney, heart and vasculature (Nicholas et al., 1996, Kanagy, 2005, 
Bylund, 1995). Alpha-2-adrenoreceptor mRNA is expressed throughout rat CNS, 
predominately found in the DRG, intermediolateral cell column of the thoracic spinal 
cord, dorsal horn and the cerebral cortex, whilst in mice the mRNA is expressed in 
the brain, mainly the thalamus and purkinje layer of the cerebellum (Nicholas et al., 
1996, Wang et al., 1996). The chromosomal location of alpha-2-adrenoreceptor in 
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humans is located on chromosome 10 whilst in mice it is located on chromosome 19 
(Yang-Feng et al., 1990).  
Alpha-2-adrenoreceptors play an important role not only in regulation of blood 
pressure but also in the regulation of noradrenergic neurotransmission in human 
CNS and PNS (Bawa-Khalfe et al., 2007). The long-term, chronic, paralysis that 
results from SCI is reversed when alpha-2-adrenoreceptor agonist, clonidine is 
administered in cats, resulting in “normalisation” of sensory-motor and autonomic 
dysfunction in preliminary experiments in humans with traumatic SCI indicating that 
autonomic dysreflexia and spasticity can be controlled and minimised (Naftchi, 1982). 
Clonidine also reduces the conditioned aversion in the central nuclei of the amygdala 
in the visceral pain-induced aversion in rats (Deyama et al., 2010). Early research 
demonstrates that alpha-2-adrenoreceptor plays a central role in the modulation of 
sensory inputs to the visual cortex in rats (Kolta et al., 1987). Alpha-2-adrenoreceptor 
agonists provide neuroprotective effects in rat optical nerve degeneration model and 
the loss of RGCs two weeks after injury was three times lower than that of controls 
and therefore reduced intraocular pressure (Yoles et al., 1999). Dormant microglia 
predominately express beta-2-adrenoreceptors but switch to alpha-2-
adrenoreceptors under pro-inflammatory conditions, and despite differential 
expression of receptors, norepinephrine causes process retraction in both resting 
and activated microglia suggesting its role in modulating the motility of microglia 
(Gyoneva and Traynelis, 2013). Patients with Alzheimer’s disease were found to 
have 50% increase in densities of alpha-2-adrenoreceptors in cerebral microvessels 
compared to matched controls and thus associated with blood-brain barrier 
abnormalities (Harik and Kalaria, 1991). It has been reported that alpha-1 and -2 
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antagonists induce wound healing in rat cutaneous wounds 14 days after injury, 
affecting leukocyte migration, proliferation of epithelial and connective tissue and pro-
MMP-9 levels, and when compared to beta-1 and-2 antagonists wound healing was 
not delayed (Romana-Souza et al., 2009). 
 
6.7.1.2 Annexin A3 (ANXA3)  
ANXA3 is a member of calcium-dependent phospholipid-binding protein 
annexin family playing a role in the regulation of cellular growth, proliferation, 
apoptosis and differentiation whilst also playing a role in various signal transduction 
pathways (Raynal and Pollard, 1994, Gerke and Moss, 2002, Gerke et al., 2005). 
Annexin family is made up of five major groups; A-E, that are present in humans 
(annexins A1-A13), animals (annexin B9-B12), fungi/moulds (annexin C1, C2 and 
C5), plants (annexin D1-D25) and protists (annexin E1-E3) (Gerke and Moss, 2002). 
ANXA3 is a 33kDa protein that is expressed in neutrophils with a 36kDa variant 
found in monocytes, and more recently ANXA3 mRNA and protein has been 
detected in zebrafish eggs  and in mouse adipose tissues than any other tissues (Le 
Cabec and Maridonneau-Parini, 1994, Le Cabec et al., 1992, Sopkova et al., 2002, 
Ozerova and Minin, 2008, Watanabe et al., 2012).  
In vitro observations demonstrate that ANXA3 is an angiogenic factor by 
inducing migration and tube formation of human umbilical vein endothelial cells 
(HUVECs) (Park et al., 2005). Not only was VGEF detected in the cultured medium 
but so was HIF-1 activity suggesting that ANXA3 induces VEGF expression through 
the HIF-1 pathway.  
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Figure 6.29 Alpha-adrenergic receptor (ADR) signalling pathway. ADR are receptors 
for adrenaline, norepinephrine and clonidine within the sympathetic nervous system. 
ADR are coupled through G-proteins that subsequently activate PLC-γ leading to the 
hydrolysis of membrane PIP2 producing DAG and IP3. DAG binds and activates 
PKC that activates the MAPK signalling pathway, whilst IP3 binds to its receptor; 
IP3R, located on the endoplasmic reticulum that leads to the release of calcium ions. 
The calcium ions activate glycogen synthase by interacting with Calm and CalmK 
(adapted from Qiagen).    
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ANXA3 has been investigated in the CNS using lactacystin; a proteasome 
inhibitor, that is used to stimulate ubiquitin proteasome system dysfunction in 
neurones to mimic pathological features of neurodegenerative disorders. Results 
revealed significant increases in ANXA3 in mouse and murine cortical neurones at 
12-15 hours post-lactocystin treatment correlating with neuronal injury and onset of 
neuronal death (Chong et al., 2010). In animal models of cerebral ischemia and 
motor nerve injury, ANXA3 is unregulated and expressed by microglia after injury 
identifying it as a novel marker of brain microglial (Junker et al., 2007, Kessler et al., 
2008, Konishi et al., 2006). Observed ANXA3 immunoreactivity results confirmed that 
ANXA3 was produced by activated microglial cells and occasionally located around 
neurones suggesting its role in the removal of dying neurones after stroke (Kessler et 
al., 2008).  
 
6.7.1.3 CD44 
CD44 is a multifunctional, cell surface glycoprotein that is involved in various 
cellular processes that include cell growth and adhesion during neurite outgrowth, 
differentiation, motility, survival, and tumor metastasis (Jones et al., 2000, Matsumoto 
et al., 2012). CD44; the main receptor for osteopontin and hyaluronan, has been 
implicated in the inflammatory processes associated with many neuronal injuries, 
aiding as potential biological markers for disease states, definition of disease severity 
and CNS metastasis (Matsumoto et al., 2012). In vitro experiments using RGCs 
suggest a novel biological function for CD44 in axon growth and that reduced CD44 
expression results in the reduction of axon initiation in RGCs (Ries et al., 2007). 
Gliomas provide detrimental effects to the CNS, and in vitro and in vivo experiments 
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demonstrate that increased CD44 expression in brain tissue containing glioma in 
mouse models correlate with the progression of the glioma, and thus CD44 may act 
as a potential biomarker in gliomas (Wiranowska et al., 2006). 
CD44 plays an important role in disease severity and progression and patients 
with neurodegenerative Alzheimer’s disease displayed increased CD44 gene 
expression in lymphocytes compared to healthy controls (Uberti et al., 2010). In 
mouse models of EAE, CD44 deficient mice displayed a delayed response of onset 
EAE compared with wild type mice, furthermore improved symptoms, reduced 
demyelination and impaired CD4+ T-cell extravasation was observed in these mice, 
suggesting that increased expression of CD44 and other inflammatory markers are 
responsible for increased severity of EAE (Li et al., 2011a, Winkler et al., 2012, Sinha 
et al., 2011). Amyotrophic lateral sclerosis (ALS) is a motor neurone degenerative 
disease and in mouse models of ALS CD44 expression was not only increased with 
the onset of the disease but also continued to increase thereon after (Matsumoto et 
al., 2012). Furthermore in vivo and in vitro experiments demonstrate that CD44 
expressing microglial and astrocytes play a role in the inflammatory response and 
thus the progression of ALS. This phenomenon was also observed after SCI in dogs 
where increased CD44 expression on microglia further enhanced their function in 
leukocyte adhesion and aggregation, and therefore contributing to the secondary 
injury after SCI (Boekhoff et al., 2012). After SCI in rats increased CD44 protein 
expression was localised to some astrocytes in the periphery lesions, majority of the 
inflammatory cells, vessels and myelin sheaths in the lesion core compared to sham 
controls suggesting that CD44 contributes to the early stages after SCI in cell 
adhesion and glial cell attraction (Moon et al., 2004). CD44 plays a role after injury to 
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both the CNS and PNS, where injury to the PNS the appearance of CD44 was 
localised to affected neurones, their dendrites and axons which was also seen after 
SCI but was abolished after spinal root transection. Non-neuronal CD44 was 
restricted to the sites of direct injury, confined to monocytes and granulocytes after 
sciatic nerve injury but after injury to the cerebral cortex immunoreactivity was 
localised to astrocytes and leukocytes. After optic nerve crush CD44 
immunoreactivity was confined to reactive retinal astrocytes and microglia, 
suggesting that this molecule is important in the brain pathology in response to 
trauma in roles in the neuronal, glial and leukocytes cells (Jones et al., 2000). Triple 
negative breast cancer is uncommon and has the ability to spread to the CNS and 
therefore the identification of CD44+ cells have higher CNS affinity that could result in 
metastasis (Katakkar, 2012). 
CD44 not only shows to play an important role in inflammation but also wound 
healing. CD44 immunoreactivity coincided with hyaluronan in the early stages of 
wound healing in rabbit corneal epithelial wound healing and in rat liver injury (Asari 
et al., 1996, Kikuchi et al., 2005). But wound healing has shown to be age dependant 
and in which case increases of CD44 plays a detrimental role where it is associated 
with delayed wound healing in aged skin rat models compared to young rats (Oriana 
et al., 2013). CD44 deficient mice have shown to improve healing properties after 
patellar tendon injury model (Ansorge et al., 2009). CD44 is also involved in 
pathological angiogenesis  and is expressed on many cell types including endothelial 
cells (Pall et al., 2011). But over expression of CD44 can have detrimental effects 
resulting in metastatic behaviour and aid in the expansion of tumour cells (Gunthert 
et al., 1991, Kogerman et al., 1997). In vitro experiments demonstrate that CD44 
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expression is induced in endothelial cells cultured with angiogenic growth factors 
(Griffioen et al., 1997). CD44 deficient mice resulted in inhibited tumour and wound 
angiogenesis and this impairment may be due to the loss of endothelial CD44, and in 
vitro experiments revealed that the endothelial cells had impaired ability to form tubes 
although their cell proliferation, survival and wound-induced migration was not 
affected. These results suggest a role in the stability of endothelial tubular networks 
during in vivo angiogenesis (Cao et al., 2006). 
 
6.7.1.4 H2.0-like homeobox 1 (HLX1) 
HLX1 belongs to the H2.0 homeobox family that is located on chromosome 
1q41-q42 (Kennedy et al., 1994, Nishimura et al., 1993). The human HLX1 protein 
shares 85.5% homology to the murine HLX gene, that is also closely linked to the 
human TGFβ-2 gene (Kennedy et al., 1994, Nishimura et al., 1993). HLX1 is 
predominately expressed by reproductive tissues and limited immune cells, where it 
plays a role in embryogenesis and haematopoiesis. In vitro experiments demonstrate 
that HLX1 mRNA and protein is expressed in a trophoblast cell line; HTR-8/SVneo, 
via hepatocyte growth factor (HGF) and that using a siRNA to HLX1 inhibited 
responses to HGF treatment, further reducing the growth and invasion capacities of 
the trophoblast cell line (Liu et al., 2012). These results suggest that HLX1 is an 
essential downstream signalling component of HGF that leads to the invasiveness 
and growth of the trophoblast cells.  
The effect HLX1 has on the developing CNS has been investigated in 
zebrafish. Early experiments show that HLX1 is expressed at specific dorsal ventral 
levels along the hindbrain and spinal cord  and loss-of-function (antisense 
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morpholino oligodendrocytes directed against HLX1) and gain-of-function 
(blastomeres injected with synthetic HLX1 mRNA) experiments revealed severe 
defects in brain morphogenesis as a result of abnormal ventricle formation when 
HLX1 is over-expressed (Fjose et al., 1994). Animals displayed a reduction in the 
size of forebrain neuronal clusters and axonal path finding. Whilst using HLX1 
antisense morpholinos perturbed hindbrain morphogenesis leading to defects in the 
integrity of the neuroepithelium. Their results suggest various roles for HLX1 during 
zebrafish morphogenesis (Hjorth et al., 2002). 
 
6.7.1.5 Integrin β2 (ITGβ2) 
Integrin β2 (CD18) is part of a large family of integrins that are integral cell 
surface proteins composed of an alpha chain and a beta chain. These heterodimeric 
cell adhesion molecules mediate cell-cell and cell-ECM interactions and are involved 
in many processes that include wound healing, neuroprotection and the inflammatory 
response after injury (Hynes, 2002). In humans there are 24 different integrin 
molecules that each contain an extracellular region (containing α and β chains), a 
transmembrane domain and a cytoplasmic tail (Hynes, 2002, Suzuki and Naitoh, 
1990). The beta subunit is divided into two classes; β1 and β2, in which β2 is further 
subdivided into four isoforms with their expression limited to mainly white blood cells 
and thus important in the function of leukocytes (Springer, 1990, Noti et al., 2000). 
The use of anti-CD11d monoclonal antibody against the subunit of 
CD11d/CD18 integrin has shown many neuroprotective benefits in the CNS 
particularly after SCI. Early use of CD11d monoclonal antibody after SCI has shown 
to reduce neutrophil infiltration and delay the entry of macrophages into the injured 
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lesion whilst further reducing intraspinal concentration of reactive oxygen and 
nitrogen species. Furthermore there was evidence of reduced pain, autonomic 
dysreflexia and improved locomotor performance and tissue preservation (Gris et al., 
2004, Bao et al., 2004). Extensive research has been carried out that display similar 
results after treatment with anti-CD11d monoclonal antibody after SCI where 
reduction in not only acute inflammation but also oxidative stress and cell death often 
seen after SCI enhances locomotor recovery and neurological function (Bao et al., 
2005, Oatway et al., 2005, Bao et al., 2011). Furthermore microarray analysis on 
animals treated with anti-CD11d monoclonal antibody compared to controls revealed 
reduced gene expression of pro-inflammatory cytokines and increased gene 
expression of inflammatory mediators that promote wound healing and the 
expression of scar proteins predicted to improve nerve growth (Gris et al., 2009). The 
use of anit-CD11d monoclonal antibody has also been implemented in other CNS 
disorders including traumatic brain injury demonstrating the beneficial use in 
improving functional recovery by reducing inflammation, oxidative activity and tissue 
damage (Geremia et al., 2012, Bao et al., 2012).  
Whilst treatment with CD11d monoclonal antibody has provided beneficial 
evidence to the possible treatment to SCI, it is very much dependent on the injury 
model produced. Contradictory to earlier reports that a significant reduction in 
neurological deficits is seen after treatment in spinal cord ischemia injury models, it 
was later demonstrated that it is not dependent on neutrophils particularly the CD18 
integrin molecules (Clark et al., 1991, Forbes et al., 1994). Furthermore SCI induced 
by spinal cord clip compression resulted in no significant differences in motor 
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recovery, myelin preservation and mechanical allodynia in animals that received this 
treatment compared to controls (Hurtado et al., 2012). 
ITGβ2 has demonstrated to play a role in wound healing and patients that 
suffer from mutations in ITGβ2 results in a condition called leukocyte adhesion 
deficiency type 1 (LAD1) that results in impaired wound healing and recurrent 
infections (Parvaneh et al., 2010, van de Vijver et al., 2012). In patients that suffer 
from SCI, reduced gene expression of CD18 contributes to the delayed wound 
healing to their pressure ulcers due to the reduced expression, impaired cell-cell 
interaction and lack of ECM protein expression (Cruse et al., 2002, Cruse et al., 
2000).  
 
6.7.1.6 Metallothionein 1H (MT1H) 
Metallothioneins (MTs) are intracellular, low molecular weight, metal binding 
proteins that have a high content of cysteine residues, that was first isolated from 
horse kidney (Coyle et al., 2002, Han et al., 2013, Cherian et al., 2003, Margoshes 
and Vallee, 1957). Human MT genes are clustered together on a locus on 
chromosome 16 q13  and their neuronal receptor; LRP2 (megalin), was first identified 
in 1997 found on human astrocytes (Stennard et al., 1994, Cherian et al., 2003, 
Michael et al., 2011, El Refaey et al., 1997). These proteins are transcriptionally 
regulated due to their unique structural characteristics by heavy metals and 
glucocorticoids (Coyle et al., 2002). MTs are part of a superfamily of 15 subfamilies 
involved in various biological processes with four subfamilies present in mammal’s; 
MT1-MT4. MT1 and MT2 have been shown to be involved in zinc homeostasis and 
provide protection against heavy metal toxicity and oxidative stress, and MT3 and 
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MT4 expression is mainly confined to neurones and glia, and differentiating stratified 
squamous epithelial cells, respectively (Carpene et al., 2007, Kagi, 1991, Vasak, 
2005, Rigby Duncan and Stillman, 2006, Li et al., 2006). In the CNS MTs are 
released by astrocytes showing its association with neuroprotection (Michael et al., 
2011).  
CNS disorders such as bipolar disorder with psychotic features are closely 
related to schizophrenia and therefore, psychosis is an alternative phenotype. Cross-
study analysis of 7 gene expression microarrays that include psychosis and non-
psychosis subjects was performed and quantitative PCR validated that MT genes 
were upregulated that included MT1H in psychosis patients compared to controls 
(Choi et al., 2008). Early reports show that MT1H is essential for wound repair in the 
CNS and deficiencies impair neuronal survival (Penkowa et al., 1999). MTs also 
demonstrate a neuroprotective role in the CNS where whole genome transcriptome 
analysis showed increased expression of metallothionein genes that include MT1E, 
MT1F, MT1G, MT1H, MT1M and MT1X and MT2A found in reactive astrocytes and 
increased expression of its receptor LRP2 in sporadic cases of Parkinson’s disease 
(PD) compared to non-PD controls (Michael et al., 2011). After human SCI MT’s 
including MT1H gene expression was increased at 2 and 5 days post-SCI and 
protein and immunoreactivity levels were increased at 5 days post-SCI only, 
indicating these proteins may be early targets for degradation post-SCI (Urso et al., 
2007). 
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6.7.1.7 Retinoic acid receptor beta (RARβ)  
Retinoic acid receptor is a member of the thyroid-steroid hormone receptor 
superfamily of nuclear transcriptional regulators that consist of three members; alpha, 
beta and gamma (Evans, 1988, Green and Chambon, 1988, Geisen et al., 1997, 
Mendelsohn et al., 1994). Each of these members has at least two isoforms that are 
derived from primary transcripts, but in particular RARβ has four isoforms (RARβ1-4) 
with RARβ2 and 4 being confined to mainly embryonic CNS (Mendelsohn et al., 
1994, Mendelsohn et al., 1991). Retinoic acid receptor binds retinoic acid, the 
biologically active form of vitamin A, to mediate cellular signalling in embryonic 
morphogenesis, cell growth, differentiation, organogenesis and neuronal 
development (Wilson et al., 1953, Desai et al., 2006, Bi et al., 2013). Whilst isoform 
RARβ2 and RARβ4 is modulated by retinoic acid RARβ1 and RARβ3 are not 
(Mendelsohn et al., 1994, Mendelsohn et al., 1991, Mey and Hammelmann, 2000). 
The adult CNS including the cerebellum and the cerebral cortex has also been 
shown to express RARβ2, and outside of the CNS, RARβ gene has been observed 
and expressed in normal lung tissue (Agudo et al., 2010, Houle et al., 1993) 
Early research demonstrates that RARβ, particularly, RARβ2 is an early 
marker of the developing alimentary tract and the CNS in early embryonic stages in 
chicken (Smith, 1994). Many reports since state that RARβ plays a critical role in all 
areas of the CNS, particularly in inducing axonal regeneration and growth in the 
developing brain, eye and spinal cord (Carter et al., 2011). Loss of RARβ expression 
restricts axonal regeneration of adult rat RGCs, therefore indicating that there is a 
crucial period in the developing retina up until which the RGCs start to restrict axonal 
regrowth (Koriyama et al., 2013). Furthermore, using an inhibitor, trichostatin A, to 
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histone deacetylase (HDAC) induced axonal regeneration of RGCs via RARβ 
induction and thus promoted neurite outgrowth (Koriyama et al., 2014). In vitro over-
expression of RARβ2 in adult rat DRG cultures increases neurite outgrowth, also 
seen in vivo, enabling axons to regenerate across the inhibitory dorsal root entry 
zone, projecting into the GM of the spinal cord and thus enhancing neuronal activity 
and significant improvement in sensorimotor tasks (Wong et al., 2006).  
It has been demonstrated that not only does retinoic acid signal through 
RARβ2 to promote neurite outgrowth in the PNS in embryonic and adult DRG but 
also in the CNS only in mouse embryonic spinal cord, and in contrast, in the adult 
mouse spinal cord there is no upregulation of RARβ2 by retinoic acid and thus no 
neurite outgrowth (Corcoran et al., 2002). And that using a virus vector expressing 
RARβ2 to transduce adult rat or mouse spinal cord, neurite outgrowth occurs. In vitro 
delivery of RARβ2 using a lentiviral vector to dissociated adult cortical neurones 
resulted in significantly enhanced neurite outgrowth. Furthermore lentiviral-mediated 
transduction of corticospinal neurones resulted in robust axonal projections in the 
corticospinal tract of the spinal cord, and thus enhanced regeneration of descending 
corticospinal tract fibres and further promoting functional recovery (Yip et al., 2006). 
Inhibited neurite outgrowth is observed in neurones in the cerebellum that are grown 
in the presence of inhibitory myelin-associated glycoprotein (MAG), and that using a 
RARβ agonist (CD2019) activates RARβ2 in a dose-dependent manner resulting in 
neurite outgrowth via signalling through the PI3K pathway, and in a model of SCI 
RARβ agonist induces axonal outgrowth of descending corticospinal fibres thus 
promoting functional recovery (Agudo et al., 2010). Further supporting regenerative 
abilities seen in the PNS and CNS, RARβ also promotes regeneration in the tail of 
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adult newt using the cloned full-length sub-type RARβ2 (NvRARβ2). NvRARβ2 cDNA 
was significantly upregulated 2 weeks after amputation of the tail particularly in the 
rostral cut surface of the cord, and using an inhibitor significantly inhibited ependymal 
outgrowth and decreased tail regeneration length, further supporting spinal cord 
regeneration (Carter et al., 2011). 
 
 6.7.1.8 Protein kinase C eta (PRKCH) 
Protein kinase C (PKC) is part of a mutligene family of serine/threonine-
specific protein kinases that are activated by calcium and the second messenger 
diacyglycerol. PKC family members phosphorylate a wide variety of protein targets 
that are known to be involved in the diverse cellular signalling pathways including 
growth factor-dependent signalling (Steinberg, 2008). PKC isoforms share specific 
structural features; catalytic domain for ATP binding and catalysis and a regulatory 
domain containing a NH2 domain that maintains the inactive protein conformation. 
PRKCH is located on human chromosome 14 (14q22-23) whilst in mice it is located 
on chromosome 12 (12C3-D2), and is highly expressed in epithelial tissues by 
specific activation from sulphated metabolites of cholesterol and cerebroside and 
cholesterol sulphate. It has been shown that over expression of PRKCH induces G1 
arrest and differentiation in keratinocytes and that PRKCH-knockout mice are more 
sensitive to carcinogenesis suggesting that PRKCH is negatively involved in tumour 
promotion via keratinocyte differentiation  (Kashiwagi et al., 2002).  
PRKCH has been considered as a therapeutic target for the management of 
glioblastoma multiforme (GBM); primary CNS tumours that are currently resistant to 
chemotherapy/radiation methods, as PRKCH not only increases cell proliferation but 
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is also resistant to radiation in GBM cell lines (Martin and Hussaini, 2005). SNPs in 
PRKCH have also been shown to play a role in the pathogenesis of multiple sclerosis 
relapse via vitamin D expression (Lin et al., 2014). Over expression of atypical 
kinases such as PRKCH is sufficient to inhibit neurite growth in embryonic rat 
hippocampal neurones (Buchser et al., 2010). 
 PRKCH also plays a role in wound healing and tumour suppression using a 
PRKCH-deficient mouse model. The PRKCH-deficient mice exhibited increased 
susceptibility to tumor formation in skin carcinogenesis and after a punch biopsy 
wound healing on the dorsal surface was significantly delayed, indicating that 
PRKCH plays a role in the maintenance of epithelial architecture and thus wound 
healing in vivo (Chida et al., 2003).  
 
6.7.1.9 Transforming growth factor beta type 1 receptor (TGFβR1) 
As previously mentioned, the largest family of secreted growth factors in 
mammals is the TGFβ family. TGFβ bind to their type 1 and 2 receptors to produce a 
receptor complex and activate SMAD proteins to initiate signal transduction pathways 
(Chapter 3 Introduction and Figure 3.2) (Li et al., 2011b). TGFβR1 is one of seven 
type 1 receptors for TGFβ ligand (Massague, 1992, Massague, 1998). Heterozygous 
mutations in TGFBR1 and 2 causes Loeys-Dietz syndrome, which is an autosomal 
dominant aortic aneurysm syndrome with widespread systemic involvement (Loeys 
et al., 2006).  
TGFβR1 has been shown to play a role in the CNS in an angiogenic 
dependant manner where outgrowth endothelial cells (OECs) from ischemic stroke 
patients in the colony stage rather than mature stage presented over expression of 
276	  |	  P a g e 	  
	  
TGFβR1 along with other angiogenic genes thus confirming that OECs demonstrate 
a higher level of pro-angiogenic factors at early stages of ischemic stroke (Navarro-
Sobrino et al., 2013). TGFβR1 has been shown to play a role in regenerative wound 
healing in mouse ear punch models, where a point mutation on TGFβR1 lead to a 3-
fold decrease in the diameter of the wound compared to wild-type mice (Liu et al., 
2011). Contradictory to this earlier report that TGFβR1 may be beneficial in aiding in 
wound healing, it has further been shown that using Moxifloxacin blocked TGFβR1 
and thus inhibited TGFβ-induced fibroblast to myofibroblast differentiation and thus 
may participate in corneal wound healing (Chen et al., 2013).   
In conclusion, these data demonstrates the vast amount of differences that 
mice and rats exhibit during the sub-acute SCI response and the large amount of 
genes that play a part in the healing response. These genes and pathways could 
provide possible insights into the post-injury mechanisms associated with SCI and 
therefore could be used to establish possible therapies to reduce cavitation and thus 
secondary damage.  
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GENERAL DISCUSSION 
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7.1 Summary research findings 
 The research presented in this thesis demonstrates that mice and rats display 
unique differences that may contribute to lesion cavity development that is normally 
observed in rats after sub-acute SCI. This therefore provides crucial evidence that 
may aid in potential therapeutic treatments for clinical situations. Parallel to current 
research, the extent of cavitation to the injured rat cord increases over time 
compared to mice (Inman and Steward, 2003, Sroga et al., 2003, Byrnes et al., 
2010). In rats the fluid-filled cavity expands both rostrally and caudally from the lesion 
epicentre, however in mice the lesion areas are completely filled with ECM and thus 
free from cavities, a scenario which has been shown to aid in axon regeneration in 
the PNS (Previtali et al., 2008). Furthermore, a correlation was observed between the 
extent of cavity formation and the lack of laminin deposition over time. In mice after 
injury laminin deposition increased over time, however, in rats laminin deposition was 
devoid in the lesion areas and confined only to the boundaries of the cavity. This time 
course revealed that the biggest difference in cavity formation and laminin deposition 
between the two species was observed at 8 dpl. Sub-acute injury responses in mice 
also revealed an increase in GFAP+ astrocytes and fibronectin+ ECM material in the 
lesion core however this was not seen in rats indicating that mice have a better 
balance of scar deposition after SCI. This led to the hypothesis that the cavity free 
response seen in mice is due to an increase in angiogenesis and a better balance of 
scar deposition and thus mice may be conducive to wound healing after SCI. There 
is evidence that demonstrates a link between wound healing and functional recovery 
after SCI, particularly the presence of MMP-2 after injury (Hsu et al., 2006). MMP-2 
not only facilitated the wound healing process but it also regulated the formation of 
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the glial scar and white matter sparing and thus promoted functional recovery in 
mice.  
 A range of pro-angiogenic/wound healing-related proteins were tested on 
mouse and rat spinal cord lesions at 8 dpl. In this manner pro-angiogenic/wound 
healing-related proteins such as VEGF-A, TGFβ-2, PDGF-BB, FGF2, angiogenin, 
angiopoietin-1, MMP-1, MMP-9 localisation and protein expression were all 
significantly increased in mice lesion areas compared to rats. Whilst anti-
angiogenic/wound healing-related proteins such as TIMP-2 and semaphorin 3A were 
significantly higher in rats compared to mice, further supporting the hypothesis that 
the absence of cavity development in mice is due to the adequate balance of 
angiogenesis, wound healing and scar deposition. Differences were also observed in 
axonal sparing between mice and rats, demonstrating that at 8 dpl after sub-acute 
SCI there was a greater reduction of axonal sparing in rats compared to mice, 
suggesting that cavitation is detrimental to axon integrity. One would expect these 
results to coincide with better functional recovery in mice compared to rats after SCI. 
However, our results show that the presence of a large cavity in rats had no effect on 
mechanical allodynia but thermal allodynia was affected in both mice and rats 
immediately after injury, recovering to normal levels within 7 dpl demonstrating acute 
and transient functional deficits. Whilst our injury damages all axons within the dorsal 
funiculi, previous research demonstrates that behavioural deficits correlate strongly 
with injury depth  and therefore more overt injury models are required to demonstrate 
functional deficits after SCI (Hill et al., 2009).   
 Since prior studies demonstrate that mice and rats exhibit differential 
inflammatory responses after SCI, the aim here was to investigate if induced 
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inflammation immediately after injury using zymosan would induce cavity formation in 
mice similar to that seen in rats after injury. Increased accumulation of micro-cavities 
was observed in mice and rats in those treated with zymosan compared to PBS 
injected controls (Sroga et al., 2003, Byrnes et al., 2010). After induced inflammation 
differences were observed in the inflammatory responses between mice and rats. 
There was no difference in the microglia response in the lesion site in mice compared 
to rats, however, the levels of macrophages and resident T-cells were significantly 
increased in rats compared to mice after zymosan injection compared to control PBS. 
The DC scarring response demonstrated that there was an increase in fibronectin+ 
ECM after induced inflammation in rats compared to mice and their representative 
PBS controls. Whilst increases were observed in angiogenic VEGF-A in mice 
compared to rats, MMP-1 and laminin were significantly higher in rats compared to 
mice, and anti-angiogenic semaphorin 3a was significantly higher in mice compared 
to rats after zymosan injection. Chronic inflammation results in areas of hypoxia that 
can cause inflammatory mediators to either directly or indirectly promote 
angiogenesis  further contributing to prolonged inflammation, and in a model of 
neurodegeneration, angiogenesis induced CNS inflammation promoted neuronal 
remodelling (Jackson et al., 1997, Arroyo and Iruela-Arispe, 2010, Muramatsu et al., 
2012). This may suggest that in rats chronic inflammation promotes angiogenesis 
and aims to undergo neuronal remodelling in an attempt to preserve axonal damage- 
a function that is disabled and results in cavitation in response to induced 
inflammation after sub-acute SCI. 
 In response to the significant difference seen between mice and rats after T8 
sub-acute SCI at 8 dpl microarray analysis was carried out to assess the genome 
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wide response in known angiogenic/wound healing-related genes and the possibility 
of unknown, novel genes that may be significantly up or down regulated after SCI. 
This may reveal clues to the reasons why rat’s cavitate and mice do not. Stringent 
analysis using multiclass analysis revealed 1090 genes in mice and 1616 genes in 
rats that were deemed as significantly expressed after SCI. IPA analysis on these 
values revealed that in mice and rats 562 and 689 genes, respectively, were unique 
whilst 874 and 721 genes, respectively, were mapped and differentially regulated 
whilst 388 and 98 genes, respectively, were un mapped after SCI. Known canonical 
pathways were used to assess IL8 mediated regulation of angiogenesis and tumour 
growth, NGF signalling for neurite outgrowth and differentiation, PDGF signalling for 
cell proliferation and survival and VEGF signalling for hypoxia and angiogenesis 
pathways that showed significant differences between mice and rats after SCI. 
Known angiogenic/wound healing-related genes that were either 2-fold up or down 
regulated after sub-acute SCI at 8 dpl were extracted from the raw data sets, and of 
those 9 genes (alpha-2-adrenergic receptor beta, annexin A3, CD44, HLX-1, integrin 
beta 2, metallothionein 1H, protein kinase C-eta, retinoic acid receptor beta and 
transforming growth factor beta receptor 1) were chosen to be validated by qPCR. 
Whilst alpha-2-adrenergic receptor beta, annexin A3, CD44, metallothionein 1H, 
protein kinase C-eta and retinoic acid receptor beta gene expression was increased 
in injured mouse compared to other treatment groups, HLX-1 gene expression was 
reduced in injured rat compared to other treatment and integrin beta 2 and 
transforming growth factor beta receptor 1 gene expression was increased in injured 
rat compared to other treatment groups only annexin A3, CD44 and metallothionein 
1H showed overall significance.  
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 Whilst microarray analysis provides average gene expression in the samples, 
biological variation is not accounted for therefore causing huge variation in the gene 
expression data. Each injured sample was compared to its relative control sample 
indicating that there was huge variation in HLX-1, integrin beta 2 and transforming 
growth factor beta receptor 1 in both species, whilst metallothionein 1H and protein 
kinase C-eta in rat and mouse, respectively. The top 20 and bottom genes expressed 
in both mouse and rat was analysed to determine if genes were expressed on the 
same level. In this manner Gpnmb, Serpina3n, Ccl3 and cd68 genes were in the top 
20 genes that were highly expressed in the treated samples compared to control in 
both species. However, there were no genes that were in the bottom 20 that were 
common in both species. This large amount of data demonstrates that there is a 
large amount of genes that play a part in the healing response in mice and rats after 
SCI, and could be used to establish possible mechanisms to reduce cavitation and 
therefore secondary damage that human experience.  
  
7.2 Advantages / disadvantages associated with the current model 
 In hind sight it is quite difficult to mimic clinical human SCI using animal 
models as the anatomical location of injury differs greatly between the two (Kundi et 
al., 2013). In clinical situations humans present with SCI at the cervical region  but to 
mimic that in an experimental model could lead to potential life threatening 
complications to the animals and therefore SCI at the thoracic level is more 
commonly used (Akhtar et al., 2008). The use of laminectomy and anaesthesia also 
contributes largely to experimental SCI not mimicking the clinical injury presented by 
humans. Both of these factors can have a major impact and alter the physiological 
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responses to injury and therefore using a laminectomy free method such as balloon 
compression may mimic the human condition more accurately (Kundi et al., 2013).  
Rodents and humans differ considerably in size which is factor that should be 
taken into consideration particularly when investigating axon regeneration as several 
millimetres are sufficient enough to induce functional recovery in rodents. However, 
in humans distances of many centimetres may be required (Nout et al., 2012). This 
difference in scale posses as a significant issue particularly when investigating 
surgically applied therapies and feasibility.  Another factor to take into consideration 
is the difference in functional roles of axon systems between rodents and humans 
and a fine example of this is the corticospinal tract (CST) (Nout et al., 2012). In 
humans the CST is essential for fine motor control but not so essential in rats 
(Courtine et al., 2007, Lawrence and Kuypers, 1968, Lemon and Griffiths, 2005). 
 It is important to remember that while the injury induced in this study is a mild 
form that gives little insight to the functional recovery after injury, it still provides the 
pathological and physiological changes that are associated and observed after SCI.  
 
7.3 Advances made in SCI research 
 Since investigating the angiogenic and lesion cavity responses between mice 
and rats after sub-acute SCI there has been limited, ongoing research to investigate 
other possible mechanisms that may be affected and differential between the two 
species. Platelet-derived growth factor (PDGF)-responsive neural precursors (PRP) 
isolated from the forebrain of fetal mice has been used to test the potential of 
remyelinating axons after injury (Plemel et al., 2011). PRPs transplanted 1 week after 
T8 spinal cord contusion in rats developed the typical phenotype of mature 
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oligodendrocytes 2 weeks post-transplantation, expressing the oligodendrocyte 
marker APC-CC1. These cells also had close association with myelin basic protein 
indicating mature myelin sheath formation. Furthermore transplantation of the PRPs 
in demyelinated Shiver mice confirmed the ability of the PRPs to produce myelin 
sheaths suggesting it as a novel candidate in CNS repair.  
Sigma-1 receptors, localised in the nervous system, play an essential role in 
pain sensitisation. Recent studies show that increases in sigma-1 receptor mediates 
increases in spinal p38 MAPK phosphorylation that causes the induction of 
mechanical allodynia in mice and neuropathic pain in rats but not thermal 
hyperalgesia (Moon et al., 2013). More importantly sigma-1 receptor modulation of 
phosphorylated p38 MAPK plays an important role in the induction but not the 
maintenance of mechanical allodynia in neuropathic pain. Furthermore, in a rat 
model of neuropathic pain in the sciatic nerve, mechanical allodynia and thermal 
hyperalgesia was evaluated in mice and rats. Results demonstrated that spinal 
sigma-1 receptors modulate NAPDH oxidase 2 activation and reactive oxygen 
species (ROS) production in the spinal cord, contributing ultimately to sigma-1 
receptor-induced pain hypersensitivity in mice and mechanical allodynia in 
neuropathic rats (Choi et al., 2013).  
The Wnt family of proteins plays a vital role during CNS development and 
therefore is involved in many neurological pathologies including SCI. A recent study 
has demonstrated that Wnt expression in the spinal cord of adult mice is modulated 
by SCI and differs to previous findings described in rats (Gonzalez-Fernandez et al., 
2014). These studies demonstrate that mice and rats exhibit differential responses 
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and mechanisms to SCI that include remyelination, neuropathic pain and Wnt 
signalling and could contribute to secondary damage seen after injury.   
 
7.4 Conclusion 
In conclusion, differences do exist between mice and rats in cavity formation, 
matrix deposition and pro-angiogenic protein levels after DC injury, indicating that 
mice have a more robust angiogenic and wound healing response to SCI that is 
associated with an absence of cavitation and axon sparing, despite acute deficits in 
functional recovery in mice and rats. Our results support the hypothesis that the 
absence of cavitation in mice is due to an adequate balance between angiogenesis, 
wound healing and scar deposition compared to rats which fail to lay down ECM after 
sub-acute SCI and thus display large cavities. These key differences between the 
wound healing responses in mice compared to rats warrant further investigation. 
 
7.5 Future work 
Whilst key differences have been established in the sub-acute response to 
SCI between mice and rats further work needs to be carried out to optimise the 
mechanisms that are responsible for cavitation and ultimately axonal degeneration. 
While advances in sub-acute SCI research have been made the aim for clinical trials 
is still a long way off.  
 
7.5.1 In vitro astrocyte culture 
Rat or human astrocyte cultures can be used to asses wound healing properties 
particularly in the CNS with an aim to assess cavitation (Fitch et al., 1999, Souza et 
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al., 2013).  The idea would be to grow confluent adult rat astrocytes to coincide with 
the adult data already obtained. Once cultures are confluent a vertical scratch would 
be made in each of the wells and the amount of wound closure would be observed by 
taking pictures at 0, 24, 48 and 72 hrs (time points suggested in previous astrocyte 
culture studies (Yang et al., 2009, Puschmann et al., 2010, Nishio et al., 2005).  The 
aim of using adult astrocytes would be to: 
1. To assess typical wound closure after injury in a controlled environment.   
2. To assess the wound closure and cavity development in the CNS after 
induced inflammation using zymosan compared to controls. 
The idea would be to further analyse whether the in vitro studies resemble what was 
seen in vivo i.e. an accumulation of microcavities in response to induced 
inflammation after SCI. 
 
7.5.2 In vitro knockdown/over expression  
Rat or human astrocyte or endothelial cell cultures using HUVECs (human umbilical 
vein endothelial cells) could further be used for knockdown or over expression 
assays particularly to assess the angiogenic/wound healing abilities and cavity 
development. The microarray data revealed angiogenic/wound healing-related genes 
that were either significantly upregulated or downregulated after sub-acute SCI and 
the idea would be to pick 2-4 identified genes that were differentially regulated 
between mice and rats. To knockdown gene expression in culture would require the 
use of a siRNA to that particular gene. The idea would be to further validate the 
function of these genes and whether they truly play a role in angiogenesis/wound 
healing and more importantly cavitation and neurite outgrowth. 
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7.5.3 In vivo gel based therapeutics 
The angiogenic process requires the activation of various angiogenic genes and 
therefore a combination of angiogenic/wound healing-related genes would be 
beneficial for gel based therapeutics to achieve maximal axon regeneration through 
the lesion cavity. In the Logan lab a collagen based gel has been produced and 
preliminary results have shown that once injected in to the injured area immediately 
after SCI in rats promotes axon regeneration in combination with Decorin; an anti-
scarring proteoglycan. The aim would be to use 2-3 angiogenic proteins identified 
from microarray analysis that are ultimately involved in various stages of the 
angiogenic process in combination with this gel and inject it directly into the lesion 
area of rats and compare any possible axonal regeneration across the lesioned area 
and assess reduction in cavity formation in rats compared to mice.   
 
7.5.4 Anti-viral work  
Viral vectors are a method of gene based delivery that allows DNA or a drug to be 
delivered to a specified cell. The idea would be to prepare viral gene constructs 
preparation against 2-4 genes angiogenic/wound healing-related genes to reduce 
cavity formation in rats 
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Appendix 1 
 
Appendix 1.1 Bioanalyzer (Agilent) analysis to determine the RNA integrity of the 
control rat and mouse samples extracted using TRIzol Reagent. For microarray 
analysis RNA integrity (RIN) values needed to be above 7.  
340	  |	  P a g e 	  
	  
 
 
Appendix 1.2 Bioanalyzer (Agilent) analysis to determine the RNA integrity of 
samples from DC injured rat and mouse spinal cords extracted using TRIzol 
Reagent. For microarray analysis RNA integrity (RIN) values needed to be above 7.  
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Appendix 2 
Microarray data using one-color labelling reaction on 8 x60k microarray chips on 
mouse vs. rat after sub-acute spinal cord injury (discs include raw data tables, and 
tables and information extracted from the raw data). 
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Appendix 3 
Raw microarray data assessed in LIMMA package to show the codes that were used 
for analysis to show global variation. 
 
> library(limma) 
> setwd("~/Desktop/Microarray analysis/Both/Rat") 
> targets <- readTargets("~/Desktop/Microarray analysis/Both/Rat/targets.txt") 
> RG <- read.maimages(targets, path="~/Desktop/Microarray analysis/Both/Rat", 
columns = list(G = "gMedianSignal", Gb = "gBGMedianSignal", R = 
"gProcessedSignal", 
+ Rb = "gIsPosAndSignif"), annotation = c("Row", "Col","FeatureNum", 
"ControlType","ProbeName")) 
> RG <- backgroundCorrect(RG, method="normexp", offset=16) 
> RG$G <- normalizeBetweenArrays(RG$G, method="quantile") 
> RG$G <- log2(RG$G) 
> E <- new("MAList", list(targets=RG$targets, genes=RG$genes, 
source=RG$source, M=RG$Gb, A=RG$G)) 
> E.avg <- avereps(E, ID=E$genes$ProbeName) 
> f <- factor(targets$Condition, levels = unique(targets$Condition)) 
> design <- model.matrix(~0 + f) 
> colnames(design) <- levels(f) 
> fit <- lmFit(E.avg$A, design) 
> contrast.matrix <- makeContrasts("treated-control", levels=design) 
> fit2 <- contrasts.fit(fit, contrast.matrix) 
> fit2 <- eBayes(fit2) 
> output <- topTable(fit2, adjust="BH", coef="treated-control", 
genelist=E.avg$genes, number=80000) 
> write.table(output, file="~/Desktop/Microarray analysis/Both/Rat/Rat Mean 
treated_vs_control.txt", sep="\t", quote=FALSE) 
